The Valve Wire Archive

Sex-Based Patterns and Trends in Transcatheter Aortic Valve Implantation.

IMPORTANCE: Sex-related disparities affect diagnosis, referral, and prognosis of aortic valvular diseases. Contemporary US data on transcatheter aortic valve implantation (TAVI) by sex are limited. OBJECTIVE: To characterize 10-year trends in TAVI use, periprocedural complications, and long-term outcomes among Medicare beneficiaries, stratified by sex. DESIGN, SETTING, AND PARTICIPANTS: This nationwide, retrospective, population-based cohort study used US Medicare claims data from fee-for-service beneficiaries discharged after TAVI from January 1, 2013, to December 31, 2022. The median follow-up time was 2.19 (IQR, 0.94-3.79) years. Exclusions included patients who had concomitant valve surgery, infective endocarditis, valve-in-valve TAVI, transapical TAVI, TAVI for pure aortic insufficiency, or later conversion to Medicare Advantage. Analyses were conducted between October 1, 2024, and April 1, 2025. EXPOSURE: TAVI. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality. Secondary outcomes included periprocedural mortality, vascular complications, acute kidney injury, major or life-threatening bleeding, stroke, acute myocardial infarction (AMI), permanent pacemaker implantation (PPI), and hospitalization for heart failure (HF). Adjusted odds ratios (AORs) and hazard ratios (AHRs) with 95% CIs were estimated. RESULTS: The study included 314 123 patients (141 233 women [45.0%] and 172 890 men [55.0%]). Women were older than men (mean [SD] age, female: 80.3 [7.8] years; male: 79.4 [7.7] years; standardized mean difference, 12%). The proportion of female patients who underwent TAVI declined from 47.6% in 2013 to 43.6% in 2022 (P < .001). Compared with men, women had higher periprocedural mortality (2.5% vs 2.2%; AOR, 1.20 [95% CI, 1.14-1.26]), vascular complications (5.8% vs 3.6%; AOR, 1.65 [95% CI, 1.60-1.71]), and bleeding (10.4% vs 6.8%; AOR, 1.67 [95% CI, 1.62-1.71]) but less PPI (16.9% vs 20.0%; AOR, 0.81 [95% CI, 0.79-0.82]). Long-term mortality was lower in female patients (AHR, 0.92; 95% CI, 0.91-0.93), although their risks of HF hospitalization, AMI, stroke, and bleeding were higher. CONCLUSIONS AND RELEVANCE: Among Medicare beneficiaries, women constituted a progressively declining proportion of patients treated with TAVI, experienced more periprocedural complications, and demonstrated modestly better long-term survival compared with men. Further work is needed to understand factors influencing these trends and to refine sex-specific strategies for optimal outcomes.

Validation of a 2-Gene Blood Test for Kawasaki Disease in Febrile Children.

IMPORTANCE: Kawasaki disease (KD) remains a clinical diagnosis without an objective molecular test. Early identification is critical to prevent coronary artery complications through timely intravenous immunoglobulin therapy. OBJECTIVE: To validate a 2-gene whole-blood quantitative polymerase chain reaction (qPCR) assay measuring IFI27 and MCEMP1 expression for distinguishing KD from other pediatric febrile illnesses. DESIGN, SETTING, AND PARTICIPANTS: This multicenter diagnostic study was conducted in Taiwan and Shanghai, China. Patient blood samples were collected prospectively between 2012 and 2023 in Taiwan and between 2022 and 2023 in Shanghai and analyzed retrospectively from children younger than 8 years with KD and febrile controls (FCs) with viral, bacterial, or mixed infections. Data were analyzed from January 2022 to August 2025. MAIN OUTCOMES AND MEASURES: Diagnostic accuracy of a prespecified 2-gene KD score derived from change in cycle threshold values normalized to glyceraldehyde 3-phosphate dehydrogenase, assessed by area under the receiver operating characteristic curve (AUC), sensitivity, specificity, predictive values, and likelihood ratios. RESULTS: A total of 541 children (mean [SD] age, 3.7 [1.9] years; 300 [55.5%] male), including 243 children with KD and 298 febrile controls, were analyzed. The KD score achieved an AUC of 0.91 (95% CI, 0.88-0.94), with a sensitivity of 94% (95% CI, 93%-97%) and a specificity of 82% (95% CI, 78%-86%). The positive likelihood ratio was 5.12, and the negative likelihood ratio was 0.05. Performance was consistent across cohorts, including incomplete KD, diverse FC etiologies, and coronary artery phenotypes. The assay was implemented as a laboratory-developed test. Analytical validation demonstrated high linearity (R2 > 0.99), precision (coefficient of variation <5%), and sample stability for up to 6 days at 4 °C or for 24 hours at room temperature. CONCLUSIONS AND RELEVANCE: This diagnostic study found that a 2-gene laboratory-developed whole-blood qPCR assay measuring IFI27 and MCEMP1 expression accurately distinguished KD from other febrile illnesses using standard molecular platforms. Prospective evaluation in broader populations is warranted to determine its clinical utility for reducing diagnostic delay and coronary complications.

Iron Deficiency Criteria for Patients Undergoing Transcatheter Aortic Valve Replacement: - JACC Journals

Iron Deficiency Criteria for Patients Undergoing Transcatheter Aortic Valve Replacement:&nbsp;&nbsp;JACC Journals

Successful Bailout for Transcarotid Delivery Failure of Transcatheter Aortic Valve: - JACC Journals

Successful Bailout for Transcarotid Delivery Failure of Transcatheter Aortic Valve:&nbsp;&nbsp;JACC Journals

ICARUS: Intentional Clip Annular Reduction for Subsequent Replacement - JACC Journals

ICARUS: Intentional Clip Annular Reduction for Subsequent Replacement&nbsp;&nbsp;JACC Journals

JACC: Safety and Feasibility of TAVR in Hematologic Neoplasms

JACC: TAVR Safety in Hematologic Neoplasms

Beyond Valve Deployment: Real-Time Hemodynamic Optimization During the Double-Tap Technique in TAVR.

Leaflet Perforation During TAVR for Pure Aortic Regurgitation: Importance of the Annulo-Aortic Angulation.

Transcatheter Annuloplasty Using the Cardioband System: Insights From a European Multicenter Registry (TITAN Registry).

First Large Comprehensive Core-Laboratory Evaluation of Implantation Depth and Clinical Outcomes in TAVR: Final Global Results from the Optimize PRO Prospective Study.

UNLABELLED: (350/350) BACKGROUND: Standardized implant protocols have shown promise in improving outcomes in transcatheter aortic valve replacement (TAVR). However, the impact of implant depth on clinical outcomes remains unclear. OBJECTIVES: To evaluate clinical and hemodynamic outcomes across varying TAVR implantation depths using data from the Optimize PRO study. METHODS: This prospective, multicenter Optimize PRO study included patients with symptomatic severe aortic stenosis undergoing TAVR with Evolut PRO/PRO+ systems. Patients were stratified by core laboratory-adjudicated non-coronary cusp implant depth. The echocardiographic outcome composite included none/trace paravalvular regurgitation, aortic mean gradient ≤10mmHg and no prosthesis-patient-mismatch at discharge. RESULTS: Patients (N=603) were stratified by implant depth: <1mm (N=88), 1 to ≤3mm (N=196), >3 to ≤5mm (N=170), and >5mm (N=149). Baseline characteristics were similar across implant depth groups, except for a higher proportion of females in higher implant depths. Higher implant depths were associated with less resheathing and recapture (27.3% [24/88], 33.7% [66/196], 48.8% [83/170], 51.7% [77/149]; P<.001), and shorter median [Q1, Q3] hospital stay (days: 1[1,1], 1[1,2], 2 [1,3], 2 [1,4]; P<.001). Rates of valve migration (0% [95% CI:NA], 0.5% [95% CI:0.1-3.6], 0.6% [95% CI:0.1-4.1], 1.3% [95% CI:0.3-5.3]; P=.63) were low across implant depth groups. The 1-year all-cause mortality or all-stroke rate was comparable across implant depth groups (8.1% [95% CI:3.9-16.2], 7.2% [95% CI:4.3-11.8], 10.7% [95% CI:6.9-16.5], 12.5% [95% CI:8.1-19.2]; P=.40). After 1 year, higher implant depths were associated with lower rates of permanent pacemaker implantation (PPI, 2.3% [95% CI:0.6-8.8], 9.2% [95% CI:5.9-14.3], 15.9% [95% CI:11.2-22.4], 20.3% [95% CI:14.6-27.7]; P<.001). Rates of New York Heart Association functional class I were numerically different across implant depth groups but did not reach statistical significance (NYHA, 77.8% [56/72], 71.8% [130/181], 65.2% [101/155], 67.7% [84/124], P=.09 across all classes). In males, echo outcome composite rates were not statistically different across depth groups (58.6%[17/29], 50.6% [39/77], 43.8% [35/80], 36.1% [26/72]; P=.14), although the exploratory trend test reached statistical significance (P=.02). CONCLUSIONS: Higher TAVR device implantation was associated with improved clinical outcomes with similar safety events, including valve migration, across depths. The long-term effect of this approach including the ability to perform redo-TAVR safely, will be further studied in the future.

Intermittent Left Bundle Branch Block After Transcatheter Aortic Valve Replacement: Electrophysiological and Clinical Significance.

CASE SUMMARY: An 87-year-old man with pre-existing first-degree atrioventricular block underwent transfemoral transcatheter aortic valve replacement (TAVR) for severe aortic stenosis. Postprocedure, he developed worsening first-degree atrioventricular block and intermittent left bundle branch block with a paradoxical electrocardiographic pattern: Slightly longer PR intervals were associated with narrow QRS beats, whereas shorter PR intervals resulted in marked QRS widening. Electrophysiology study revealed advanced infra-Hisian conduction disease, with greater prolongation of the His-ventricular interval before narrow QRS beats, prompting permanent pacemaker implantation. TAKE-HOME MESSAGE: This case demonstrates that intermittent left bundle branch block after TAVR-particularly when associated with marked PR prolongation preceding apparent QRS narrowing-warrants careful evaluation, as it may mask high-risk trifascicular disease.

PR Interval Alternans and the Mystery of Inverse Decremental Conduction.

CASE SUMMARY: A 73-year-old man with severe aortic stenosis and preexisting right bundle branch block (RBBB) underwent transcatheter aortic valve replacement. Postprocedural day 4 mobile cardiac outpatient telemetry revealed intermittent atrioventricular block. A 12-lead electrocardiogram obtained in the emergency department revealed PR interval alternans with RBBB, with longer PR following longer preceding RP intervals, and shorter PR following shorter RP intervals. He suddenly experienced cardiac arrest due to proximal atrioventricular block, requiring cardiopulmonary resuscitation. TAKE-HOME MESSAGES: Inverse decremental conduction, known as Yan conduction, demonstrates an inverse relationship between conduction time and frequency of upstream stimulation. Inverse decremental conduction within the left bundle branch in the setting of RBBB may manifest as PR alternans, heralding proximal atrioventricular block.

From Complete Heart Block to Torsades de Pointes: An Axis to Remember.

BACKGROUND: Complete atrioventricular block is a recognized cause of acquired QT prolongation and Torsades de Pointes. CASE SUMMARY: An 80-year-old woman with no known prior cardiac history presented to the emergency department with acute confusion and altered mental status. There was no reported history of syncope, palpitations or structural heart disease. Baseline electrocardiography demonstrated complete atrioventricular block with a stable junctional escape rhythm and marked corrected QT prolongation (QTc 545 ms). Continuous electrocardiography monitoring revealed sudden-onset polymorphic ventricular tachycardia consistent with Torsades de Pointes. TAKE-HOME MESSAGES: Cardiac memory-induced repolarization abnormalities can trigger Torsades de Pointes in complete complete atrioventricular block despite stable RR intervals. Sudden changes in QRS morphology and axis due to alteration of the escape rhythm during atrioventricular block with persistent T-wave orientation represent an important electrocardiographic warning sign (cardiac memory) because they may lead to further prolongation of the QTc interval and the onset of Torsades de Pointes.

7-Year Outcomes of Balloon-Expandable Versus Self-Expanding Valves in Women Undergoing Transcatheter Aortic Valve Replacement.

BACKGROUND: Female patients with aortic stenosis frequently present with a small aortic annulus (SAA), which may result in unfavorable echocardiographic cardiac function after transcatheter aortic valve replacement. However, evidence comparing the long-term outcomes of balloon-expandable valves (BEVs) and self-expanding valves (SEVs) in this context is limited. OBJECTIVES: This study compares the 7-year clinical outcomes after transcatheter aortic valve replacement using BEV and SEV in female patients. METHODS: Overall, 1,827 female patients treated with BEV and 805 treated with SEV were identified from the Optimized transCathEter vAlvular intervention-Transcatheter Aortic Valve Implantation (OCEAN-TAVI) registry. One-to-one propensity score matching (PSM) was performed to adjust for confounding factors, resulting in 744 matched patients per group. The primary clinical endpoints included all-cause mortality, stroke, and heart failure rehospitalization. RESULTS: Overall, 1,303 patients (87.6%) had a SAA. Echocardiographic assessments indicated that BEV had smaller effective orifice area and higher mean pressure gradient than did SEV throughout the follow-up period. In the PSM analysis, BEV was associated with lower all-cause mortality (51.5% vs 57.4%; log-rank, P = 0.021) and stroke at 7 years (10.8% vs 16.7%; Fine-Gray, P = 0.008). Heart failure rehospitalization rates were similar between groups. In multivariable analyses, valve type was not independently associated with long-term outcomes, and subgroup analyses considering annulus size yielded consistent results. CONCLUSIONS: For women predominantly presenting with a SAA, BEV demonstrated decreased echocardiac performance compared with SEV. Although PSM analysis indicated more favorable outcomes with BEV, valve type was not independently associated with long-term prognosis after multivariable adjustment. These findings suggest that both types of transcatheter heart valves may be an acceptable option in this patient population.

Antiplatelet Therapy and All-Cause Mortality After Transcatheter Aortic Valve Replacement: The TRITAVI Registry.

BACKGROUND: Current guidelines recommend single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement (TAVR) in patients without an indication for anticoagulation. This recommendation is mainly based on a better risk profile in terms of bleeding over dual antiplatelet therapy (DAPT), although data on mortality are inconclusive. OBJECTIVES: We analyzed 6-month and 24-month mortality associated with SAPT and DAPT after femoral TAVR from the Transfusion Requirements in Transcatheter Aortic Valve Implantation registry. METHODS: The Transfusion Requirements in Transcatheter Aortic Valve Implantation is a multicenter registry including 10,071 patients undergoing TAVR. For the purpose of the present study, 4,557 patients with indication to anticoagulation, nonfemoral access, recent percutaneous coronary intervention, and procedural complications were excluded. The remaining 5,514 patients (age 81 ± 7 years, 51% males) were discharged either on SAPT (n = 3,197) or DAPT (n = 2,317). RESULTS: The SAPT group, compared with the DAPT group, experienced lower 6-month all-cause mortality (2.4% vs 5.4%; log-rank P < 0.0001) and major bleeding (0.5% vs 1.3%; log-rank P = 0.001). SAPT was associated with reduced both cardiovascular (1.3%) and noncardiovascular mortality (1.1%), as compared to DAPT (2.2%, P = 0.008 and 3.2%, P = 0.0001, respectively). At 24-month follow-up, overall mortality remained significantly lower with SAPT vs DAPT (11.7% vs 14.2%; log-rank P = 0.007). Cox regression hazard model confirmed the association of DAPT with 6-month (adjusted HR: 1.69; 95% CI: 1.20-2.37; P = 0.002) and 24-month (adjusted HR: 1.21; 95% 1.01-1.46; P = 0.04) all-cause mortality. CONCLUSIONS: In a large real-world population of all comers undergoing TAVR, SAPT was associated with a significantly lower 6-month and 24-month all-cause mortality as compared with DAPT. (Transfusion Requirements in Transcatheter Aortic Valve Implantation [TRITAVI] Study; NCT03740425).

Achieving Commissural Alignment During Intra-Annular Self-Expandable Transcatheter Heart Valve Implantation With a Radiopaque Marker-Guided Technique.

Clinical Outcomes of the Prospective Pakistan Registry of Echocardiographic Screening in Asymptomatic Pregnant Women.

BACKGROUND: Cardiovascular disease is increasingly recognized as a leading nonobstetric cause of maternal morbidity and mortality worldwide, including low- and middle-income countries. OBJECTIVES: This study evaluated fetomaternal outcomes in women with and without structural heart disease (SHD). METHODS: From a total of 25,000 patients enrolled in the Prospective Pakistan Registry of Echocardiographic Screening in Asymptomatic Pregnant Women registry between February 2023 and April 2025, 489 pregnancies with SHD were identified and compared with 510 pregnancies without SHD. Adverse fetomaternal outcomes were evaluated in both groups as a composite endpoint, comprising fetal outcomes (preterm delivery, fetal death, or low birth weight) and maternal outcomes (maternal death and pulmonary edema). RESULTS: The SHD cohort had a higher mean maternal age (27.3 ± 5.7 vs 26.1 ± 5.2 years; P = 0.011) compared to the non-SHD cohort. Composite adverse maternal outcomes (3.7% vs 0.4%; P < 0.001), fetal outcomes (29.9% vs 13.3%; P < 0.001), and overall fetomaternal outcomes (30.7% vs 13.3%; P < 0.001) were significantly higher in the SHD compared to the non-SHD cohort. SHD was independently associated with adverse fetomaternal outcomes (adjusted OR: 2.67; 95% CI: 1.93-3.70; P < 0.001). CONCLUSIONS: Prospective Pakistan Registry of Echocardiographic Screening in Asymptomatic Pregnant Women is the first global study linking subclinical echocardiographic abnormalities in asymptomatic pregnant women to adverse fetomaternal outcomes. In a large cohort of asymptomatic pregnant women, an abnormal echocardiogram was found to be associated with 2- to 4 time as many adverse fetomaternal outcomes compared to a normal echocardiogram. Future studies are needed to evaluate optimal timing of screening, cost-effectiveness, and applicability of broad antenatal screening in higher-income countries.

Long-Term Outcomes After Transcatheter Aortic Valve Replacement in Nonagenarians: Impact of Frailty and Malnutrition.

BACKGROUND: The role of transcatheter aortic valve replacement (TAVR) in nonagenarians remains uncertain, especially regarding long-term outcomes and prognostic factors. OBJECTIVES: This study aimed to evaluate long-term outcomes of TAVR in nonagenarians, focusing on cause-specific mortality and the prognostic influence of frailty and malnutrition. METHODS: We analyzed 4,623 patients who underwent transfemoral TAVR in a multicenter Japanese registry, including 700 aged ≥90 years. Outcomes were followed for 5 years. We analyzed all-cause mortality, cause-specific mortality, and the prognostic impact of the Clinical Frailty Scale and Geriatric Nutritional Risk Index. RESULTS: At 5 years, all-cause mortality was higher in patients aged ≥90 years than in those <90 years (53.2% vs37.0%, P < 0.001), primarily due to noncardiovascular deaths such as senility and infections (32.5% vs 19.9%; P < 0.001). Cardiovascular mortality was similar (20.3% vs 17.0%; P = 0.198). Multivariable analysis showed that age ≥90 years was not an independent predictor; frailty and malnutrition were the strongest prognostic factors. A Clinical Frailty Scale-Geriatric Nutritional Risk Index heatmap revealed marked heterogeneity, identifying subgroups of nonagenarians with preserved nutrition and low frailty who achieved favorable long-term survival. CONCLUSIONS: In this large multicenter registry, excess mortality in nonagenarians after TAVR was driven mainly by noncardiovascular causes. Frailty and malnutrition, rather than chronological age, were central determinants of long-term outcomes. These findings emphasize that TAVR candidacy in nonagenarians should be guided on geriatric assessment of frailty and nutrition to identify patients most likely to achieve meaningful survival while avoiding futile interventions.

Severe Aortic Stenosis and Acute Hip Fracture: An Expedited TAVR-First Pathway.

CLINICAL CONDITION: An elderly man presented with severe symptomatic aortic stenosis (AS) and an acute acetabular fracture, representing a high-risk intersection of cardiovascular and orthopedic emergencies. KEY QUESTIONS: What are the mechanistic and clinical links between AS and hip fracture (HFx)? How should management balance the urgency of fracture fixation with the hemodynamic instability of severe AS? What are the logistical and procedural considerations for performing transcatheter aortic valve replacement (TAVR) in this setting? What antithrombotic strategy should guide periprocedural management? Which complications can be avoided with a structured, multidisciplinary pathway? OUTCOME: The patient underwent expedited, minimalist transfemoral TAVR under conscious sedation on day 1, followed by HFx repair on day 2. He recovered without complications, was discharged on day 4, and remained fully independent at 1 year with stable valve function and no paravalvular leak. TAKE-HOME MESSAGES: In carefully selected patients with severe AS and acute HFx managed at TAVR-capable centers, a coordinated, expedited TAVR-first strategy appears feasible and may enable safe, timely orthopedic repair and recovery. Antithrombotic management must be individualized. Multidisciplinary, time-sensitive management is essential, and patient selection remains paramount.

Platypnea-Orthodeoxia After TAVI for Severe Aortic Regurgitation: A Breathless Surprise.

BACKGROUND: Transcatheter aortic valve implantation (TAVI) is increasingly used in selected high-risk patients with severe native aortic regurgitation (AR). Postprocedural hemodynamic changes may cause unexpected complications. CASE SUMMARY: An 82-year-old woman underwent TAVI (JenaValve Trilogy 23 mm) for severe AR. She developed refractory hypoxemia due to platypnea-orthodeoxia syndrome from a patent foramen ovale (PFO) with right-to-left shunting. Percutaneous PFO closure (25/18 mm Amplatzer Talisman) restored oxygenation, and she was discharged in stable condition. DISCUSSION: AR correction alters ventricular loading and may reduce left-sided filling pressures, unmasking interatrial shunting, particularly in patients with preserved systolic function and septal hypertrophy. TAKE-HOME MESSAGE: Given the high prevalence of PFO, TAVI for AR may unmask right-to-left shunting, and platypnea-orthodeoxia syndrome should be considered in new-onset postprocedural hypoxemia.

Endocarditis Masquerading as Malignancy: Native Valve HACEK Infection.

BACKGROUND: HACEK (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) endocarditis is a rare cause of subacute infective endocarditis typically occurring in patients with pre-existing valvular pathology or structural heart disease. CASE SUMMARY: A 65-year-old male presented with months of night sweats, fevers, anemia, and weight loss concerning for malignancy. Transthoracic echocardiography was negative for vegetations. Blood cultures grew Aggregatibacter actinomycetemcomitans, and transesophageal echocardiography confirmed vegetations on the mitral and aortic valves. The patient was treated successfully with a 6-week course of intravenous ceftriaxone. DISCUSSION: This case highlights the diagnostic challenge of indolent HACEK endocarditis in the absence of traditional risk factors, presenting as malignancy, underscoring the importance of transesophageal echocardiography, even when transthoracic imaging is unrevealing. TAKE-HOME MESSAGE: In patients with persistent constitutional symptoms with negative malignancy workup, HACEK endocarditis should remain in the differential, and transesophageal echocardiography is essential for diagnosis.

Innovative Electrosurgery Application in the Era of TAVR-In-TAVR: A Step Forward in Regaining Coronary Access.

Intraprocedural Leaflet Dysfunction and the Importance of Device Planning in Contemporary Transcatheter Aortic Valve Replacement.

First-in-Human Mechanical Leaflet Modification of Native Aortic Stenosis During TAVR.

BACKGROUND: Coronary obstruction is a life-threatening complication of transcatheter aortic valve replacement (TAVR). Mechanical leaflet modification (LM) has been developed to mitigate this risk in patients with degenerated bioprostheses. However, their use in native valves has not previously been reported. CASE SUMMARY: We report two cases of mechanical LM performed in patients with severe native aortic stenosis at high risk for coronary obstruction during TAVR. In both cases, successful LM was achieved using a dedicated device (ShortCut, Pi-Cardia), followed by TAVR. Imaging validated leaflet split and preserved coronary flow. Post procedure the patients had optimal valve hemodynamics without neurological adverse events. DISCUSSION: These cases demonstrate the technical feasibility of dedicated mechanical LM in native calcific aortic valve disease. This strategy warrants further clinical investigation. NOVELTY: This report describes, to our knowledge, the first-in-human application of mechanical LM for native aortic stenosis at risk for coronary obstruction during TAVR.

Redo-TAVR (TAV-in-TAV) Best Practices Part 2: Tall-in-Short and Tall-in-Tall - A Heart and Valve Collaboratory Document.

Redo-TAVR (TAV-in-TAV) Best Practices Part 1: Short-in-Short and Short-in-Tall - A Heart and Valve Collaboratory Document.

SGLT-2 Inhibitors and Outcomes After Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.

BACKGROUND: Despite successful transcatheter aortic valve implantation (TAVI) for severe aortic stenosis, residual heart failure risk and postprocedural complications persist. OBJECTIVES: The aim was to assess the association between sodium glucose co-transporter 2 inhibitor (SGLT-2i) use and clinical outcomes in patients undergoing TAVI. METHODS: A systematic search was conducted across PubMed, Cochrane Library, Google Scholar, ScienceDirect, and ClinicalTrials.gov for eligible randomized controlled trials (RCTs) and observational studies. Adjusted HRs and risk ratios were pooled for time-to-event outcomes and dichotomous outcomes, respectively. Risk of bias was assessed using the Risk of Bias 2.0 and Risk of Bias in Non-randomized Studies of Interventions-I tools for RCTs and cohort studies, respectively. RESULTS: Six studies (1 RCT, 5 cohorts) including 35,075 patients were included in the analysis. In pooled analyses, SGLT-2i use was associated with a significantly lower risk of major adverse cardiovascular events (pooled HR: 0.65; 95% CI: 0.44-0.95; P = 0.03; I2 = 26%), heart failure hospitalization (pooled HR: 0.58; 95% CI: 0.40-0.86; I2 = 59%; P = 0.007), all-cause mortality (pooled HR: 0.71; 95% CI: 0.55-0.91; P = 0.007; I2 = 75%), and cardiovascular death (pooled risk ratio: 0.55; 95% CI: 0.34-0.89; P = 0.01; I2 = 36%). The Grading of Recommendations Assessment, Development, and Evaluation assessment was downgraded due to heterogeneity, potential bias, and nonrandomized design of studies. CONCLUSIONS: This meta-analysis suggests that peri-operative SGLT-2i use was associated with lower cardiovascular events post-TAVI albeit with low certainty due to predominance of observational studies. These findings are hypothesis generating rather than causal inference. Future clinical trials are warranted.

Transcarotid UNICORN Procedure to Facilitate Valve-in-Valve TAVR.

Leaflet Modification With the UNICORN Technique: Why CT Planning and TEE Guidance Matter.

Intra-Aortic Ultrasound Guidance for UNICORN Technique: First Description.

UNICORN for Native Transcatheter Aortic Valve Replacement in a Bicuspid Aortic Valve.

First-in-Human Transcatheter Aortic Root Tricuspidization of Stenotic Bicuspid Valves: A Strategy to Optimize TAVR.

First-in-Human Wire Anchoring-Assisted Leaflet Modification to Prevent Coronary Obstruction in TAVR.

Leaflet Modification to Mitigate Coronary Obstruction Risk During TAVR: Results From the LOFTER-TAVR Registry.

BACKGROUND: Coronary obstruction (CO) is a rare but life-threatening complication of transcatheter aortic valve replacement (TAVR). Leaflet modification techniques have been developed to mitigate this risk; however, real-world evidence remains scarce. OBJECTIVES: The aim of this study was to report procedural and 30-day outcomes of patients at high risk for CO undergoing leaflet modification. METHODS: LOFTER-TAVR (Leaflet mOdiFication Techniques to prEvent coRonary obstruction risk during Transcatheter Aortic Valve Replacement) was an international, multicenter registry of consecutive patients undergoing leaflet modification before TAVR (September 2019 to January 2026). Coprimary endpoints were leaflet modification-directed technical success and Valve Academic Research Consortium 3 (VARC-3) technical success. Secondary endpoints included in-hospital and 30-day outcomes. RESULTS: A total of 293 patients underwent leaflet modification, including 202 (68.9%) through a leaflet-splitting approach and 91 (31.1%) through an intraleaflet disruption approach. Overall, 139 of 293 (47.4%) treated valves were natives. Successful leaflet traversal occurred in 310 of 318 leaflets (97.5%; 95% CI: 94.9%-98.9%) and successful leaflet modification in 306 of 318 leaflets (96.2%; 95% CI: 93.3%-97.9%). Leaflet modification-directed technical success was achieved in 251 of 293 patients (85.7%; 95% CI: 81.0%-89.4%) and VARC-3 technical success in 254 of 293 patients (86.7%; 95% CI: 82.1%-90.3%). Notably, 91.1% (95% CI: 87.1%-94.0%) of patients underwent TAVR without CO events. Delayed CO occurred in 3 of 293 patients (1.0%; 95% CI: 0.3%-3.0%). The median follow-up duration was 100 days (Q1-Q3: 30-443 days). At 30 days, freedom from VARC-3 early safety was achieved in 181 of 293 patients (61.8%; 95% CI: 56.5%-67.6%). CONCLUSIONS: Leaflet modification techniques demonstrated high technical feasibility across a broad anatomical spectrum but carried considerable early clinical risk. These findings support its role as an adjunctive strategy for selected patients undergoing TAVR, although in the context of careful preprocedural planning and a structured multidisciplinary approach.

BATMAN for Prevention of LVOT Obstruction: When Simplicity Meets Anatomical Reality.

Frame Matters: Platform-Specific Barriers to Leaflet Modification in Redo-TAVR.

BenchTop Validation of UNICORN Leaflet Modification Technique in Redo-Transcatheter Aortic Valve Replacement.

BACKGROUND: Coronary obstruction is a critical risk in valve-in-valve transcatheter aortic valve replacement (TAVR). The UNICORN (undermining iatrogenic coronary obstruction with radiofrequency needle) technique mitigates this risk via intraleaflet valve deployment. However, comprehensive bench testing data regarding this technique is lacking in the literature. OBJECTIVES: The aims of this study were to evaluate leaflet behavior after intraleaflet balloon dilatation across different transcatheter heart valve (THV) platforms, simulate the crossing of a second THV across de novo fenestrations, and understand leaflet behavior during and after deployment. METHODS: In vitro bench testing used 4 index THV platforms: SAPIEN 3, Evolut, Navitor, and ACURATE neo2. Following leaflet traversal, target leaflets underwent sequential balloon dilatation (8-14 mm). We assessed the maximum balloon size tolerated without laceration, the minimum size required for a second balloon-expandable THV (SAPIEN 3 Ultra RESILIA) to cross the fenestration, deployment feasibility, and postdeployment valve geometry. RESULTS: Most index THV leaflets tolerated balloon dilatation up to 12 to 14 mm without laceration. A minimum fenestration size of 12 to 14 mm facilitated most of the second THV crossing. Postdeployment models confirmed coronary clearance on the treated side. Successful intraleaflet THV deployment was achieved with the SAPIEN 3, Evolut, and ACURATE neo2. Conversely, intraleaflet deployment in the Navitor (and Portico) platform was unsuccessful; the leaflet remained intact following expansion, resulting in frame distortion and inner-valve tilting possibly due to stiff leaflet and compliant frame. CONCLUSIONS: This bench study defines optimal balloon sizing for UNICORN across common THV platforms and confirms coronary clearance. It was determined that one index valve resisted intraleaflet deployment. Further clinical validation is required before widespread adoption.

Leaflet Modification Technique With UNICORN in Failed Aortic Bioprosthesis: Procedural Step-by-Step, Best Practice, and Troubleshooting.

The UNICORN (undermining iatrogenic coronary obstruction with radiofrequency needle) technique was developed in 2022 to reduce the risk for coronary obstruction during valve-in-valve transcatheter aortic valve replacement. The procedure involves traversing the target leaflet with an electrified wire, followed by serial dilation with coronary and peripheral balloons. A balloon-expandable valve is then delivered into the de novo fenestration for intraleaflet deployment. As the balloon-expandable valve expands, the target leaflet is opened and displaced away from the at-risk coronary ostium, resulting in a minimal neoskirt on the target side. Since its introduction, the technique has been adopted at numerous centers worldwide, with various modifications and adaptations. In this paper, a step-by-step description of the UNICORN procedure is provided, and troubleshooting strategies for potential challenges are discussed.

Successful Bailout for Transcarotid Delivery Failure of Transcatheter Aortic Valve.

CASE SUMMARY: Transcarotid-transcatheter aortic valve implantation (TC-TAVI) generally enables smooth transcatheter heart valve crossing given its proximity to the aortic annulus; however, severe anatomical constraints may still lead to delivery failure. We report a TC-TAVI case in which transcatheter heart valve passage across the aortic valve was initially unsuccessful because of aortic angulation and extensive leaflet calcification. This technical difficulty was effectively resolved using the buddy balloon technique, which enabled successful valve advancement. This case demonstrates that the superior pushability of the TC approach may not overcome extreme anatomical resistance, necessitating predilatation aggressively indicated for such challenging anatomies. TAKE-HOME MESSAGES: Pronounced aortic angulation and severe leaflet calcification can hinder transcatheter heart valve delivery, even during TC-TAVI, where easier valve crossing is typically anticipated. These anatomical factors remain significant predictors of delivery failure, irrespective of the vascular access route.

Intravascular Ultrasound-Guided and Angiography-Guided Chimney Stenting for Proactive Coronary Protection in High-Risk TAVR.

BACKGROUND: We report a proactive coronary protection strategy during transcatheter aortic valve replacement (TAVR) using intravascular ultrasound (IVUS)-guided decision making and chimney stenting in patients with high-risk anatomy. CASE SUMMARY: Two patients with severe symptomatic aortic stenosis and unfavorable coronary anatomy on preprocedural computed tomography underwent TAVR with planned coronary protection. Despite preserved angiographic flow after valve deployment, IVUS identified critical leaflet-to-coronary proximity in one case, whereas significant ostial compromise was detected by angiography in the other. Chimney stenting was performed, ensuring maintained coronary patency. Both patients had favorable clinical outcomes without periprocedural complications and good follow-up results. DISCUSSION: These cases highlight some limitations of angiography and the complementary value of IVUS in selected situations and support a proactive decision-making process for an imaging-guided approach to coronary protection during TAVR. TAKE-HOME MESSAGE: A proactive, imaging-guided decision-making approach to coronary protection is recommended in cases of high-risk TAVR.

BEVs Versus SEVs in Women With Small Annuli: 7-Year Insights From the OCEAN-TAVI Registry.

Effect of Nominal-Volume ("Double Tap") Postdilatation on Significant THV Mid-Stent Frame Underexpansion After Balloon-Expandable TAVR.

Minimally Invasive TAVR Explantation and Aortic Valve Replacement in a Patient With a Retrosternal Conduit.

BACKGROUND: Reports of minimally invasive approaches, such as right minithoracotomy, for valve surgery after transcatheter aortic valve replacement (TAVR) are limited, particularly in patients undergoing retrosternal esophageal reconstruction. CASE SUMMARY: A 78-year-old woman with a retrosternal colonic conduit postesophagectomy underwent transfemoral TAVR 4 years ago. She presented with progressive dyspnea due to structural valve degeneration. Valve-in-valve TAVR was unsuitable because of the anticipated patient-prosthesis mismatch. A right minithoracotomy was performed to avoid conduit injury. The degenerated prosthesis was safely explanted using traction sutures and forceps-assisted crushing, and a sutureless prosthesis was implanted. Concomitant mitral and tricuspid annuloplasty and excision of the left atrial appendage were also performed. Postoperative echocardiography confirmed normal function of the implanted aortic valve. DISCUSSION: When valve-in-valve TAVR is not feasible, minimally invasive TAVR explantation via right minithoracotomy may be considered to avoid conduit injury. TAKE-HOME MESSAGES: TAVR explantation and redo aortic valve replacement can be safely performed via the right minithoracotomy approach. In patients undergoing retrosternal conduit reconstruction, a right minithoracotomy approach is useful for avoiding conduit injury. Pericardial suspension allows the reconstructed conduit to be held and effectively protected during the surgery.

From Theory to Practice: GPT-Supported Data Extraction in Observational Studies on Transcatheter Aortic Valve Replacement.

BACKGROUND: Manual record abstraction is the standard method for data collection in observational studies but is labor-intensive, error-prone, and difficult to scale, particularly when information is embedded in unstructured electronic health records. Large language models (LLMs) may streamline this process, yet evidence from real-world clinical research remains limited. OBJECTIVES: This study evaluated the performance of a generative pre-trained transformer (GPT)-based LLM in extracting sociodemographic, procedural, and outcome variables from free-text electronic health records of patients undergoing transcatheter aortic valve replacement. METHODS: We conducted a retrospective analysis of medical and nursing records for all transcatheter aortic valve replacement procedures performed at Ca' Foncello Hospital (Treviso, Italy) between January and June 2024. Manual abstraction by 2 reviewers served as the reference standard. Accuracy, sensitivity, and specificity with 95% CIs were calculated. Agreement for continuous variables was assessed using Bland-Altman analyses. RESULTS: A total of 108 cases were included. GPT achieved accuracy ranging from 0.657 (valve brand) to 1.00 (gender, Barthel index, procedure timings, and several intraoperative complications). Sensitivity reached 1.00 for rare but clinically important events, including intraoperative neurological complications, whereas specificity exceeded 0.90 for most variables. For vital parameters, Bland-Altman analyses demonstrated minimal bias and narrow limits of agreement. CONCLUSIONS: GPT-based data extraction showed high accuracy across a broad range of variables, particularly continuous repeated measurements and rare intraoperative outcomes. Performance was lower for some infrequent postoperative events, reflecting sparse true positives. These findings support the feasibility of integrating LLM-assisted extraction into observational research workflows, with further validation needed in larger or multicenter cohorts.

Modified Guide Anchoring "UNICORN" Technique for Valve-in-Valve TAVI: Navigating Hostile Anatomy With Leaflet Laceration.

BACKGROUND: Sutureless bioprostheses present unique challenges for valve-in-valve (ViV) transcatheter aortic valve implantation due to their frame architecture and proximity to coronary ostia. CASE SUMMARY: A 71-year-old woman with a failing Perceval valve with high-risk coronary anatomy precluding chimney stenting and Bioprosthetic Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction. Leaflet traversal of the right coronary cusp was achieved through an MPA1 guide. The guide was advanced across the bioprosthetic frame into the left ventricle immediately post-traversal to secure position. This facilitated wire exchange and leaflet laceration. A balloon-expandable valve was then successfully implanted. DISCUSSION: Unlike stented valves, the sutureless valve crown creates a mechanical trap. Its 1-mm clearance precluded chimney stenting due to sandwich compression risk, whereas effaced sinuses prevented Bioprosthetic Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction leaflet splaying. The modified UNICORN guide anchoring maneuver bypassed these hurdles, securing the ventricle to facilitate stable, efficient mechanical modification in no-option anatomy. TAKE-HOME MESSAGE: Guide anchoring provides a shorter blueprint for complex scenarios by securing ventricular access and enabling mechanical laceration.

Leaflet Avulsion Following Leaflet Splitting During Valve-in-Valve Transcatheter Aortic Valve Replacement.

Bailout LLAMACORN for BASILICA Failure.

2 for 1: Perfusing Both Coronary Sinuses With Solo BASILICA.

Commissural Misalignment-Mediated Sinus Sequestration Following Balloon-Augmented BASILICA During Redo-TAVR.

Multileaflet BASILICA to Prevent Coronary Obstruction in a Small Aortic Annulus.

BASILICA for TAVR After Ozaki Aortic Valve Neocuspidization.

Impact of Leaflet Modification on Redo-TAVR Feasibility: A Computed Tomography Simulation Study.

On-Table LM View to Predict Left Main Obstruction in TAV-in-TAV.

Evolution in Transcatheter Heart Valve Technology: The Role of Bench Testing.

Impact of Tissue Treatment and Leaflet Design on Fifth-Generation Balloon-Expandable Transcatheter Heart Valve Function.

BACKGROUND: The SAPIEN 3 Ultra RESILIA (S3UR) transcatheter heart valve incorporates RESILIA-treated tissue and new commissural attachments in smaller valve sizes (20 and 23 mm). However, detailed performance data are lacking. OBJECTIVES: The aim of this study was to compare the S3UR with the SAPIEN 3 Ultra (S3U) transcatheter heart valve on the bench for transcatheter aortic valve replacement (TAVR), valve-in-valve (VIV), and redo-TAVR. METHODS: For index TAVR, 23- and 26-mm S3UR and S3U valves were compared at nominal size and during underexpansion. For VIV testing, 23-mm study valves were implanted in 25-mm Epic and 23-mm Mitroflow valves. Redo TAVR involved the implantation of 23-mm study valves in a 26-mm Evolut PRO valve. Hydrodynamic testing assessed mean gradient (MG), geometric orifice area, effective orifice area (EOA), opening index, pinwheeling, and leaflet motion. Histology, light transmission, micrometering, micro-computed tomography, and uniaxial tensile testing compared S3UR and S3U pericardium samples. Leaflet splay area was compared after leaflet modification. RESULTS: For index TAVR, 26-mm S3U and S3UR valves demonstrated comparable performance. In contrast, the 23-mm S3UR valve showed a lower MG (6.7 mm Hg vs 7.3 mm Hg) and larger EOA, geometric orifice area, and opening index than the 23-mm S3U valve, with MG differences increasing during underexpansion. In VIV, the 23-mm S3UR valve demonstrated systolic leaflet fluttering and hydrodynamics similar to those of S3U. In redo-TAVR, the S3UR showed a slightly lower MG and a marginally larger EOA. By micrometering, S3UR leaflet pericardium was thinner than S3U leaflet pericardium (0.28 ± 0.02 mm vs 0.36 ± 0.03 mm), but S3UR pericardium showed significantly higher tensile strength. S3UR leaflets splayed almost 40% less after modification with a central basal split. CONCLUSIONS: Commissural changes in smaller S3UR valves and thinner leaflets drive differences in hydrodynamics, leaflet motion, tensile strength, and leaflet splay after leaflet modification. This warrants further study.

Decoding Redo-TAVR: Moving Beyond Intuition to Standardized Leaflet Modification.

A Proposed Anatomical-Fluoroscopic Workflow to Identify the Optimal Split Line for Leaflet Modification in Redo-TAVR.

BACKGROUND: The optimal leaflet modification strategy in redo transcatheter aortic valve replacement (TAVR) needs further refinement. OBJECTIVES: The aims of this study were to clarify the anatomical relationship between transcatheter aortic valve leaflets and related structures by assessing leaflet suture lines, nodes, and commissural tabs and to propose a workflow to guide leaflet modification in redo-TAVR. METHODS: The leaflet suture line and its relationship with nodes and commissural posts on the frames of SAPIEN 3, Evolut, Navitor, and ACURATE neo2 transcatheter aortic valves were identified. Leaflet regions were classified as modifiable, challenging, or nonmodifiable. Vertical leaflet split lines within the modifiable zone were proposed, and the lowest node along each split line was identified as a fluoroscopic landmark to guide leaflet modification. Preprocedural computed tomography helped determine the relationship between commissural orientation and coronary ostia to identify ideal split line(s) in proximity to the ostia to avoid obstruction. RESULTS: For each valve type, the leaflet suture line and its relationship to commissural posts and valve frame were visible at multiple perspectives. The number and respective lengths of proposed split lines were identified (SAPIEN 3, A-D, 6.0-16.0 mm; Evolut, A-E, 5.0-13.0 mm; Navitor, A-C, 10.0-23.0 mm; and ACURATE neo2, A-D, 7.0-18.0 mm). Preprocedural computed tomography identified the ideal split line(s) facing the coronary ostia. A 4-step workflow to guide leaflet modification in redo-TAVR was proposed. CONCLUSIONS: The authors propose a systematic, imaging-guided approach to leaflet modification in redo-TAVR. Further studies are ongoing to evaluate and validate its feasibility and effectiveness.

Redo-TAVR Leaflet Modification: When Mechanics Trump Technique and Why Lifetime Strategy Begins With the First Valve.

Leaflet Modification for Redo-TAVR: Impact of Valve Type, Expansion, and Failure Mode-A Bench Study.

BACKGROUND: Leaflet modification (LM) techniques are of interest in redo transcatheter aortic valve replacement (TAVR). However, factors impacting the efficacy of LM are poorly understood. OBJECTIVES: The aim of this study was to investigate the effects of valve constraint, redo-TAVR sizing, flow, and valve pathology on LM efficacy. METHODS: Naive and degenerated transcatheter heart valves (THVs) were used to evaluate BASILICA (bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction), balloon-assisted BASILICA (BA-BASILICA), and balloon laceration. Conditions included: 1) degree of annular constraint of the index THV (modeled using different annular sizes); 2) flow conditions during deployment of the second THV (pulsatile vs continuous flow in a simulated deployment system); 3) leaflet modification pattern; 4) degree of oversizing of the second THV; and 5) extent and type of leaflet degeneration in the index THV. Quantitative outcomes included splay area, functional splay area, and variability in splay geometry across repeated deployments. RESULTS: When unconstrained, BASILICA created a splay in SAPIEN, Evolut, and ACURATE valves but not in Navitor valves, with BA-BASILICA improving splay for ACURATE and Evolut valves. Annular constraint at the minimum diameter per the THV instructions for use reduced splay in all THVs, with the greatest effect in Evolut valves. Nonbasal and angled leaflet splits impacted leaflet splay. Simulated redo-TAVR under flow conditions caused variability of leaflet splay for all THVs. Balloon laceration resulted in highly variable splay patterns ranging from complete clearance to obstruction. Oversizing of the second THV resulted in larger splay areas. Leaflet fibrosis diminished functional splay area. Increasing calcification resulted in irregular cuts and decreased splay. CONCLUSIONS: Leaflet splay following LM for redo-TAVR is highly dependent on THV type and constraint, implantation of the second THV, laceration pattern, and the nature of index THV degeneration.

Comparison of Leaflet Modification Techniques for TAV-in-TAV: Insights From Bench Testing.

BACKGROUND: Transcatheter aortic valve (TAV) leaflet modification can reduce the risk for coronary obstruction caused by the leaflet neoskirt created during TAV-in-TAV procedures. OBJECTIVES: The aim of this study was to evaluate the leaflet splay geometry created by different leaflet modification techniques across the spectrum of TAV-in-TAV combinations. METHODS: BASILICA (bioprosthetic or native aortic scallop laceration to prevent iatrogenic coronary artery obstruction during TAV replacement), balloon-assisted BASILICA (BA-BASILICA), and UNICORN (undermining iatrogenic coronary obstruction with radiofrequency needle) were simulated on the bench in short-in-tall, short-in-short, and tall-in-short TAV-in-TAV combinations. High-resolution images were used to evaluate leaflet splay geometry and measure the leaflet splay area. Splay obstruction caused by the skirt from the index or second TAV was subtracted from the leaflet splay area to define the functional splay area (FSA). Factors influencing the FSA were evaluated. RESULTS: Across all tested TAV-in-TAV combinations, BASILICA and BA-BASILICA created similar vertical V-shaped LSAs, measuring between 19.2 and 64.9 mm2. UNICORN created the largest LSAs for short-in-tall and short-in-short combinations, measuring 2 to 10 times larger than those created with BASILICA and BA-BASILICA. UNICORN with intraleaflet deployment was not feasible for tall-in-short combinations and required predeployment balloon laceration of the leaflet, which created an unpredictable splay outcome. The greatest degree of splay obstruction, up to 93%, was observed for tall-in-short combinations, resulting in the smallest FSA after BASILICA and BA-BASILICA. The FSA following leaflet modification could be improved by ensuring commissural alignment and lowering the implantation depth of the second TAV. CONCLUSIONS: BASILICA and BA-BASILICA create similar sized vertical splays in the leaflet neoskirt, whereas UNICORN generates larger FSAs but only when intraleaflet deployment is feasible. The design, alignment, and implantation depth of the second TAV may influence the FSA after leaflet modification.

Cracks in the BASILICA: Stentless ViV-TAVR.

Coronary Obstruction During TAVR: A Rare Catastrophic Risk Requiring Anticipation, Vigilance, and Readiness.

CT-Based Risk Stratification of Coronary Obstruction During TAVR: Clinical Utility and a New Volumetric Parameter.

BACKGROUND: Coronary obstruction (CO) during transcatheter aortic valve replacement (TAVR) is rare but potentially fatal. Computed tomography (CT)-based risk assessment algorithms aim to identify high-risk patients, but their utility remains underexplored. OBJECTIVES: The aim of this study was to examine the clinical utility of a CT-derived algorithm for predicting CO during TAVR and identify predictors of CO despite coronary protection (CP). METHODS: In this prospective study, 164 patients at risk for CO during TAVR were enrolled. Preprocedural CT was used to classify risk using a published algorithm. A novel volumetric parameter, valve-to-coronary volume (VTCV), was calculated in high-risk cases using sinus width and valve-to-coronary (VTC) distance. The decision to use CP was left to the heart team. Clinical endpoints followed Valve Academic Research Consortium 3 definitions. RESULTS: According to the CT-based algorithm, 58.5% of patients (96 of 164) were at low risk, 24.4% (40 of 164) at intermediate risk, and 17.1% (28 of 164) at high risk. CP was performed in 12.8% of low-risk patients (16 of 125), 52.8% of intermediate-risk patients (28 of 53), and 93.9% of high-risk patients (31 of 33). All CO events (n = 7) occurred in the high-risk group. VTC distance and VTCV were significantly lower in patients with CO (P = 0.006 and P = 0.005, respectively). VTCV independently predicted CO (area under the curve, 0.841; 95% CI: 0.702-0.979; P < 0.001), outperforming VTC distance alone. The predictive value of VTCV was validated in an external cohort including 11 European centers. CONCLUSIONS: A CT-based algorithm stratifies patients into 3 CO risk categories, though the decision for CP in clinical practice seems to incorporate additional clinical and procedural variables. Although CP reduces CO risk, its efficacy is limited in patients with very small VTCV, which can be predicted preprocedurally via CT. (Leipzig TAVR Registry; NCT05015452).

Leaflet Modification in Valve-in-Valve Transcatheter Aortic Valve Replacement: Potential Benefits Beyond Coronary Protection.

Impact of Leaflet Modification on the Occurrence of Hypoattenuated Leaflet Thickening After Valve-in-Valve Transcatheter Aortic Valve Replacement.

BACKGROUND: Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) is an established therapy for failed bioprosthetic valves but carries risks for coronary obstruction and subclinical leaflet thrombosis, characterized by hypoattenuated leaflet thickening (HALT) on multidetector computed tomography. Intentional leaflet modification techniques, such as BASILICA (bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction), have been developed to prevent coronary obstruction, but their impact on leaflet thrombosis remains unclear. OBJECTIVES: The aim of this study was to evaluate the association of intentional leaflet modification with the incidence of HALT in patients undergoing ViV TAVR. METHODS: In a retrospective analysis of 141 patients undergoing ViV TAVR with postprocedural multidetector computed tomography, 61 patients received leaflet modification, and 80 underwent standard ViV TAVR without leaflet modification. Baseline characteristics, post-TAVR computed tomographic findings including HALT, and other procedural outcomes were compared. A sensitivity analysis stratified outcome by transcatheter heart valve type. Predictors of HALT were assessed using multivariable logistic regression with clinically relevant covariates. RESULTS: Leaflet modification was more frequently performed in female patients (62.3% vs 45%; P = 0.04) and those with small (≤21 mm) prosthetic valves (50% vs 22.5%; P < 0.001). Patients undergoing leaflet modification had significantly lower postprocedural mean transvalvular gradients (13 ± 6 mm Hg vs 18 ± 9 mm Hg; P < 0.001) and a reduced incidence of HALT (19.7% vs 40%; P < 0.01) compared with those without leaflet modification. These findings persisted after the analysis was restricted to self-expanding transcatheter heart valves. HALT involving multiple leaflets was numerically less common with leaflet modification (33.3% vs 65.6%; P = 0.054), and thrombosis predominantly affected nonlacerated cusps (66.6% vs 33.3%). No cases of HALT were observed in patients undergoing dual-leaflet modification. Reduced leaflet motion was identified in one-third of patients with HALT, with no significant difference between groups. CONCLUSIONS: In patients undergoing ViV TAVR, intentional leaflet modification is associated with a significantly reduced incidence of HALT, suggesting a protective association with subclinical leaflet thrombosis. These results support a potentially hemodynamic benefit of leaflet modification beyond coronary obstruction prevention.

Pulmonary Artery Perforation From Right Heart Catheterization: Successful Management Using the Ping Pong Guide Technique.

BACKGROUND: Pulmonary artery perforation is an uncommon complication of right heart catheterization (RHC), with potentially lethal consequences. CASE SUMMARY: An older woman undergoing transcatheter edge-to-edge repair under general anesthesia, had sudden bleeding from her endotracheal tube after RHC. This was followed by de-saturation and drop in blood pressure. Repeat RHC demonstrated left pulmonary artery perforation and pseudoaneurysm. Following wedge balloon occlusion of the perforation, a second femoral access was used to deliver a 12-mm Amplatzer vascular plug to seal the neck. The ping pong technique controlled active bleeding and allowed for successful device delivery for definitive management. DISCUSSION: Pulmonary artery perforation is both a rare and lethal complication that requires rapid diagnosis and treatment. TAKE-HOME MESSAGES: Respiratory tract bleeding following RHC should be considered pulmonary artery perforation until proven otherwise. The Ping Pong Guide technique is a feasible and safe treatment option.

Understanding Outcomes in Hemodialysis Patients Who Underwent Transcatheter Aortic Valve Replacement With the Latest Devices.

BACKGROUND: The poor prognosis of hemodialysis (HD) patients following transcatheter aortic valve replacement (TAVR) has been established; however, data on the outcomes in the latest generation of devices remain inconsistent. OBJECTIVES: The authors aimed to compare the 1-year clinical outcomes post-TAVR using the latest generation of devices in HD and non-HD patients. METHODS: From the multicenter registry, 760 HD and 3,928 non-HD patients were identified from the OCEAN-TAVI (Optimized transCathEter vAlvular iNtervention-Transcatheter Aortic Valve Implantation; UMINID:000020423) registry. To minimize differences in baseline characteristics, 1:1 propensity score matching (PSM) was performed (490 patients each). The primary clinical endpoint was all-cause mortality at 1 year. Secondary endpoints included cardiovascular death, stroke, and heart failure rehospitalization. RESULTS: In the overall cohort, during 208 (41-373) days of follow-up, HD patients had higher 1-year mortality than non-HD patients (105 of 760 [13.8%] vs 189 of 3,928 [4.8%], HR: 2.62; 95% CI: 2.13-3.23; P < 0.001); this difference was attenuated (59 of 490 [12.0%] vs 65 of 490 [13.3%], HR: 1.03; 95% CI: 0.75-1.42; P = 0.858) following well-balanced PSM. There were no significant differences in any secondary endpoints between the 2 groups after PSM; however, HD remained an independent predictor of 1-year mortality in a multivariate analysis of the cohort before PSM. CONCLUSIONS: The poor prognostic value of HD was attenuated after adjusting for baseline risk factors. These findings suggest that the poor outcomes of HD patients result from the burden of multiple comorbidities in addition to the HD risk itself. Considering TAVR as a treatment option for exceptionally high-risk populations will aid in the careful patient selection and realistic prognostic assessments.

Valve-in-Valve TAVR for Degenerated Perceval Valves: From Entrapment to Success.

BACKGROUND: Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is an established treatment option for bioprosthetic valve failure. The sutureless Perceval bioprosthesis presents unique technical challenges because of the valve's supra-annular nitinol ring, lack of radiopaque markers, and potential difficulty with central valve crossing and entrapment of devices within the supra-annular ring. CASE SUMMARY: We report 2 cases of Perceval degeneration managed with ViV-TAVR using balloon-expandable Edwards Sapien 3 Ultra valves. In the first case, standard retrograde crossing led to delivery system entrapment despite multiple conventional methods for assessing central crossing, requiring multiple complex bailout maneuvers including balloon-assisted displacement and TAVR delivery system snaring. In the second case, after failed central retrograde crossing, antegrade transseptal approach with arteriovenous loop formation enabled precise central crossing. After wire externalization via the femoral artery, standard retrograde TAVR delivery and successful valve deployment were performed without complication. Both patients experienced favorable outcome and symptom resolution at follow-up. TAKE-HOME MESSAGES: These cases highlight the importance of preprocedural planning, advanced imaging guidance, and alternative access and crossing strategies when performing ViV-TAVR in Perceval valves. The antegrade approach may be safer, is reproducible, and saves on procedure time.

Left Ventricular Assist Device Implantation and Aneurysmectomy for a Giant Left Ventricular Aneurysm.

BACKGROUND: Implanting a left ventricular assist device (LVAD) for end-stage heart failure with a giant left ventricular aneurysm is challenging, primarily owing to risks of unstable anchoring and inflow malalignment. CASE SUMMARY: A 68-year-old woman with a giant left ventricular aneurysm underwent bridge-to-transplant LVAD implantation, revascularization, and partial aneurysmectomy. A modified turtleneck technique secured the device. However, profound reverse remodeling caused delayed downward pump migration at 9 months, resulting in cerebral infarction. DISCUSSION: While the turtleneck technique provides reliable initial anchoring, dynamic postoperative geometric shifts pose ongoing risks. This case underscores the necessity of vigilant serial imaging to detect and manage late pump displacement. TAKE-HOME MESSAGES: The modified turtleneck technique facilitates stable LVAD implantation in end-stage heart failure patients with giant left ventricular aneurysms. However, profound reverse remodeling postoperatively necessitates serial imaging surveillance to detect and manage delayed pump migration.

Redefining Feasibility for Transcatheter Aortic Valve Replacement in the Presence of Mechanical Mitral Prostheses.

TAVR With Patient-Specific Coronary Alignment for a Patient With an Anomalous Left Coronary Artery.

BACKGROUND: An anomalous coronary artery is rare in patients undergoing transcatheter aortic valve replacement (TAVR). Achieving coronary alignment when performing TAVR can be challenging, but it is essential to preserve future coronary access and redo-TAVR options, particularly in younger patients with a longer life expectancy. CASE SUMMARY: A 62-year-old patient with severe, symptomatic bicuspid aortic stenosis and an anomalous left coronary artery underwent TAVR without complications. TAVR with coronary alignment was achieved by relying on patient-specific fluoroscopic projections and meticulous preprocedural cardiac computed tomography (CT) planning. DISCUSSION: An anomalous coronary anatomy can complicate TAVR planning and execution. Meticulous preprocedural planning based on cardiac CT is key in order to be successful and obtain patient-specific coronary alignment. TAKE-HOME MESSAGES: When treating younger patients with TAVR, identifying an anomalous coronary artery with an aberrant origin is important. TAVR with patient-specific coronary alignment in case of an anomalous coronary artery is feasible and requires meticulous preprocedural CT planning.

Simplifying Vascular Closure in Transfemoral TAVR: Is Less More?

What Will Define the Next Era of Transcatheter Aortic Valve Replacement: Cost, Volume, and Quality?

Frailty Is Not Futility: TAVR in Functionally Dependent Patients.

Emergency Transcatheter Aortic Valve Replacement in Cardiogenic Shock Caused by Severe Bicuspid Aortic Valve Stenosis.

BACKGROUND: Treatment of severe aortic stenosis in cardiogenic shock remains challenging, particularly in younger patients with bicuspid valve stenosis (BVS). CASE SUMMARY: A 51-year-old woman with severe high-gradient BVS presented in cardiogenic shock with multiorgan dysfunction. Given hemodynamic instability, the heart team proceeded with urgent transcatheter aortic valve replacement. A 26-mm balloon-expandable Edwards SAPIEN 3 Ultra RESILIA valve was successfully implanted, resulting in rapid hemodynamic stabilization. DISCUSSION: This case highlights the importance of urgent heart team decision-making in unstable patients with severe BVS. Lifetime management requires individualized device selection considering annular dimensions, calcification pattern, coronary access, and future redo-procedure strategies. TAKE-HOME MESSAGES: In the presence of refractory cardiogenic shock, transcatheter aortic valve replacement may be the preferred treatment strategy and should be considered as part of an individualized lifetime management strategy.

Percutaneous "Double-Seal" Strategy With Occluder Plus TAV-in-TAV for Post-TAVR Aortic Root-to-Right Ventricle Fistula.

Aortic Valve Hemodynamic Physiology: New Insights to Improve Patient Selection.

Abbreviated DAPT Regimens Across the Entire Spectrum of Bleeding Risk According to the PRECISE-HBR Score.

BACKGROUND: Among high-bleeding risk (HBR) patients undergoing coronary stenting, abbreviated dual antiplatelet therapy (DAPT) reduces bleeding without ischemic risk trade-off; whether these benefits persist across the entire spectrum of bleeding risk has not been investigated. OBJECTIVES: The aim of this study is to explore the value of the novel PRECISE-HBR score as a risk stratification tool to guide DAPT duration in patients at high bleeding risk. METHODS: The XIENCE Short DAPT program combined 3 international single-arm studies of HBR patients treated with cobalt-chromium everolimus-eluting stents who discontinued DAPT at 1 month (XIENCE 28 USA/Global) or 3 months (XIENCE 90), if event free and treatment adherent. Bleeding risk was classified as nonhigh (PRECISE-HBR score ≤22), high (score 23-26), or very high (score ≥27). Clinical outcomes were assessed between 1 and 12 months using propensity score stratification. RESULTS: Among 3,364 patients, the PRECISE-HBR score was ≤22, 23-26, and ≥27 in 359 (10.7%), 744 (22.1%), and 2,261 (67.2%), respectively. Rates of BARC (Bleeding Academic Research Consortium) type 3-5 bleeding (0.3%, 2.5%, 5.6%) and death or myocardial infarction (2.9%, 4.6%, 9.8%) increased progressively across risk categories. One- versus 3-month DAPT was associated with a significant reduction in BARC type 3-5 bleeding in patients with a score ≥27 (HR: 0.59, 95% CI: 0.39-0.88) but not in those <27 (HR: 2.31, 95% CI: 0.89-5.99; P-interaction = 0.012). Ischemic risk was similar between 1- and 3-month DAPT, irrespective of the PRECISE-HBR score (P-interaction = 0.40). CONCLUSIONS: The PRECISE-HBR score identified patients at increased risk for both bleeding and ischemic events who seemed to derive greater benefit from 1-month DAPT after stent implantation.

Understanding the Volume-Outcome Curve in Contemporary Transcatheter Aortic Valve Replacement: Complications or Failure to Rescue?

Hospital Volume and Failure to Rescue Post-TAVR: Insights From the STS/ACC TVT Registry.

BACKGROUND: There is an inverse volume-mortality relationship for transcatheter aortic valve replacement (TAVR), with higher adjusted mortality among hospitals with lower TAVR volumes. OBJECTIVES: The aim of this study was to identify potential mediators of the volume-mortality relationship including the risk of major complications occurring and/or failure to rescue (FTR) from these complications. METHODS: Using the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry, we identified patients who underwent TAVR from 2017 to 2023. The rate of FTR-defined as 30-day risk-adjusted mortality following a major complication post TAVR-was compared across hospitals stratified by quartiles (Q1-Q4) of annualized TAVR volume. RESULTS: A total of 487,159 patients (median age: 79 years, 57% male) who underwent TAVR across 808 sites were included. Lower-volume centers (Q1) had significantly higher rates of 30-day mortality (adjusted OR: 1.12; 95% CI: 1.00-1.25; P = 0.045) and major complications (adjusted OR: 1.19; 95% CI: 1.08-1.32; P = 0.0006) than higher-volume centers (Q4). The overall rate of FTR across all hospitals was 11.0%. There were no significant differences in FTR rates by hospital volume (adjusted OR: 0.97 per 100 cases; 95% CI: 0.93-1.01; P = 0.11) and no evidence of a threshold relationship. CONCLUSIONS: In this large contemporary study, we found that higher annualized TAVR volume was associated with lower complication rates but not with lower FTR rates. These findings suggest that the inverse relationship between hospital TAVR volume and post-TAVR mortality may be more strongly associated with complication rates than with FTR.

Iron Deficiency Criteria for Patients Undergoing Transcatheter Aortic Valve Replacement.

Procedural Strategies for Optimal Transcatheter Aortic Valve Replacement: An International Position Statement.

The extension of transcatheter aortic valve replacement (TAVR) to younger patients with longer life expectancy has driven a shift in focus toward procedural optimization, with the goals of maximal clinical improvement, durable outcomes, maintained coronary access, and avoidance of permanent pacemaker implantation. A TAVR CODE framework including 4 key fluoroscopic parameters-coaxiality, orientation, depth, and expansion-has recently been proposed to standardize the intraprocedural evaluation of optimal transcatheter heart valve (THV) implantation. Systematic implementation of these concepts during TAVR is expected to improve valve performance and durability. This is hypothesized to improve afterload reduction, enhance left ventricular reverse remodeling, and confer increased and longer lasting clinical benefits. To date, procedural strategies to optimize TAVR outcomes have been largely based upon expert opinion, supported predominantly by mechanistic and retrospective studies. Ongoing randomized trials are evaluating the effects of systematic pre- and postdilatation during TAVR, the impact of same-volume double-tap techniques with balloon-expandable valves, and the effectiveness of different commissural alignment techniques. Meanwhile, intravascular ultrasound is under investigation as a tool to evaluate THV expansion to guide postdilatation, while technical consistency may be improved by innovative THV designs that promote symmetrical expansion, better fluoroscopic visualization, and robotic insertion systems using artificial intelligence. In this article, we detail the possible impact of implementing the TAVR CODE framework on THV function, durability, and clinical outcomes, and provide an expert perspective on procedural strategies to achieve optimal index TAVR outcomes, including management frameworks and position statements according to contemporary best practices.

Impact of Coronary Microvascular Dysfunction on Patient-Reported Symptoms After PCI.

BACKGROUND: Coronary microvascular dysfunction (CMD) has been proposed as a mechanism underlying residual angina after percutaneous coronary intervention (PCI). OBJECTIVES: The objective of the study was to investigate the impact of CMD on symptoms in patients undergoing PCI. METHODS: Patients with hemodynamically significant coronary artery disease (CAD) (fractional flow reserve ≤0.80) were included. CAD was classified as focal or diffuse using the pull back pressure gradient (PPG) (diffuse CAD defined as PPG <0.62). CMD was defined as microvascular resistance reserve <3.0. The Seattle Angina Questionnaire (SAQ) was administered at baseline and 1 year. RESULTS: Among 201 patients (mean age 68.5 ± 10.1 years; 71% male), CMD was present in 75 (37.3%), with no difference between focal and diffuse CAD (41% vs 34%; P = 0.35). At baseline, CMD was associated with more severe symptoms without reaching statistical significance (SAQ summary score 64.0 ± 25.3 vs 69.6 ± 21.0; P = 0.09). At 1 year, symptoms were similar between groups (SAQ summary score 87.6 ± 16.0 vs 89.4 ± 16.4; P = 0.47). A significant interaction between PPG and microvascular resistance reserve was observed for residual angina (P for interaction = 0.015); patients with focal CAD and concomitant CMD had the highest burden of residual symptoms. CONCLUSIONS: CMD is present in approximately one-third of patients undergoing PCI and occurs with similar frequency in focal and diffuse CAD. CMD alone was not associated with residual angina. However, its clinical relevance varied according to the epicardial disease pattern: in focal CAD, concomitant CMD was associated with less symptomatic improvement after PCI, whereas in diffuse CAD, residual symptoms appeared to be driven predominantly by persistent epicardial disease.

Clarifying the Obesity Paradox in Transcatheter Aortic Valve Replacement: Findings From the STS/ACC TVT Registry.

BACKGROUND: Higher body mass index (BMI) has been associated with better outcomes after transcatheter aortic valve replacement (TAVR), but whether this "obesity paradox" varies by age is unclear. OBJECTIVES: The objective of the study was to determine whether age modifies the association between BMI and 1-year outcomes after TAVR. METHODS: The authors performed a retrospective analysis of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry, including patients who underwent TAVR between January 2021 and February 2023. Patients were categorized by age (<65 or ≥65 years) and BMI (<25 or ≥25 kg/m2). The primary outcome was 1-year all-cause mortality. Secondary outcomes included major adverse cardiovascular and cerebrovascular events: stroke, cardiac mortality, myocardial infarction, and readmission. Inverse probability of treatment weighting regression models were used to assess outcomes. RESULTS: Among the 6,639 patients (mean age 76.7 ± 11.6 years; mean BMI 29.7 ± 9.9 kg/m2), 1-year all-cause mortality occurred in 427 (6.4%). Among patients <65 years, outcomes did not differ between BMI groups (P > 0.05). Among patients ≥65 years, BMI <25 kg/m2 was associated with a higher risk of all-cause mortality (adjusted HR [aHR]: 1.29; 95% CI: 1.05 to 1.57; P = 0.013) and major adverse cardiovascular and cerebrovascular events (aHR: 1.20; 95% CI: 1.08-1.34; P = 0.001) vs those with BMI ≥25 kg/m2. The association between higher BMI and lower mortality strengthened with advancing age and was significant in patients 75 to 84 years (aHR: 0.60; 95% CI: 0.44-0.82; P = 0.001) and ≥85 years (aHR: 0.36; 95% CI: 0.25-0.51; P < 0.001), but not in younger strata. CONCLUSIONS: Higher BMI was not uniformly protective. Among older adults, lower BMI was associated with a higher-risk phenotype and worse 1-year outcomes.

The RASE Technique for Extraction of a Protruding Aorto-Ostial Coronary Stent.

BACKGROUND: Significant protrusion of an aorto-ostial coronary stent into the aortic root may complicate transcatheter aortic valve replacement (TAVR) by increasing the risk of valve-stent interaction, TAVR balloon rupture, or stent deformation. Safe management strategies remain poorly defined. CASE SUMMARY: An 84-year-old man undergoing pre-TAVR evaluation was found to have ostial right coronary artery disease; this was treated with percutaneous coronary intervention, resulting in 7-mm stent protrusion into the aorta, precluding safe TAVR. After heart team evaluation, the patient underwent intentional stent fracture, reverse hairpin-assisted guidewire re-entry, and controlled snare-assisted extraction of the protruding stent (termed the RASE technique [reverse hairpin-assisted avulsion and stent extraction]). Successful staged TAVR was later performed. DISCUSSION: This case describes a novel guidewire-controlled technique for safe extraction of a protruding aorto-ostial stent, enabling definitive transcatheter valve therapy. TAKE-HOME MESSAGES: Aorto-ostial stent protrusion may preclude safe TAVR and requires multimodality assessment and heart team planning. The RASE technique may facilitate safe and controlled extraction of the protruding stent segment.

Simultaneous Transcatheter Aortic Valve Replacement and Percutaneous Coronary Intervention Under ECMO Support.

BACKGROUND: Patients with severe aortic stenosis (AS) often have concomitant coronary artery disease (CAD), but optimal timing of percutaneous coronary intervention (PCI) remains unclear, especially in those with very high risk. CASE SUMMARY: A 63-year-old man with severe AS (aortic valve area 0.9 cm2), reduced left ventricular ejection fraction (40%), and triple-vessel CAD including bilateral chronic total occlusions underwent a single-session transcatheter aortic valve replacement (TAVR) plus PCI under prophylactic veno-arterial extracorporeal membrane oxygenation because of extreme risk of hemodynamic collapse. TAVR was performed first, followed by rotational atherectomy-assisted PCI. DISCUSSION: Prophylactic veno-arterial extracorporeal membrane oxygenation provided a critical safety net, allowing valve recapture and repositioning despite heavy calcification and successful chronic total occlusion revascularization. This 1-stop strategy avoided staged procedures and cumulative cardiac stress. TAKE-HOME MESSAGE: For high-risk AS with complex CAD, a 1-stop TAVR-plus-PCI strategy under prophylactic ECMO support is feasible and potentially life-saving; careful imaging and advanced intraoperative techniques are essential.

Delayed Chimney Stent Fracture After Transcatheter Aortic Valve Replacement.

BACKGROUND: Chimney stenting represents an established coronary protection strategy during transcatheter aortic valve replacement (TAVR) in high-risk anatomical settings, although chimney stent fracture remains a rare complication. CASE SUMMARY: A 55-year-old woman with severe aortic stenosis underwent TAVR with a self-expanding valve and left main chimney stenting due to a low-lying left coronary artery (10.2 mm). One month postprocedure, she presented with recurrent chest pain and elevated troponin. Coronary angiography revealed delayed chimney stent fracture with compromised left main flow, requiring urgent balloon dilatation and restenting. At 1-year follow-up, left ventricular function was preserved. CONCLUSION: This case highlights delayed stent fracture as a rare but serious complication of chimney stenting following TAVR. Imaging surveillance is warranted in patients with postprocedural chest pain to avoid diagnostic oversight. TAKE-HOME MESSAGES: Delayed stent fracture following chimney stenting for coronary protection during TAVR may present weeks after an initially successful procedure with acute coronary syndrome-like symptoms, requiring urgent coronary angiography and reintervention. Continuous radial force from self-expanding transcatheter valve frames may contribute to chronic mechanical stress on chimney stents. Preoperative assessment of coronary ostial angulation should be considered in patients with high-risk coronary anatomy undergoing TAVR.

Extracorporeal Membrane Oxygenation for Transcarotid Transcatheter Aortic Valve Replacement in Severe Aortic Stenosis.

BACKGROUND: Patients with severe aortic stenosis and profoundly reduced left ventricular ejection fraction (LVEF) face a prohibitive risk of intraprocedural hemodynamic collapse during transcatheter aortic valve replacement (TAVR). This risk is exacerbated when complex valve anatomy prolongs the procedure, and it is compounded further when hostile iliofemoral anatomy precludes conventional transfemoral access. CASE SUMMARY: We present a 71-year-old woman with severe aortic stenosis, a rigid type 0 bicuspid aortic valve, and an LVEF of 15%. Preprocedural imaging revealed narrow iliofemoral arteries prohibitive for a standard TAVR delivery system. Guided by a multidisciplinary heart team approach focusing on the "access-valve-coronary-brain" axis, a tailored strategy was executed. Prophylactic venoarterial extracorporeal membrane oxygenation (ECMO) was established via the femoral vessels to provide continuous circulatory support, followed by successful TAVR via the left common carotid artery. The procedure was well tolerated, and the patient demonstrated rapid reverse ventricular remodeling, with LVEF improving to 48% at discharge. DISCUSSION: Integrating prophylactic ECMO with transcarotid access is a feasible procedural strategy to mitigate the risk of intraprocedural collapse in patients with severe left ventricular dysfunction, complex bicuspid aortic valve anatomy, and prohibitive femoral access.

TAVR Using a Premounted Dry Valve in a Patient With Severe Aortic Stenosis and Tortuous Descending Aorta.

BACKGROUND: Transcatheter aortic valve replacement (TAVR) with wet tissue valves have several limitations that compromise their durability and lifespan, and it is technically challenging in patients with a tortuous descending aorta. CASE SUMMARY: We report an 81-year-old woman with severe symptomatic aortic stenosis, characterized by a functionally bicuspid aortic valve with extensive calcification, horizontal heart configuration. and tortuous descending aorta. The patient underwent successful transfemoral TAVR using a premounted dry valve system with cerebral embolic protection and a minimalist approach. DISCUSSION: This case confirms the feasibility of long sheath-assisted TAVR using a premounted dry valve system. Given the availability of premounted dry valves in China, the use of a premounted dry valve with potentially enhanced durability was chosen to avoid the risk of reintervention in this elderly patient. TAKE-HOME MESSAGE: Successful TAVR using a premounted dry valve system in patients with complex anatomy requires meticulous preprocedural planning, advanced imaging analysis, and appropriate device selection.

Transcatheter Management of Severe Aortic Stenosis, Acute Pulmonary Embolism, and Gastrointestinal Bleeding.

BACKGROUND: The concurrent presentation of severe aortic stenosis (AS), acute pulmonary embolism (PE), and gastrointestinal bleeding creates a clinical dilemma where treating one condition may exacerbate another. CASE SUMMARY: A 72-year-old woman presented with fatigue, palpitations, and melena. She was found to have severe AS, bilateral acute PE, and a bleeding duodenal ulcer. After initial stabilization with transfusion, we used a staged multidisciplinary approach: catheter-directed thrombectomy with adjunctive balloon angioplasty for residual stenosis, followed by transfemoral transcatheter aortic valve replacement. DISCUSSION: This case illustrates the challenges of coexisting AS, gastrointestinal bleeding, and PE. Although Heyde syndrome was considered a possible unifying mechanism, absent angiodysplasia and von Willebrand factor testing preclude definitive diagnosis. A staged, physiology-driven strategy prioritized immediate threats and enabled safe definitive therapy. TAKE-HOME MESSAGES: In patients with competing thrombotic and bleeding pathologies, a staged, physiology-first approach prioritizing the most immediate threat enables safe sequential intervention. Percutaneous techniques minimize cumulative risk in high-risk patients.

Commissural Alignment During TAVR With a New-Generation Self-Expandable Valve in a Single Coronary Artery.

BACKGROUND: Transcatheter aortic valve replacement (TAVR) in patients with a single coronary artery (SCA) is challenging because loss of coronary access may have catastrophic consequences. CASE SUMMARY: A 92-year-old woman with severe aortic stenosis underwent transfemoral TAVR. Preprocedural computed tomography revealed an SCA arising from the left coronary cusp with a small annulus. TAVR was performed using an Evolut FX+ valve with intentional commissural alignment guided by cusp-overlap and en face fluoroscopic views. Postprocedural imaging demonstrated preserved coronary access and flow, with a large stent-frame cell facing the coronary ostium. The patient recovered uneventfully. DISCUSSION: Intentional commissural alignment with imaging-guided deployment may preserve coronary access without coronary protection in patients with complex coronary anatomy. TAKE-HOME MESSAGE: Intentional commissural alignment may facilitate safe TAVR while preserving coronary access in patients with SCA.

Valve Deterioration After Supra-Annular Transcatheter Aortic Valve Replacement: Impact of Annular Size and Gradient.

No Boundaries for TAVI? Balancing Feasibility of TAVI in Hemodialysis Patients With Prognostic Value of Comorbidities.

Balloon Sizing-Guided Valve Selection for Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve.

Valve size selection for transcatheter aortic valve replacement using a balloon-expandable valve in a bicuspid aortic valve (BAV) involves a trade-off among the risks of aortic rupture, residual paravalvular leak, and inadequate valve expansion. We report 2 cases of type 1 BAVs with a tapered configuration that created challenges regarding valve size selection. Two consecutive valve sizes were considered based on multidetector computed tomography measurements. Therefore, predilatation with contrast injection was performed using a balloon that was slightly smaller than the smaller of the 2 valve sizes. These cases suggest that a smaller valve should be selected when balloon indentation is observed without contrast backflow into the left ventricle because selecting the larger valve may result in insufficient expansion. Balloon predilatation with contrast injection may be a useful strategy for determining the appropriate valve size for transcatheter aortic valve replacement using a balloon-expandable valve in type 1 BAVs with a tapered configuration.

From Valvular Stenosis to Global Cardiac Damage: What PAPi Adds After TAVR.

Old Tools, New Perspectives: Right Heart Catheterization in the Modern TAVR Era.

Applied Anatomy of Perimembranous Ventricular Septal Defect for Transcatheter Device Closure.

Perimembranous ventricular septal defect is a common congenital heart disease effectively treated by transcatheter device closure with high success rates and minimal complications. This review categorizes perimembranous ventricular septal defects into 7 morphologic variants based on anatomical extension and correlates these with echocardiographic classifications: type 1 is central perimembranous; type 2 is superior-anterior extension; type 3 is superior-posterior extension; type 4 is inferior-anterior extension; type 5 is inferior-posterior extension; type 6 is confluent extensions with more than one extension direction; and type 7 is complex type with outlet septum involvement. Type 2 defects are often associated with aortic valve prolapse and regurgitation, requiring soft, flexible devices to minimize valve injury. Type 5 defects lie close to the conduction system; deploying devices within an aneurysmal pouch helps prevent heart block and tricuspid regurgitation. Type 6 and 7 defects sometimes necessitate multiple devices for complete closure. Understanding these anatomical variants aids in selecting appropriate devices and optimizing procedural outcomes.

How to Plan a Transcatheter Aortic Valve Replacement in a Failed Aortic Homograft.

Conduction Disturbances After TAVR: To Pace or Not to Pace?

The Narrow QRS Deception: Alternating Bundle Branch Block Uncovered on Ambulatory Monitoring After TAVR.

BACKGROUND: Conduction disturbances are common after transcatheter aortic valve replacement (TAVR), whereas alternating bundle branch block reflects advanced conduction system disease. CASE SUMMARY: A 76-year-old man underwent TAVR with an initially normal postprocedural electrocardiogram (ECG). Six days later, he presented with syncope. The admission ECG demonstrated wide QRS complexes. A retrospective review of early 12-lead Holter monitoring revealed alternating bundle branch block. Conduction system pacing was performed. DISCUSSION: This case illustrates how dynamic conduction instability after TAVR may remain undetected on a resting ECG and require extended rhythm assessment for early recognition. TAKE-HOME MESSAGES: Extended rhythm surveillance after TAVR can detect transient or intermittent conduction abnormalities not apparent on a standard ECG. Early identification of such changes may enable timely electrophysiological evaluation and appropriate device therapy.

Precision Management of High-Risk Coronary Obstruction During TAVR Using a Physiology-Guided Strategy.

BACKGROUND: Coronary artery obstruction (CAO) is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Prophylactic chimney stenting is a bailout strategy but carries long-term risks. CASE SUMMARY: A 72-year-old female with severe aortic stenosis and high-risk CAO anatomy (low left coronary ostium height of 9.1 mm, redundant calcified leaflet) underwent TAVR. Post-deployment angiography showed ambiguous left coronary leaflet displacement with delayed contrast clearance. However, immediate and dynamic fractional flow reserve (FFR) assessments consistently remained above the ischemic threshold (>0.80) despite aggressive balloon post-dilations. Consequently, chimney stenting was safely deferred. The patient was asymptomatic at the 3-month follow-up. DISCUSSION: Relying solely on anatomical predictors may lead to overtreatment. Physiological assessment using FFR effectively defines the functional significance of anatomical proximity, safely avoiding unnecessary permanent implants. TAKE HOME MESSAGES: Dynamic FFR monitoring differentiates anatomical proximity from true functional ischemia during TAVR, safely guiding the avoidance of unnecessary chimney stenting.

A Combined Strategy for TAVR in High-Risk Anatomy: Small Ventricle and Low Coronary Ostia.

BACKGROUNDS: Transcatheter Aortic Valve Replacement (TAVR) in patients with a critically small left ventricle (LV) carries risks of hemodynamic collapse ("suicide LV") and coronary occlusion. CASE SUMMARY: A 73-year-old woman with severe aortic stenosis, marked LV hypertrophy, and a tiny LV cavity (LVEDD 29.3mm) faced imminent bilateral coronary occlusion due to low ostia and small sinuses. We employed aggressive volume loading to maintain preload and a prophylactic bilateral chimney stenting strategy. A 23-mm self-expanding bioprosthesis was successfully implanted with the chimney stents preserving coronary perfusion. Post-procedural echocardiography showed excellent valve function with minimal paravalvular leak, and the patient recovered without complications. DISCUSSION: This case underscores the necessity of managing both intraventricular space constraints and extreme coronary risks simultaneously. The double-chimney approach provided robust protection where anatomical reserves were absent. TAKE-HOME MESSAGE: For TAVR candidates with a critically small LV and high-risk coronary anatomy, a unified protocol combining volume optimization and prophylactic bilateral chimney stenting ensures procedural safety and success.

Hemodynamic Improvement With the Double-Tap Technique During Transcatheter Aortic Valve Replacement Using a Pressure-Sensing Guidewire.

Postdilatation using the original delivery system balloon at the same filling volume (the double-tap technique) has been proposed to improve balloon-expandable transcatheter heart valve (THV) expansion during transcatheter aortic valve replacement (TAVR); however, its immediate hemodynamic impact remains unclear. Here, we report a case series of 6 consecutive patients who underwent TAVR with balloon-expandable valves in whom the double-tap technique was performed with hemodynamic assessment using a pressure-sensing guidewire. The mean transvalvular pressure gradients and midportion THV diameters were evaluated before and after the double-tap technique. This technique was significantly associated with reduced mean transvalvular pressure gradients (median difference: -6.5 mm Hg; P = 0.036) and increased midportion THV diameter (median difference: 0.8 mm; P = 0.036), whereas paravalvular leak was reduced to trivial or none in all patients, and no cardiovascular death, stroke, or permanent pacemaker implantation occurred at 30 days. The double-tap technique under pressure-sensing guidewire guidance may facilitate safer valve optimization during TAVR.

Trilogy Transcatheter Aortic Valve Implantation for Freestyle Graft With Flail Left Coronary Cusp.

CASE SUMMARY: This clinical vignette describes successful transcatheter aortic valve implantation (TAVI) in a Freestyle graft with a flail left coronary cusp using a 27-mm Trilogy valve (JenaValve Technology). Using a Trilogy valve in cases with a flail cusp raises concerns of insufficient valve sealing and stability; our report demonstrates the feasibility and safety of the procedure with excellent procedural outcomes. TAKE-HOME MESSAGES: TAVI using the Trilogy valve for degenerated Freestyle graft with flail left coronary cusp is feasible, with several advantages over commercially available TAVI platforms. However, additional cases are required to demonstrate its safety and reproducibility.

Transcatheter Aortic Valve Implantation in a Massive Aortic Annulus With a Novel Balloon-Expandable Valve.

CASE SUMMARY: This clinical vignette describes successful transcatheter aortic valve implantation (TAVI) in the largest reported annulus (1,040 mm2) using a novel 35-mm balloon-expandable valve. TAVI can be performed off-label in selected patients with a massive aortic annulus using commercially available 29-mm transcatheter aortic valves by adding additional volume; however, this risks paravalvular leak, valve embolism, and damage to bioprosthetic leaflets. TAKE-HOME MESSAGE: TAVI is feasible in patients with a massive aortic annulus measuring >1,000 mm2 using Myval 35-mm balloon-expandable valve with balloon overfilling.

Stroke Risk After TAVR: Balloon-Expandable vs Self-Expanding Valves in Community Practice.

BACKGROUND: Stroke is a serious complication after transcatheter aortic valve replacement (TAVR), yet contemporary data from community hospital practice are limited. OBJECTIVES: The purpose of this study was to evaluate the association between valve type and the risk of stroke within 1 year after contemporary TAVR in community practice. METHODS: We analyzed patients who underwent TAVR across CommonSpirit Health hospitals from January 2021 to February 2023 using data from the Society of Thoracic Surgeons (STS)/American College of Cardiology Transcatheter Valve Therapy Registry. Valve type was categorized as balloon-expandable valves or self-expanding valves (SEV). The primary outcome was stroke within 1 year. Kaplan-Meier methods were used to compare stroke-free survival between valve types. Baseline differences were adjusted using inverse probability of treatment weighting. Independent predictors of stroke were identified using weighted time-to-event models. RESULTS: A total of 6,663 patients underwent TAVR during the study period; 5,445 (81.7%) received balloon-expandable valve, and 1,218 (18.3%) received SEV. More females received a SEV (56.7% vs 37.5%; P < 0.001). The STS risk score (4.5 ± 3.8 vs 4.0 ± 3.5; P < 0.001) was higher in the SEV group. A total of 87 (1.3%) patients experienced stroke within the study period. The primary endpoint of stroke-free survival at 1 year was not different between valve types (log-rank P = 0.448). After inverse probability of treatment weighting adjustment, valve type was not associated with stroke (adjusted HR: 1.54; 95% CI: 0.79-2.68; P = 0.294). Age, lower body mass index, prior stroke, STS risk, and alternative access were associated with stroke. CONCLUSIONS: In this registry of patients receiving TAVR, valve type did not predict stroke at 1 year. The predominant drivers of stroke were clinical variables: age, STS risk, and a history of stroke.

Opportunistic CT-Derived Periaortic Fat Attenuation as a Novel Marker of Mortality in Patients Undergoing TAVR.

Two-Staged Transcatheter Aortic Valve Replacement in Severely Calcified Sinotubular Junction.

OBJECTIVE: Severe sinotubular junction (STJ) calcification presents important challenges during transcatheter aortic valve implantation, including risk of aortic dissection or aortic root rupture and valve malposition. We describe a straightforward and reproducible two-stage balloon inflation technique with a balloon-expandable SAPIEN 3 valve to optimize precision and procedural safety in this difficult setting. TECHNIQUE: Step 1: Initial balloon inflation at 2 mL less than nominal volume to secure annular anchoring and limit radial force on the calcified STJ. Step 2: Balloon advanced 1-2 mm under fluoroscopy toward the inflow and inflated to the full nominal volume, completing valve deployment. PITFALLS: Inadequate anchoring may cause migration or embolization, underestimation of calcification can compromise expansion, and balloon overinflation may cause root injury. CONCLUSION: This staged inflation method anchors the valve, minimizes STJ stress, and provides a simple, reproducible strategy that may improve safety in anatomically complex patients.

Thrombolysis for Obstructive HALT in Complex Valve-in-Valve TAVR.

Acquired von Willebrand Syndrome and Hemolysis in High-Shear States: Time for Cardio-Hematology Collaboration.

Polymeric Transcatheter Heart Valves: Are We Entering the Next Era of TAVR Durability?

TAVR and TEVAR for Patients With Concomitant Aortic Valve and Descending Thoracoabdominal Aortic Disease: To Stage or Not to Stage?

Gender Matters: A State-of-the-Art Review of Transcatheter Structural Interventions in Older Women Vs Men.

With rising life expectancy, the population of older adults over the age of 65 is rapidly expanding, with women comprising the majority. Structural heart disease is common in this group, and transcatheter interventions have transformed its management. Optimal outcomes require careful consideration of sex-specific differences. This review examines transcatheter structural heart interventions in older adults with a focus on sex-based outcomes, procedural planning, and current knowledge gaps.

[World Report] The medicine of…cruise ships

Although the hantavirus outbreak on MV Hondius has drawn the world's attention, day-to-day practice is usually a little more prosaic. Talha Burki embarks on an examination of cruise ships.

[Comment] Offline: Hantavirus—surprise, complacency, and peril

Memories resurface. An unfamiliar virus. Deaths. A stricken cruise ship. Quarantines. Hastily arranged WHO press briefings. Scientists interviewed on radio and television about what is known—and, more importantly, not known—about disease transmission. WHO has assessed the public health risk as low. But for the families of the three passengers on the MV Hondius who died, together with those with either confirmed or suspected hantavirus infection, the news of an outbreak of a mysterious virus will be frightening.

Coronary revascularisation before TAVI.

Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.

BACKGROUND: Coronary artery disease is common in patients undergoing transcatheter aortic valve implantation (TAVI). We aimed to assess whether deferral of percutaneous coronary intervention (PCI) is non-inferior to routine PCI before TAVI in patients with coronary artery disease. METHODS: In this investigator-initiated, open-label, randomised controlled trial, done at 12 hospitals in the Netherlands, TAVI patients with coronary artery disease were randomly assigned in a 1:1 ratio to deferral of PCI or PCI before TAVI. Randomisation was done by use of a web-based system with random block sizes of 2 and 4, and stratification by presence of coronary artery disease involving proximal left anterior descending artery. The primary endpoint was a composite of all-cause mortality, myocardial infarction, stroke, and major bleeding at 1 year. Non-inferiority testing was done in the intention-to-treat population against the prespecified margin of 11 percentage points. The study is registered with ClinicalTrials.gov (NCT05078619) and long-term follow-up is ongoing. FINDINGS: Between Oct 7, 2021, and Nov 19, 2024, 466 patients were enrolled: 233 were assigned to deferral of PCI and 233 to PCI before TAVI. Median age was 81 years (IQR 78-84), and 166 (36%) of 466 patients were female. The primary endpoint occurred in 56 (24%) of 233 patients in the deferral group as compared with 60 (26%) of 233 patients in the PCI group (rate difference -1·7% [95% CI -9·5 to 6·2]; hazard ratio 0·89 [95% CI 0·62-1·28]; p=0·0008 for non-inferiority; p=0·68 for superiority). INTERPRETATION: In patients with coronary artery disease undergoing TAVI, deferral of PCI was non-inferior to PCI before TAVI for the 1-year composite of all-cause mortality, myocardial infarction, stroke, and major bleeding. These findings suggest that an initial conservative strategy can be appropriate in selected patients, although patient-tailored treatment decisions remain essential. FUNDING: ZonMw.

Routine FFR-guided revascularization in patients undergoing transcatheter aortic valve implantation, one step too far?

FFR-guided revascularization in patients undergoing TAVI: insights on the FAITAVI trial.

Wearable-Echo-FM: an ECG echo foundation model for 1-lead electrocardiography.

AIMS: Artificial intelligence (AI) models can now detect patterns of structural heart diseases (SHDs) from electrocardiograms (ECGs), though scaling them requires the broader use of 1-lead ECGs that are now ubiquitous in wearable and portable devices. However, model development for these devices is limited by a lack of diagnostic labels for SHDs for wearable ECGs. METHODS AND RESULTS: Here, we present Wearable-Echo-FM, a foundation model that encodes 1-lead ECGs with information from echocardiographic text reports. Using 194 551 1-lead ECG-echo pairs from 77 378 adults (2015-2018), we contrastively pre-trained ECG convolutional neural network (CNN) and RoBERTa text encoders. The ECG encoder was fine-tuned on a distinct progressively larger ECG set (250 to 250 260 ECGs) to detect different cardiac disorders: (i) left-ventricular systolic dysfunction (LVSD), (ii) diastolic dysfunction, and (iii) a composite SHD. This was compared with a randomly initialized CNN, with both approaches evaluated in an independent held-out test set. With the full training set, Wearable-Echo-FM matched the baseline CNN (AUROC 0.894 vs. 0.884 for LVSD; 0.849 vs. 0.843 diastolic dysfunction; 0.887 vs. 0.869 composite). With only 0.5% (∼1000 ECGs) of data, it markedly outperformed baseline (0.855 vs. 0.548; 0.819 vs. 0.582; 0.863 vs. 0.496, respectively). CONCLUSION: Contrastive pre-training of 1-lead ECGs on echocardiographic text reduces label requirements for label-efficient development of SHD screening models on 1-lead ECGs, providing a foundation for future validation on wearable and portable devices.

Structural heart disease screening using artificial intelligence-enabled electrocardiogram and novice handheld cardiac ultrasound: a cost analysis.

AIMS: Early detection of structural heart disease (SHD) improves patient outcomes. However, population-based screening is not recommended due to the lack of accurate and cost-effective tools. We evaluated the costs of artificial intelligence-enabled electrocardiogram (AI-ECG) alone vs. AI-ECG followed by handheld cardiac ultrasound (HCU) for SHD screening. METHODS AND RESULTS: We performed a model-based cost analysis using data from 286 adult patients who underwent ECG and same-day HCU performed by a novice operator. Transthoracic echocardiogram (TTE) was the reference standard. We compared two screening strategies: (i) AI-ECG alone and (ii) a stepwise approach (AI-ECG followed by HCU). We assessed costs per diagnosis of aortic stenosis (AS), increased left ventricular wall thickness (ILVWT), and left ventricular systolic dysfunction (LVSD). Sensitivity analyses were conducted for varying disease prevalence. The stepwise approach decreased the cost per diagnosis of AS from $6386 (AI-ECG alone) to $2746 (57.0% savings), ILVWT from $4448 to $2895 (34.9% savings), and LVSD from $1469 to $1296 (11.8% savings). Overall, the cost per diagnosis for all SHDs combined decreased from $1940 to $1570 (19.1% savings). Sensitivity analysis demonstrated that cost savings were inversely proportional to disease prevalence. Nevertheless, stepwise screening remained cost-saving compared with AI-ECG alone until prevalence exceeded ∼55.9% for AS, 28.9% for ILVWT, 20.7% for LVSD, and 40.8% for all SHDs combined. CONCLUSION: A stepwise screening strategy incorporating HCU after a positive AI-ECG reduces the immediate costs of SHD detection by minimizing unnecessary TTEs. This approach may enhance the feasibility of population-based SHD screening, particularly in lower-prevalence settings.

Impact of cardiac amyloidosis on survival in aortic stenosis patients undergoing TAVR: a systematic review and reconstructed time-to-event meta-analysis.

BACKGROUND: New evidence suggests a relatively high prevalence of occult cardiac amyloidosis (CA) among patients with aortic stenosis (AS). While transcatheter aortic valve replacement (TAVR) is an established treatment for AS, the impact of concomitant CA on long-term outcomes remains unclear. We conducted a systematic review and meta-analysis to evaluate survival and procedural outcomes of TAVR in AS patients with and without CA. METHODS: PubMed, Scopus, Web of Science, Google Scholar, and the Cochrane Library were searched through 21 April 2026. Studies comparing outcomes of TAVR in patients with and without CA and reporting Kaplan-Meier survival curves were included. Individual patient survival data were extracted from Kaplan-Meier curves and reconstructed for pooled analysis. Secondary outcomes were analyzed using random-effects meta-analysis. RESULTS: Seven studies including 2747 patients were analyzed. In the primary analysis, which included both definitive and probability-based definitions of CA, CA was associated with increased all-cause mortality following TAVR (HR: 1.58; 95% CI 1.23, 2.03; P < 0.001). However, in a sensitivity analysis restricted to studies with confirmed CA, this association was no longer significant (HR: 1.32, 95% CI 0.84, 2.07, P = 0.226). There were no significant differences in pacemaker implantation (OR: 1.33; 95% CI 0.69, 2.56; P = 0.40) or more than mild aortic regurgitation (OR: 0.96; 95% CI 0.25, 3.78; P = 0.96). CONCLUSION: The association between CA mortality after TAVR in AS patients is highly dependent on how CA is defined. While analyses including screening-based cohorts suggest increased risk, this was not observed in analyses of studies with confirmed CA. These findings highlight the impact of differing diagnostic approaches in CA and underscore the need for future studies to use standardized criteria and prospective designs to clarify the independent prognostic role of confirmed CA.

Isolated Absence of the Right Pulmonary Artery: A Rare Cause of Pulmonary Hypertension in Adults.

Transcatheter ventricular septal defect closure in children: ten-year experience with multiple devices and long-term outcomes.

BACKGROUND: Transcatheter closure has become a widely accepted alternative to surgery for VSD, but long-term pediatric data are limited. This study evaluated procedural success, complications, and long-term outcomes with different occluders. METHODS: We retrospectively analyzed 118 children who underwent attempted transcatheter VSD closure between 2014 and 2024, with clinical, echocardiographic, and electrocardiographic follow-up. RESULTS: Closure was successful in 110 patients (93%). Failures were due to multifenestrated anatomy, embolization, residual shunt, atrioventricular (AV) block, tricuspid regurgitation, or insufficient aortic rim. Major complications occurred in six patients, including device embolization, progressive aortic regurgitation requiring surgery, persistent nodal rhythm requiring device removal, ventricular perforation, infective endocarditis, and subarachnoid hemorrhage. Minor complications included mild to moderate tricuspid regurgitation (n = 4) and mild aortic regurgitation (n = 5). Arrhythmic events comprised supraventricular tachycardia (n = 2, both resolved), nodal rhythm (n = 1, transient), right bundle branch block (n = 5, persistent in four), and left bundle branch block (n = 1, resolved). Residual shunt was present in 36.4% immediately, declining to 9.8% at follow-up. Larger VSD diameter (OR 1.75, 95% CI 1.14-2.69) and higher body weight (OR 1.07, 95% CI 1.00-1.15) were independent predictors. No late complete AV block, endocarditis, or embolization occurred. Patients treated with Konar-MF were younger and lighter, while Nit-Occlud was associated with higher residual shunt rates (85.7% vs. 33.0%, p = 0.010). CONCLUSION: Transcatheter VSD closure in children demonstrated high success, acceptable complication rates, and favorable long-term outcomes. Results were influenced by device choice, defect size, and patient characteristics, highlighting the need for individualized strategies and continued surveillance.

Stable valve function after post-transapical TAVR with anchoring strut fracture: a 3-year multimodal imaging follow-up case report.

BACKGROUND: Transcatheter aortic valve replacement (TAVR) for native aortic regurgitation (AR) remains technically challenging due to the absence of annular calcification and difficulties in achieving stable anchoring. Mechanical complications such as anchoring strut fracture are rare but may have implications for long-term valve durability. CASE SUMMARY: A 64-year-old man with severe symptomatic native AR underwent transapical TAVR using a 29-mm self-expanding J-Valve system. Routine echocardiography and gated CT on postoperative day 7 identified an isolated fracture of the right coronary sinus anchoring strut without migration, leaflet dysfunction, or haemodynamic compromise. No balloon post-dilatation was performed. Serial multimodal imaging over nearly 3 years demonstrated persistent structural stability, preserved valve function, and marked left-ventricular reverse remodelling. DISCUSSION: This case provides long-term multimodal imaging follow-up of isolated anchoring strut fracture after TAVR for native AR. Early fracture detection and absence of calcification support a deployment-related stress mechanism rather than late cyclic fatigue. Although this favourable evolution suggests that isolated fracture does not necessarily result in immediate structural valve dysfunction, prognostic conclusions cannot be generalized. Careful, individualized imaging surveillance remains essential.

Electrical storm treated with radiation therapy in a patient with ischaemic cardiomyopathy and left ventricular thrombus: a case report.

BACKGROUND: Electrical storm in patients with structural heart disease is associated with high morbidity and mortality. Catheter ablation is recommended for drug-refractory ventricular tachycardia (VT), but may be contraindicated in the presence of a left ventricular (LV) thrombus due to increased thromboembolic risk. Stereotactic arrhythmia radiotherapy (STAR) has emerged as a non-invasive treatment option for refractory VT. This case highlights the potential role of STAR as a rescue therapy when conventional approaches are not feasible. CASE SUMMARY: An 80-year-old man with advanced ischaemic cardiomyopathy presented after out-of-hospital cardiac arrest due to monomorphic VT. Evaluation revealed severe LV dysfunction (LVEF 15%), an anteroapical LV aneurysm and a newly detected LV thrombus. Catheter ablation was deferred due to embolic risk. Eleven weeks later, the patient was admitted with recurrent VT and developed electrical storm refractory to antiarrhythmic drug therapy, overdrive pacing, and bilateral stellate ganglion blockade. Non-invasive target delineation using contrast-enhanced cardiac computed tomography with scar characterization and ECG-based localization was performed. A single fraction of 25 Gy stereotactic arrhythmia radiotherapy was delivered to the suspected VT substrate. Electrical storm terminated immediately after treatment, and no further VT episodes occurred during hospitalization or during 6 months of follow-up. DISCUSSION: This case demonstrates that stereotactic arrhythmia radiotherapy may provide an effective non-invasive rescue strategy for electrical storm when catheter ablation is contraindicated. Integration of advanced cardiac imaging with ECG-based localization enables target definition in the absence of invasive electroanatomical mapping.

A diagnostic pitfall of CT calcium scoring in paradoxical low-flow, low-gradient severe aortic stenosis with rheumatic morphology: a case report.

BACKGROUND: Computed tomography (CT) calcium scoring is used to adjudicate paradoxical low-flow, low-gradient (LFLG) severe aortic stenosis (AS). However, its reliability may be limited in rheumatic disease. CASE SUMMARY: An 82-year-old woman with prior mitral valve replacement for rheumatic mitral stenosis was referred for AS. Transthoracic echocardiography revealed an aortic valve area (AVA) of 0.50 cm2, mean pressure gradient of 27 mmHg, stroke volume index of 30 mL/m2, and preserved systolic function, suggesting paradoxical LFLG severe AS. The CT calcium score was 889 Agatston units, below the female threshold for severe AS. Three-dimensional transoesophageal echocardiography (TEE) demonstrated commissural fusion, leaflet tip thickening, and planimetry-derived AVA of 0.69 cm2, confirming severe AS. The patient underwent transcatheter aortic valve implantation, with 6-min walk distance improving from 150 to 254 m. DISCUSSION: In rheumatic morphology, low CT calcium burden may not exclude severe AS because obstruction may be driven by commissural fusion and fibrosis rather than bulky calcification. Three-dimensional TEE planimetry can serve as an anatomy-based adjudicator when echocardiographic and CT calcium findings are discordant.

Fulminant prosthetic valve endocarditis after transcatheter aortic valve implantation caused by non-typeable

BACKGROUND: Infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI) is an uncommon but life-threatening complication, often associated with diagnostic challenges. Streptococcus agalactiae (GBS) is increasingly recognized as a cause of invasive infection in older adults and may exhibit a rapidly progressive clinical course with central nervous system involvement. CASE SUMMARY: An 85-year-old woman with a history of TAVI presented with acute-onset fever and was diagnosed with GBS bacteraemia. Initial transthoracic echocardiography (TTE) showed no vegetations. On hospital Day 3, she developed delirium and neck stiffness suggestive of meningitis, with intracranial haemorrhage on computed tomography. Repeat TTE demonstrated newly developed vegetations on the prosthetic aortic valve and anterior mitral leaflet, with worsening mitral regurgitation, leading to a diagnosis of IE. The causative organism was identified as non-typeable GBS. Despite intensive antimicrobial therapy, her condition rapidly deteriorated with shock and multiorgan failure, and she died on hospital Day 7. DISCUSSION: This case highlights the fulminant nature of invasive GBS infection in elderly patients, particularly when associated with prosthetic valve IE after TAVI. Notably, this case was characterized by multivalvular involvement and possible central nervous system involvement. These features may reflect a severe disease phenotype driven by highly invasive bacteraemia and structural vulnerability related to the transcatheter valve system. Initial echocardiographic findings may be inconclusive, necessitating repeated evaluation. In addition to embolic complications, central nervous system involvement should be considered in cases of neurological deterioration. Early recognition is critical; however, prognosis remains poor once severe complications develop.

Transfemoral transcatheter aortic valve replacement in a patient with a history of artificial aortic arch replacement and stent implantation: a case report and strategies for a super-stiff approach.

BACKGROUND: Transfemoral transcatheter aortic valve replacement (TAVR) is challenging in patients with stiff and tortuous anatomy. In the present case, we presented a patient with super-stiff aortic arch (prior history of aortic arch replacement, stent implantation, and anastomotic fistula plugging) and a summary of strategies for managing such stiff approach. CASE SUMMARY: A 59-year-old man with symptomatic severe aortic stenosis and a super-stiff aortic arch underwent transfemoral TAVR. Techniques including buddy wire, balloon deflection, balloon-assisted tracking, snare assistance, and long sheath use were considered. Balloon-assisted tracking combined with a long sheath ultimately enabled successful TAVR. Supra-annular anchoring was also confirmed in this case. DISCUSSION: For patients with extremely stiff anatomy, multiple techniques may facilitate successful transfemoral TAVR. Furthermore, in bicuspid aortic valve cases, the narrowed supra-annular region can serve as an effective anchoring zone.

Diagnostic challenge of mitral regurgitation caused by concomitant coronary obstruction and dynamic left ventricular outflow tract obstruction after transcatheter aortic valve replacement: a case report.

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an established therapy for severe aortic stenosis (AS), but rare complications can rapidly become life-threatening, particularly in anatomically high-risk patients. CASE SUMMARY: A 94-year-old woman with very severe AS underwent transfemoral TAVR using a self-expanding valve. After transcatheter heart valve implantation, she developed haemodynamic collapse with right coronary artery obstruction and severe mitral regurgitation (MR). At that time, the aetiology of the severe MR could not be clearly identified. Although intra-aortic balloon pump (IABP) was initiated, cardiac arrest occurred, requiring extracorporeal membrane oxygenation (ECMO). Percutaneous coronary intervention was unsuccessful, necessitating conversion to coronary artery bypass grafting. ECMO was discontinued on postoperative Day 1, but recurrent haemodynamic collapse developed under IABP support, revealing left ventricular outflow tract obstruction (LVOTO) and severe MR with systolic anterior motion (SAM). Discontinuing IABP and initiating medical therapy rapidly stabilized haemodynamics. DISCUSSION: This case illustrates the diagnostic and haemodynamic complexity of simultaneous coronary artery obstruction and dynamic LVOTO with SAM-associated MR after TAVR. Because management strategies for these conditions are inherently contradictory, identifying the dominant mechanism of shock can be challenging. Although severe MR was initially attributed to ischaemia secondary to coronary obstruction, retrospective echocardiographic review demonstrated early SAM. Subsequent changes in loading conditions and myocardial contractility unmasked LVOTO. This case emphasizes the importance of repeated echocardiographic assessment and stepwise haemodynamic reassessment when multiple mechanisms of instability coexist after TAVR.

Smarter FoCUS: AI-guided focused cardiac ultrasound enables novice detection of left ventricular dysfunction.

AIMS: Heart failure is prevalent; however, there is no cost-effective screening option. Against formal echocardiography, we assessed the diagnostic performance of focused cardiac ultrasound (FoCUS), performed by novice users guided and interpreted by artificial intelligence (AI) for the assessment of left ventricular ejection fraction (LVEF). METHODS AND RESULTS: We prospectively enrolled 496 adults referred for diagnostic echocardiography. Novice operators (without clinical or imaging experience) underwent a 4-h imaging workshop, then performed FoCUS using a point-of-care device (Philips Lumify) utilizing real-time AI-image guidance (UltraSight). Images were assessed by AI-image interpretation software (Mayo Clinic), and two expert blinded echocardiologists. Median age was 67, 39% female, and body mass index range 17-56 kg/m2. Forty-one subjects (8.3%) exhibited moderate or greater LV dilatation and 28 (5.6%) had LVEF <40%. The median scan time was 4 min (IQR 3-5). Adequate views were achieved in 95.0% and 97.4% of subjects for AI interpretation and expert analysis, respectively. A two-step diagnostic screening process for low EF in which only abnormal AI reads or uninterpretable scans were reviewed by experts (15.1%) had a sensitivity 96.2%, specificity 95.4%, PPV 54.3%, and NPV 99.8%. A subsequent prospective validation study of 344 subjects demonstrated similar results (sensitivity 100%, specificity 99.4%). CONCLUSION: In this early feasibility investigation, AI-guidance technology embedded on a handheld device, enabled novice users without clinical or imaging experience to acquire sufficient quality images to accurately assess LVEF with minimal training. The technology evaluated in this study may hold promise for AI-guidance and interpretation to facilitate low-cost screening for cardiac dysfunction.

Bailout transcatheter edge-to-edge mitral valve repair for acute mitral regurgitation attributable to systolic anterior motion during transcatheter aortic valve implantation: a case report.

BACKGROUND: Systolic anterior motion (SAM) of the mitral valve is a rare but life-threatening complication of transcatheter aortic valve implantation (TAVI) that can cause acute severe mitral regurgitation (MR) and/or left ventricular outflow tract (LVOT) obstruction, leading to rapid haemodynamic deterioration. Evidence supporting the use of transcatheter edge-to-edge mitral valve repair (M-TEER) for SAM-related MR during TAVI, particularly in the absence of significant LVOT obstruction, is limited. CASE SUMMARY: A 78-year-old woman with severe symptomatic aortic stenosis and multiple comorbidities underwent transfemoral TAVI. Immediately after predilatation, she experienced haemodynamic collapse and required percutaneous cardiopulmonary support. Transoesophageal echocardiography revealed SAM of the anterior mitral leaflet with severe MR without apparent LVOT obstruction. Although a transcatheter aortic valve was subsequently implanted, severe MR with haemodynamic instability persisted. As medical management did not stabilize haemodynamics, bailout M-TEER was performed 3 days after TAVI. Thereafter, MR improved from severe to mild and haemodynamic stabilization rapidly occurred. The patient was discharged with New York Heart Association class I and remained asymptomatic. Sustained MR improvement was observed during 6-month follow-up. DISCUSSION: In this case, SAM-related MR without apparent LVOT obstruction developed immediately after predilatation in a patient with a sigmoid septum, and off-label M-TEER achieved haemodynamic stabilization. Although evidence supporting M-TEER for SAM-related MR during TAVI is limited to case reports and small case series, this case suggests that M-TEER may be considered a bailout option for selected patients when MR is the primary cause of haemodynamic collapse, even without apparent LVOT obstruction.

Left ventricular changes in moderate aortic stenosis in women compared to men.

AIMS: Sex differences in myocardial changes have been identified, but longitudinal investigations in moderate aortic stenosis populations are lacking. The objective of this study was to investigate sex differences in myocardial changes in aortic stenosis. METHODS AND RESULTS: We retrospectively collected longitudinal echocardiographic and clinical data of 542 patients with a diagnosis of asymptomatic moderate aortic stenosis. Baseline was defined as the first echocardiogram showing non-severe aortic stenosis.We enrolled 205 (37.8%) females and 337 (62.2%) males, with a median age of 69 years and a median follow-up duration of 6.47 years.Over the course of aortic stenosis, women had higher left ventricular ejection fraction, lower left ventricular mass index, larger relative wall thickness, and more diastolic dysfunction compared to men. Although the prevalence and incidence of concentric hypertrophy did not differ by sex, women developed concentric hypertrophy and diastolic dysfunction at lower mean gradients than men.Incidence and time of symptom occurrence did not differ by sex. Overall, 99 (48%) women and 148 (44%) men developed symptoms, at a median age of 73.4 [64.2;81.0] years and a mean gradient of 39.8 [31.5;47.5] mmHg, which was similar between the sexes. When symptomatic, women more commonly presented with dyspnoea (87.8% vs. 74.8%; P = 0.021). Incidence and time from baseline to aortic valve replacement and mortality were similar between men and women. CONCLUSION: Women with aortic stenosis have worse diastolic function, develop concentric hypertrophy and diastolic dysfunction at lower mean gradients, and more often present with dyspnoea. We observed no sex differences in time from baseline to replacement or mortality. SOCIAL MEDIA SUMMARY: Women with moderate aortic stenosis developed concentric hypertrophy at lower mean gradients, had more and earlier diastolic dysfunction, and more often presented with dyspnoea compared to men. No difference was observed in outcomes. #vhdAS #TAVR #WomenInCardiology.

Prognostic impact of cardiovascular magnetic resonance-derived left atrioventricular coupling Index in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.

AIMS: Transcatheter aortic valve replacement (TAVR) is an established therapy improving outcome in patients with severe aortic stenosis (AS). Cardiovascular magnetic resonance (CMR)-derived left atrioventricular coupling index (LACI) has demonstrated prognostic value, however, its prognostic utility in severe AS remains unknown. METHODS AND RESULTS: Between January 2017 and September 2023 138 consecutive patients with severe AS (80 years (70-83), 62% male) referred for TAVR were prospectively recruited for pre-procedural CMR imaging. LACI was defined as the ratio of the left atrial (LA) end-diastolic volume index (LA EDVi) and left ventricular (LV) end-diastolic volume index (LV EDVi). The primary endpoint was cardiovascular (CV)-mortality. The cohort was dichotomized at a median of 44.1% (high vs. low LACI). Patients with increased LACI (≥44.1%) had higher symptom burden (NYHA III/IV prevalence (68.1% vs. 44.9%; P = 0.047)), more frequently atrial fibrillation (50.7% vs. 14.5%; P < 0.001), and elevated NT-proBNP (2017 ng/L vs. 1012 ng/L; P = 0.007). Over a median follow-up of 2.7 years (IQR 1.7-3.6), high LACI was associated with higher CV mortality (log-rank P = 0.016). In exploratory multivariable Cox regression models, LACI remained associated with CV-mortality after adjustment for established parameters of left atrial or ventricular function (LA reservoir strain: HR 2.19, 95% CI 1.05-4.57, P = 0.036; LV GLS: HR 2.21 95% CI 1.00-4.9, P = 0.049). CONCLUSION: In patients with severe aortic stenosis, CMR-derived LACI was associated with cardiovascular mortality and may serve as a structural marker of advanced atrioventricular remodelling. Given its simplicity and routine availability in standard CMR workflows, LACI may serve as a clinically practical risk marker for baseline stratification.

A Moving Target: Interpreting Post-TAVI Reintervention in a Rapidly Evolving Era

The Renaissance of Transapical TAVR: From Competing Access Route to Enabling Platform for Hybrid Heart Therapy

Risk and Outcomes of Reintervention After Transcatheter Aortic Valve Implantation

Concerns about transcatheter aortic valve implantation (TAVI) durability and failure management are increasing. This study assessed the time-varying risk and outcomes of reintervention after TAVI in Medicare patients.

Convenience Now, Complexity Later: Transcatheter Aortic Valve Replacement in Young Patients

Unmeasured Confounders and Interpretational Nuances in TAVR Comparisons Among Young Adults

Lifetime Valve Management and the Economic Forces Behind TAVR Expansion in Younger Patients

Aortic valve prosthesis choice in dialysis patients: Medicare data review

Risk and Outcomes of Reintervention After Transcatheter Aortic Valve Implantation.

BACKGROUND: Concerns about transcatheter aortic valve implantation (TAVI) durability and failure management are increasing. This study assessed the time-varying risk and outcomes of reintervention after TAVI in Medicare patients. METHODS: Between 2013 and 2022, 2,387 out of 324,701 (0.7%) TAVI patients underwent reintervention. Bayesian survival analysis was used to identify three intervals based on the change in the hazard of reintervention after TAVI. Multivariable Bayesian models were used to assess the association between survival or heart failure (HF) hospitalizations and intervals controlling for relevant confounders. RESULTS: Three intervals of reintervention were identified: early <3.5 years post TAVI, mid-term 3.5-< 7 years, and late ≥7 years. The hazard rate of reinterventions increased after TAVI from 0.26% during the early interval to 0.35% at mid-term and to 0.98% at the late interval. The most frequent cause for reintervention was valve stenosis, and it increased in mid-term (60.4%) and late (70.8%) intervals vs. early (31.3%), P<0.001. The rate of valve-in-valve procedures increased from 53.9% in the early interval to 79.6% in mid-term and to 97.2% in late interval. The 30-day and 1-year mortality risk was similar for all intervals. The adjusted risk of HF hospitalization was higher after early vs mid-term or late reinterventions. CONCLUSIONS: The hazard of reinterventions after TAVI increased over time with a major rise after 7 years. Mortality after reintervention was similar in different intervals, however, the HF risk of readmission was higher after early reinterventions. Post-TAVI care should be adapted to the increasing risk of reintervention over time.

Outcomes of Unplanned Additional Transcatheter Aortic Valve Deployment.

BACKGROUND: Significant residual aortic insufficiency (AI), paravalvular leak, and an embolized valve after transcatheter aortic valve replacement (TAVR) may require an additional TAVR valve as an unplanned intervention. However, the outcome of an unplanned additional valve deployment is scarcely documented. We evaluated postoperative outcomes in patients with unplanned additional TAVR valve deployment. METHODS: Between January 2021 and September 2023, 1131 patients underwent TAVR at Albany Medical Center Hospital (Albany, NY). A balloon-expanding valve was placed in 98.3% of patients, whereas a self-expanding valve was used in 1.7%. RESULTS: An additional unplanned transfemoral transcatheter aortic valve deployment was required in 0.01% (9 of 1131) of the patients (0.07% [7 of 1112] in the balloon-expanding valve group and 10.5% [2 of 19] in the self-expanding valve group. The indication for an additional valve was severe AI, valve embolization, or improper position of the first valve (66.7%, 22.2%, and 11.1%, respectively). AI was resolved in all patients except for 1, who died after second valve deployment for severe AI. Permanent pacemaker placement after a second TAVR was required in 2 patients (22%). The 30-day mortality was 16.7% (1 of 6) in the severe AI group, 0% (0 of 2) in the valve embolization group, and 0% (0 of 1) in the improper position group. The mean follow-up term was 5.3 (6.4) months. No aortic valve reintervention was performed in the follow-up term. The cumulative survival rates in patients with unplanned additional valve deployment were 88.9% at 1 month and 71.1% at 12 months. CONCLUSIONS: The outcome of unplanned second valve deployment in TAVR was satisfactory. However, unplanned additional valve deployment may increase the risk of permanent pacemaker placement.

A Moving Target: Interpreting Post-TAVI Reintervention in a Rapidly Evolving Era.

The Renaissance of Transapical TAVR: From Competing Access Route to Enabling Platform for Hybrid Heart Therapy.

Unmeasured Confounders and Interpretational Nuances in TAVR Comparisons Among Young Adults.

Lifetime Valve Management and the Economic Forces Behind TAVR Expansion in Younger Patients.

Right-heart reversibility, not tricuspid grade alone, should guide intervention in aortic stenosis

Carducci and colleagues1 should be congratulated for bringing attention to an important and often-underrecognized problem in contemporary aortic stenosis care: significant tricuspid regurgitation (TR) at the time of transcatheter aortic valve replacement (TAVR) evaluation is not benign. Their finding that moderate-to-severe TR predicts worse long-term survival after TAVR is clinically important.

Commentary: Aortic Valve Reinterventions post TAVI: Alarming Trends in Younger, Lower-risk Medicare Patients with High One-Year Mortality

Balloon-expandable vs. self-expandable transcatheter aortic valve implantation in bicuspid aortic valve stenosis: a meta-analysis of observational studies.

PURPOSE: If patients with bicuspid aortic valve (BAV) stenosis are high-risk candidates for traditional open-heart surgery, they can be treated with transcatheter aortic valve replacement (TAVR). The purpose of this study is to understand the effects of balloon-expandable valves (BEVs) and self-expandable valves (SEVs) as they are used in TAVR on patients with BAV stenosis. METHODS: We searched the databases PubMed, Embase, Cochrane, and ScienceDirect from their inception until January 2025. An odds ratio (OR) and corresponding 95% confidence interval (CI) were determined for every outcome, with statistical significance at p-value < 0.05. Random-effects models were used for studies with high heterogeneity (I 2 > 50%), and fixed-effects models for low heterogeneity (I 2 ≤ 50%). RESULTS: Nine observational studies were included. There was no significant difference found for the following outcomes: procedural death, 30-day mortality, 1-year all-cause mortality, annulus rupture, acute kidney injury, stroke, and moderate/severe paravalvular leak between BEV and SEV.Still, having a BEV was associated with a lower risk of needing a pacemaker or requiring second valve surgery. CONCLUSION: From this analysis, it seems that BEVs may provide better results than SEVs in terms of reducing the need for a pacemaker and a second valve in patients with BAV stenosis treated with TAVR. The number of deaths and serious complications was about the same for the two valves. Additional randomized controlled trials are needed to study both the lasting effects and the factors that shape these results. PROSPERO ID: CRD420251003387. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12055-025-02111-6.

Outcome of cerebral embolic protection during transcatheter aortic valve replacement in high-risk patient for stroke.

OBJECTIVES: The sentinel cerebral embolic protection device has been used as prophylaxis of stroke and transient ischemic attack during transcatheter aortic valve replacement. However, there are no absolute criteria guiding cerebral embolic protection device placement. This study aimed to evaluate the impact of cerebral embolic protection on postoperative cerebrovascular events in patients at high risk for stroke. METHODS: Between April 2021 and August 2023, 695 patients underwent transcatheter aortic valve replacement through a transfemoral approach. The cerebral embolic protection device was placed at the beginning of transcatheter aortic valve replacement procedure when 1 of the following criteria was met preoperatively: bicuspid aortic valve, valve-in-valve procedure, or calcium score in computed tomography greater than 1000. Of 695 patients with transcatheter aortic valve replacement, 636 met the criteria. The cerebral embolic protection device was placed in 55% of patients (350/636, cerebral embolic protection group) and not placed in 45% of patients (286/636, non-cerebral embolic protection group) because cerebral embolic protection was not feasible anatomically. A 1:1 propensity score matching was performed using the nearest neighbor method between cerebral embolic protection and non-cerebral embolic protection groups. RESULTS: A total of 245 pairs were matched in propensity score matching. After matching, postoperative stroke/transient ischemic attack occurred in 0.4% (1/245) in the cerebral embolic protection group and 2.9% (7/245) in the non-cerebral embolic protection group. A significant difference was noted in postoperative stroke/transient ischemic attack between the 2 groups (P = .03). Early mortality and other complications did not differ between the 2 groups. In postoperative follow-up, incidence of stroke/transient ischemic attack was similar in 30 days (2.0% vs 1.2%, P = .72) and 1 year (0.4% vs 1.2%, P = .62). There was no vascular complication at the cerebral embolic protection access site. CONCLUSIONS: Cerebral embolic protection during transcatheter aortic valve replacement might reduce postoperative cerebrovascular events in patients who are high risk for stroke in this patient cohort.

Commentary: Aortic Valve Reinterventions post TAVI: Alarming Trends in Younger, Lower-risk Medicare Patients with High One-Year Mortality.

Konno-Rastan aortoventriculoplasty after transcatheter aortic valve replacement explant for aortic annular enlargement.

Midterm analysis of tricuspid regurgitation in patients undergoing transcatheter mitral valve-in-valve replacement: A retrospective study.

OBJECTIVE: The evolution of concomitant tricuspid regurgitation (TR) after transcatheter mitral valve-in-valve replacement (TM-ViV) is poorly characterized. Therefore, we aimed to analyze the midterm changes in TR following TM-ViV at our center. METHODS: Clinical data of patients who underwent TM-ViV at Guangdong Provincial People's Hospital was retrospectively analyzed. In total, 96 patients underwent TM-ViV between April 2020 and October 2023. RESULTS: Preoperatively, 26 patients had mild or less TR (none/mild TR group), whereas 70 patients had moderate or more TR (moderate/severe TR group). The mean follow-up time was 32.4 ± 11.8 months, and the proportion of patients with moderate/severe TR at 1 month and 1 year postoperatively was significantly lower than the preoperative value (1 month: 47.3% vs 72.9%; P < .001; 1 year: 50.0% vs 72.9%; P = .001). No significant difference in midterm mortality outcomes was observed between the 2 groups (P > .999). CONCLUSIONS: After TM-ViV surgery, the degree of TR decreased in a majority of patients who had moderate or severe TR preoperatively at midterm follow-up. However, due to limited statistical power, our exploratory analysis could not establish an association between preoperative TR and midterm mortality. Therefore, the prognostic influence of TR severity in this setting remains uncertain and requires validation in future studies.

Outcomes of transatrial transcatheter mitral valve replacement with a balloon-expandable valve for severe mitral annular calcification.

OBJECTIVE: To evaluate operative and midterm outcomes, including 1-, 3-, and 5-year survival, of transatrial transcatheter mitral valve replacement (TA-TMVR) with a balloon-expandable valve for severe mitral annular calcification (MAC). METHODS: We retrospectively reviewed patients with severe MAC who underwent TA-TMVR from 2014 to 2024 using a balloon-expandable prosthesis. RESULTS: Twenty-five patients (68% were female, mean age 75 years) had TA-TMVR for mitral valve disease (92% severe stenosis, 52% moderate-to-severe mitral regurgitation). Previous cardiac surgery was common (48%). Median Society of Thoracic Surgeons Predicted Risk of Operative Mortality was 9% (2%-26%). Most patients were New York Heart Association class III or IV (76%). Preoperative left ventricular ejection fraction was 66%. Concomitant procedures were performed in 68% of cases (aortic valve replacement in 11, septal myectomy in 6, other procedures in 9). A SAPIEN 3 valve was used in 24 patients; most were modified with a felt skirt to improve sealing. Anterior leaflet resection was performed in 24 patients. Operative mortality was 12%. Median length of stay was 14 days. Postoperative left ventricular ejection fraction was 64%, and the mean mitral valve gradient was 5 mm Hg. Paravalvular leak were observed in 6 patients; 3 underwent successful transcatheter closure. One of these patients required a percutaneous valve-in-valve for on-going hemolysis. One-, 3-, and 5-year survival was 68%, 59.5%, and 50.6%, respectively. CONCLUSIONS: TA-TMVR with a balloon-expandable valve is a feasible and durable option for high-risk patients with severe MAC and those requiring concomitant procedures, offering an alternative to conventional surgery in anatomically complex or otherwise-inoperable cases.

Mitral valve surgery post-transcatheter aortic valve replacement: A 10-year, single-center, retrospective analysis.

OBJECTIVE: Cardiac operations after transcatheter aortic valve replacement (TAVR) are complex procedures with high morbidity and mortality. We sought to determine the outcomes of mitral valve surgery in patients with previous TAVR. METHODS: Among 2339 patients who underwent mitral valve surgery at our institution between July 2014 and July 2024, a retrospective, descriptive analysis was performed on 19 consecutive patients with a history of TAVR requiring mitral valve surgery. RESULTS: Mean age was 73.1 ± 9.5 years. The median (interquartile range) time since TAVR was 1 year (1, 3). The indication for mitral valve surgery was active infective endocarditis in 4 patients (21%), and degenerative disease in the remaining. The average Society of Thoracic Surgeons predicted risk of mortality was 12.0 ± 9.3%, with 6 (31.6%) urgent and 2 (10.5%) emergent operations. Nine patients (47.3%) had history of previous cardiac surgery. Mitral valve repair was performed in 1 patient, whereas replacement with a bioprosthetic valve in all other cases. Transcatheter valve explant was necessary in 10 operations (52.6%), and 13 patients had a concomitant procedure. The primary end point of all-cause mortality at 30 days was met in 5 patients (26.3%), 3 of whom underwent TAVR explant. One patient (5.3%) suffered a stroke. Median crossclamp and cardiopulmonary bypass times were 144 (106, 189) and 214 (155, 253) minutes, respectively. Postoperative dialysis was required in 4 (21.1%). One patient required a reintervention and 3 were re-hospitalized after discharge. CONCLUSIONS: Mitral valve surgery in the presence of TAVR is uncommon but carries a high risk of mortality and morbidity.

Predicting subclinical leaflet thrombosis in self-expandable prosthesis: A multimodal machine learning analysis.

OBJECTIVE: Subclinical leaflet thrombosis is a known finding after transcatheter aortic valve implantation, but its predictors remain poorly defined. Machine learning offers new opportunities for identifying complex, nonlinear relationships among clinical, anatomic, and hematological variables. METHODS: We analyzed data from 118 patients who underwent transcatheter aortic valve implantation with self-expanding valves and scheduled multidetector computed tomography at 6 months. A total of 120 preprocedural and postprocedural variables were included. Three machine learning models, least absolute shrinkage and selection operator logistic regression, Random Forest, and Extreme Gradient Boosting, were trained and internally validated using stratified 5-fold cross-validation. RESULTS: Subclinical leaflet thrombosis was identified in 22 patients (18.6%). Bicuspid aortic valve morphology emerged as one of the strongest predictors across all machine learning models (least absolute shrinkage and selection operator β = 1.33; Gini = 1.31; SHapley Additive exPlanations = 0.42). Other top predictors included serum creatinine (β = 0.29; Gini = 0.90), hemoglobin decrease (β = 0.05; Gini = 1.32; SHapley Additive exPlanations = 0.10), hematocrit decrease (β = 0.02; Gini = 1.43; SHapley Additive exPlanations = 0.11), and platelet nadir (SHapley Additive exPlanations = 0.09). All models demonstrated strong discriminative ability (area under the curve range, 0.84-0.89; Brier scores: 0.040-0.163). CONCLUSIONS: This is the first study to apply a multimodal machine learning framework to predict subclinical leaflet thrombosis after transcatheter aortic valve implantation. Bicuspid anatomy and perioperative hematological changes were consistently associated with subclinical leaflet thrombosis, highlighting the potential of machine learning to enhance postprocedural risk stratification. Incorporating routinely available variables into machine learning models may help guide early imaging and personalized antithrombotic strategies.

Transapical transcatheter valve implantation for aortic regurgitation: a multicenter, prospective trial.

OBJECTIVES: We evaluated the safety and efficacy of transcatheter aortic valve replacement (TAVR) up to 1-year follow-up for patients with severe pure aortic valve regurgitation (AR) or mixed severe aortic valve regurgitation and aortic valve stenosis (AR+AS) using a novel self-expandable bioprosthesis. METHODS: From 2021 and 2022, transapical TAVR using Ken-Valve (Jenscare Biotechnology Ltd, Ningbo, China) was performed in 142 symptomatic patients (mean age 70.3 ± 5.5 years) with pure AR (n = 109) or AR+AS (n = 33) across 15 hospitals in China. All patients were considered high-risk or inoperable after heart team evaluation, with a mean Society of Thoracic Surgeons score of 5.9 ± 3.0%, and 99.3% in NHYA class III/IV. Procedural characteristic, echocardiography data and clinical outcomes up to 1 year were analyzed. RESULTS: Technical success was achieved in 97.2% of cases. Two (1.4%) patients were converted to open surgery due to unsuitable anatomy or valve migration during the procedure. New permanent pacemakers were implanted in 20(14.1%) patients. Three (2.1%) patients had stroke, and 3(2.1%) patients had major bleeding. 30-day mortality was 2.1%, and all-cause mortality at 1-year was 5.6% (8/142). Mean aortic valve gradient and effective orifice area (EOA) at 1 year postoperatively were 9.4 ± 5.4 mmHg and 1.9 ± 0.6cm2, respectively. Significant improvement in clinical symptoms, positive left ventricular remodelling, and quality-of-life were observed up to 1-year. There was no significant difference in mortality, complications, and haemodynamic performance between patients with pure AR and AR+AS at 1-year. CONCLUSIONS: TAVR using the Ken-Valve was safe and effective in patients with pure AR or mixed AR+AS in mid-term.Transapical transcatheter valve implantation for aortic regurgitation: a multicentre, prospective trial.

Erratum to: Evolution of Right Ventricular Function and Pulmonary Artery Coupling After Transapical Transcatheter Mitral Valve Replacement.

Developing Transcatheter Skills as a Cardiac Surgery Resident: An Editorial Comment and Perspective. "Building the Hybrid Mindset without Losing the Craft".

Autonomous Agents for Auditable Cardiovascular Artificial Intelligence Development

Clinical artificial intelligence (AI) models are usually reported as finished artifacts, but each model reflects a limited human search across a much larger space of architectures, inputs, losses, optimizers, and training recipes. We tested whether autonomous code-writing agents could perform a controlled model-development experiment: proposing and evaluating code changes, and seeking performance gains without new data or human-guided edits. We built two such agents: an Iteration Agent that searches sequentially, keeping the best variant at each step, and an Evolution Agent that searches for variations in parallel using multiple large language models and prioritizes high-performing lineages across generations. In two architecturally distinct AI-enhanced electrocardiography (AI-ECG) models for structural heart disease, agent-optimized variants improved rank discrimination across held-out, external, and cross-institution evaluations, with area under the receiver operating characteristic curve gains of +0.006 to +0.039 (paired p < 0.05). At a fixed 90% sensitivity, specificity rose by up to 7.1 percentage points and positive predictive value by up to 4.8 percentage points. The selected code changes were substantive, spanning architecture, representation, and training recipe variations. These findings position autonomous agents as an auditable layer for clinical AI model improvement, provided that candidate selection, external validation, and post-update governance are explicit. We release these agents as an open, reusable toolkit.

Ecological Cascades and Future Hantavirus Spillover Risk in a Changing Climate

Anthropogenic climate change is reshuffling global biodiversity and accelerating zoonotic spillover at the human-wildlife interface. The 2026 multi-country cruise ship outbreak of Andes virus highlights the unpredictable and globalized threat posed by rodent-borne orthohantaviruses, which cause severe, highly fatal human diseases worldwide. Despite this significant public health risk, macroecological synthesis linking environmental drivers to systemic shifts in hantavirus hazards has been lacking. Here, we implement an integrated ecological and machine learning framework combining 89 unique virus-host associations across 61 reservoir species with mechanistic Force-of-Infection (FOI) modeling to project global spillover hazards under current and future climate scenarios (SSP2-4.5 and SSP5-8.5) for 2041-2060. Our models demonstrate a spatially uneven but geographically extensive expansion of spillover hazards, with approximately 74.9% of modeled land area experiencing an increase in FOI. We identify three distinct high-hazard belts heavily concentrated in already-temperate reservoir ranges: western and central North America, central and northeastern Europe extending into western Russia, and discrete patches within central South America. Crucially, our findings reveal that hantavirus hazards are fundamentally shaped along virus-specific ecological axes. While thermal and precipitation anomalies predominate the transmission dynamics of Old and New World lineages like Sin-Nombre virus and Thailand virus, distinct urban-centric Profiles emerge for Seoul virus and Mamore virus, driven explicitly by fine-scale anthropogenic landscape modifications. These results reveal that climate change will not simply intensify viral spillover uniformly but will fundamentally restructure it across varied climatic and human-dominated environments. Our maps provide a critical baseline for targeted global surveillance and highlight the urgent need to integrate spatial conservation planning with public health preparedness.

Recent data highlight TAVR’s long-term durability: What cardiologists need to know - Cardiovascular Business

Recent data highlight TAVR’s long-term durability: What cardiologists need to know&nbsp;&nbsp;Cardiovascular Business

Short Interest in Tavia Acquisition Corp. (NASDAQ:TAVI) Drops By 52.9% - MarketBeat

Short Interest in Tavia Acquisition Corp. (NASDAQ:TAVI) Drops By 52.9%&nbsp;&nbsp;MarketBeat

HeartBeam Patent Expands Cardiac Monitoring Platform to Include Heart Failure and Structural Heart Disease Capabilities - citybuzz -

HeartBeam Patent Expands Cardiac Monitoring Platform to Include Heart Failure and Structural Heart Disease Capabilities&nbsp;&nbsp;citybuzz -

Predicting AKI after TAVR | New SCCT president embraces listening, teamwork | Cardiologist’s lawsuit dismissed - Cardiovascular Business

Predicting AKI after TAVR | New SCCT president embraces listening, teamwork | Cardiologist’s lawsuit dismissed&nbsp;&nbsp;Cardiovascular Business

General Payment - openpaymentsdata.cms.gov

General Payment&nbsp;&nbsp;openpaymentsdata.cms.gov

Recent data highlight TAVR’s long-term durability: What cardiologists need to know

&lt;p&gt;Andy Morse, MD, the director of valvular and structural heart disease at Ascension Saint Thomas Hospital West in Nashville, leads a team that has performed more than 4,000 TAVR procedures. He spoke to Cardiovascular Business about recent findings on the long-term performance of the balloon-expandable SAPIEN 3™ platform.&lt;/p&gt;

Edwards Lifesciences served $10m penalty over JC Medical acquisition violations - Yahoo Finance

Edwards Lifesciences served $10m penalty over JC Medical acquisition violations&nbsp;&nbsp;Yahoo Finance

Recent data highlight TAVR’s long-term durability: What cardiologists need to know - Cardiovascular Business

Recent data highlight TAVR’s long-term durability: What cardiologists need to know&nbsp;&nbsp;Cardiovascular Business

Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch

Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day&nbsp;&nbsp;MarketWatch

FTC Fines Edwards $10M for Dodging Merger Review - Medical Device and Diagnostic industry

FTC Fines Edwards $10M for Dodging Merger Review&nbsp;&nbsp;Medical Device and Diagnostic industry

Baird Adjusts Price Target on Edwards Lifesciences to $94 From $87, Maintains Neutral Rating - Moomoo

Baird Adjusts Price Target on Edwards Lifesciences to $94 From $87, Maintains Neutral Rating&nbsp;&nbsp;Moomoo

Edwards Lifesciences, Genesis MedTech to Pay Combined $12M to Settle FTC Charges -- Update - Moomoo

Edwards Lifesciences, Genesis MedTech to Pay Combined $12M to Settle FTC Charges -- Update&nbsp;&nbsp;Moomoo

Edwards Lifesciences hits 52-week high after Medicare coverage proposal - MSN

Edwards Lifesciences hits 52-week high after Medicare coverage proposal&nbsp;&nbsp;MSN

Boston Scientific stock reflects steady medtech demand - Ad Hoc News

Boston Scientific stock reflects steady medtech demand&nbsp;&nbsp;Ad Hoc News

Single Heartbeat CCTA Acquisition Suffices in Many Young, Low-risk Patients - TCTMD.com

Single Heartbeat CCTA Acquisition Suffices in Many Young, Low-risk Patients&nbsp;&nbsp;TCTMD.com

Cardiologist’s lawsuit against former employer dismissed - Cardiovascular Business

Cardiologist’s lawsuit against former employer dismissed&nbsp;&nbsp;Cardiovascular Business

Newsletters - Cardiovascular Business

Newsletters&nbsp;&nbsp;Cardiovascular Business

General Payment - openpaymentsdata.cms.gov

General Payment&nbsp;&nbsp;openpaymentsdata.cms.gov

Form 4 Edwards Lifesciences Corp For: 13 July By Investing.com - Investing.com India

Form 4 Edwards Lifesciences Corp For: 13 July By Investing.com&nbsp;&nbsp;Investing.com India

Enteric pathogen burden and co-infection patterns across age and a rural-urban gradient: findings from the ECoMiD birth cohort, Northern Ecuador

Enteric pathogen infections are a major global health challenge, influenced by a variety of host and environmental factors, and their clinical presentation and treatment can be complicated by the presence of co-infections. The prevalence of enteric infections and co-infections tend to vary between rural and urban contexts, likely driven by underlying environmental, geographic, and demographic characteristics. To improve understanding of urbanicity and age on enteric pathogen prevalence and on co-infection risk, we measured 22 enteric pathogens in fecal samples collected from children aged 6, 12, and 18 months across a rural-urban gradient within the ECoMiD birth cohort study (n=473). Enteric pathogen burden was high and increased with age, with at least one pathogen detected in 91% of children at 6 months, 97% at 12 months, and 98% at 18 months. However, prevalence of some pathogens-- notably Salmonella enterica, enterovirus, and rotavirus-- decreased with age. Co-infections were also common (88%), and children were infected with as many as 11 pathogens simultaneously. The most frequently observed co-infection profiles included enteroaggregative E. coli and atypical enteropathogenic E. coli, followed by combinations with diffusely adherent E. coli, enterovirus, enterotoxigenic E. coli, and/or adenovirus. Enteric pathogen detection generally was higher in more rural settings, though patterns varied by pathogen. These results provide useful information for future examination of pathogen dynamics of co-occurrence. Given the ubiquity of enteric infections in high transmission settings, strategies that aim to reduce overall microbial exposure may be needed to supplement interventions targeting control of individual pathogens.

IL-21-producing peripheral helper T cells associate with autoimmune bile duct injury in biliary atresia

Abstract Background: Biliary atresia (BA) is a severe neonatal liver disease characterized by progressive fibrosis and bile duct obliteration. Objective: Although immune dysregulation is implicated in the pathogenesis of BA, the specific mechanisms driving bile duct injury remain incompletely understood. This study aimed to characterize tertiary lymphoid structures (TLSs) within extrahepatic biliary remnants (EBRs), identify their cellular mediators, and evaluate the therapeutic potential of targeting IL-21 receptor signaling. Design: We performed integrated bulk RNA sequencing, single-cell RNA sequencing, spatial transcriptomics, multiplex immunohistochemistry, and flow cytometry on clinical samples from BA patients and non-BA cholestatic controls. TLS maturation was assessed by CD23 immunohistochemistry in EBRs from 148 BA patients and correlated with clinical parameters. Anti-IL-21R antibody treatment was evaluated in a rhesus rotavirus-induced BA mouse model, with treatment initiated on day 4 post-infection. Results: TLSs were identified in BA EBRs with significantly higher prevalence than in matched liver tissues. Mature TLSs containing CD23 germinal centers were associated with elevated serum matrix metalloproteinase-7, more advanced hepatic fibrosis, and localized autoantibody deposition on injured bile ducts. Single-cell profiling revealed expanded CD4+ T peripheral helper (Tph) cells expressing IL-21 and CXCL13 within TLS-containing EBRs. Tph cells were enriched in peripheral blood of BA patients compared to non-BA cholestatic controls (P = 0.0025), and serum IL-21 was significantly elevated (P < 0.0001). Post-infection IL-21R blockade in the mouse model reduced jaundice incidence, improved weight gain, prevented extrahepatic biliary obstruction, and significantly improved long-term survival. Conclusion: TLSs in BA extrahepatic biliary remnants harbor expanded Tph cells associated with IL-21-mediated B cell activation and bile duct injury. IL-21R blockade ameliorated disease in a murine BA model, identifying the IL-21/IL-21R axis as a potential therapeutic target warranting further investigation.

Mechanism of membrane perforation in rotavirus cell entry

Cell entry of non-enveloped, animal viruses requires translocation of a macromolecular assembly across a cellular membrane. Double-stranded RNA viruses introduce into the target cell an inner capsid particle that does not uncoat further. Instead, it extrudes capped viral mRNA by virtue of polymerase and capping activities within it. As described here, we used cryogenic electron tomography to visualize the full course of rhesus rotavirus entry, from cell attachment and virion uptake to release of the subviral particle. The cryo-tomograms and subtomogram averaging of classified subparticles link high-resolution structures of the virion and its components with time series from live-cell fluorescence microscopy. We outlined the mechanism of each step in the entry process, including the membrane perforation step that transfers a subviral particle into the cytosol.

Acute kidney injury after TAVR: Simple biomarker helps cardiologists identify high-risk patients - Cardiovascular Business

Acute kidney injury after TAVR: Simple biomarker helps cardiologists identify high-risk patients&nbsp;&nbsp;Cardiovascular Business

Sublingual Nitroglycerin Appears Safe, Helpful for Pre-TAVI CCTA - TCTMD.com

Sublingual Nitroglycerin Appears Safe, Helpful for Pre-TAVI CCTA&nbsp;&nbsp;TCTMD.com

Vita Inclinata targets Nasdaq listing in proposed $450M SPAC deal - Stock Titan

Vita Inclinata targets Nasdaq listing in proposed $450M SPAC deal&nbsp;&nbsp;Stock Titan

The $10B TAVR Market Grew. Why Are Most Patients Still Untreated? - Yahoo Finance

The $10B TAVR Market Grew. Why Are Most Patients Still Untreated?&nbsp;&nbsp;Yahoo Finance

Tavia Acquisition Corp. (TAVI) signs non-binding LOI with Vita Inclinata - Stock Titan

Tavia Acquisition Corp. (TAVI) signs non-binding LOI with Vita Inclinata&nbsp;&nbsp;Stock Titan

Tripoli University Hospital carries out 12 advanced heart procedures - The Libya Observer

Tripoli University Hospital carries out 12 advanced heart procedures&nbsp;&nbsp;The Libya Observer

Tavi Costa’s Weaker Dollar Gold Thesis: Structural Forces Explained - Discovery Alert

Tavi Costa’s Weaker Dollar Gold Thesis: Structural Forces Explained&nbsp;&nbsp;Discovery Alert

Sublingual Nitroglycerin Appears Safe, Helpful for Pre-TAVI CCTA

Sublingual Nitroglycerin Appears Safe, Helpful for Pre-TAVI CCTA cmacahilig@crf.org Mon, 07/13/2026 - 10:19 Yael L. Maxwell Long contraindicated in patients with severe AS, the vasodilator may improve image quality with careful monitoring.

Acute kidney injury after TAVR: Simple biomarker helps cardiologists identify high-risk patients

&lt;p&gt;The CALLY index, a biomarker that examines systemic inflammation, immune system activity and nutrition, could provide care teams with significant value.&lt;/p&gt;

Edwards Lifesciences to pay record $10m for HSR evasion - Global Competition Review

Edwards Lifesciences to pay record $10m for HSR evasion&nbsp;&nbsp;Global Competition Review

Edwards Lifesciences, Genesis MedTech to Pay Combined $12M to Settle FTC Charges -- Update - Moomoo

Edwards Lifesciences, Genesis MedTech to Pay Combined $12M to Settle FTC Charges -- Update&nbsp;&nbsp;Moomoo

FTC Secures $12M Settlement Over Edwards-JC Medical Deal - Law360

FTC Secures $12M Settlement Over Edwards-JC Medical Deal&nbsp;&nbsp;Law360

Edwards Lifesciences, Genesis Medtech to pay $12m for HSR noncompliance - MLex

Edwards Lifesciences, Genesis Medtech to pay $12m for HSR noncompliance&nbsp;&nbsp;MLex

Form 4 Edwards Lifesciences Corp For: 13 July By Investing.com - Investing.com Nigeria

Form 4 Edwards Lifesciences Corp For: 13 July By Investing.com&nbsp;&nbsp;Investing.com Nigeria

Edwards Lifesciences, Genesis Medtech to pay $12m for HSR noncompliance - MLex

Edwards Lifesciences, Genesis Medtech to pay $12m for HSR noncompliance&nbsp;&nbsp;MLex

Boston Scientific stock reflects steady growth outlook as medical device demand expands - Ad Hoc News

Boston Scientific stock reflects steady growth outlook as medical device demand expands&nbsp;&nbsp;Ad Hoc News

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R) - Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R)&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

Kauvery Hospital Alwarpet Performs World's First Catheter-Based Treatment for Two Failing Heart Valves in a Man Aged 58 in Hybrid Cath Lab - ANI News

Kauvery Hospital Alwarpet Performs World's First Catheter-Based Treatment for Two Failing Heart Valves in a Man Aged 58 in Hybrid Cath Lab&nbsp;&nbsp;ANI News

Exposure to P. falciparum and common cold viruses shape vaccine responses in early life

Vaccine immunogenicity is consistently lower in low-income countries than in high-income settings, yet the factors driving this disparity remain incompletely understood. Using multiplexed electrochemiluminescence serology, we measured IgG and IgA responses to Expanded Program on Immunization (EPI) vaccines and common childhood viral infections in 89 Ugandan infants. We integrated detailed parasitological surveillance and maternal clinical data to examine how P. falciparum infection history, concurrent parasitemia, maternal gravidity, and early-life viral exposures shaped serological profiles. We found that infants mounted robust responses to most EPI vaccines, but critical gaps in protection persisted for diphtheria, measles and rubella. Children born to primigravid mothers had lower antibody levels at 8 weeks of age, independent of placental malaria and only partially explained by maternal age. Contrary to expectation, cumulative P. falciparum exposure was positively associated with antibody concentrations to diphtheria and varicella, and concurrent parasitemia was positively correlated with responses to multiple antigens. Early seroconversion to rhinovirus C was associated with higher polio IgA and rotavirus IgG concentrations at 24 weeks. Together, these findings suggest that common microbial exposures during infancy, including respiratory viruses and P. falciparum may positively modulate vaccine responsiveness.

Ascension St. Vincent Evansville Celebrates Historic 1,000th TAVR Procedure - Healthcare | Ascension

Ascension St. Vincent Evansville Celebrates Historic 1,000th TAVR Procedure&nbsp;&nbsp;Healthcare | Ascension

Ascension St. Vincent Evansville celebrates 1,000th TAVR procedure milestone - wevv.com

Ascension St. Vincent Evansville celebrates 1,000th TAVR procedure milestone&nbsp;&nbsp;wevv.com

Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch

Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors&nbsp;&nbsp;MarketWatch

Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch

Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors&nbsp;&nbsp;MarketWatch

Dithionite quenching of NBD-labeled lipids reveals artificial lipid droplet purity and neutral lipid surface accessibility

Artificial lipid droplets (aLDs) provide a controllable platform for studying lipid biochemistry, but their use is limited by contamination with other membrane structures and the lack of quantitative methods to assess sample purity. Here, we establish dithionite quenching of NBD-labeled lipids as a simple approach to evaluate aLD purity. The approach relies on dithionite's ability to selectively quench NBD fluorophores exposed in the phospholipid monolayer of aLDs and in the outer leaflet of liposome bilayers, but not those protected within the inner leaflet of liposome bilayers. Consistent with liposome contamination, bulk aLD preparations exhibit incomplete quenching, which can be separated by sucrose gradient centrifugation into liposome-like and droplet-enriched populations based on quenching behavior. Guided by this assay, sonication conditions were optimized to increase aLD purity and reduce liposome contamination. A biotin-streptavidin immobilization strategy further enabled stable imaging of individual aLDs. Finally, we applied this method to probe the accessibility of neutral lipids within aLDs. This revealed hydrophobicity-dependent quenching kinetics of neutral lipids, with less hydrophobic diacylglycerols showing greater surface exposure within aLDs than more hydrophobic triacylglycerols and cholesterol esters. Taken together, these establish dithionite quenching of NBD-labeled lipids as a simple quantitative method for assessing aLD purity and demonstrate its utility for studying lipid accessibility.

Aortic Valve System Market Growth to Accelerate by 2035 Amid TAVR Expansion and Aging Demographics - News and Statistics - IndexBox

Aortic Valve System Market Growth to Accelerate by 2035 Amid TAVR Expansion and Aging Demographics - News and Statistics&nbsp;&nbsp;IndexBox

Back In The Kitchen With Tavi - WWLTV.com

Back In The Kitchen With Tavi&nbsp;&nbsp;WWLTV.com

Tavi Named One Of The Best Restaurants In St. Tammany - WWLTV.com

Tavi Named One Of The Best Restaurants In St. Tammany&nbsp;&nbsp;WWLTV.com

AI-ECG Models Detect Structural Heart Disease, Identify At-Risk Patients - TCTMD.com

AI-ECG Models Detect Structural Heart Disease, Identify At-Risk Patients&nbsp;&nbsp;TCTMD.com

Edwards Lifesciences focuses on heart valve growth as US cardiac demand stays solid - Ad-hoc-news.de

Edwards Lifesciences focuses on heart valve growth as US cardiac demand stays solid&nbsp;&nbsp;Ad-hoc-news.de

CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients - Cardiovascular Business

CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients&nbsp;&nbsp;Cardiovascular Business

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430N) - Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430N)&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

AI-ECG Models Detect Structural Heart Disease, Identify At-Risk Patients

AI-ECG Models Detect Structural Heart Disease, Identify At-Risk Patients cmacahilig@crf.org Wed, 07/08/2026 - 14:38 Todd Neale The tools may help address underdiagnosis in this area, though there is still room for improvement in screening performance.

Edwards Lifesciences (EW) Shares Fresh Valve Data, Is The Stock Too Pricey? - simplywall.st

Edwards Lifesciences (EW) Shares Fresh Valve Data, Is The Stock Too Pricey?&nbsp;&nbsp;simplywall.st

Edwards Lifesciences (NYSE:EW) Valve Data Keeps Healthcare Focus - Kalkine Media

Edwards Lifesciences (NYSE:EW) Valve Data Keeps Healthcare Focus&nbsp;&nbsp;Kalkine Media

Edwards Lifesciences focuses on heart valve growth as US cardiac demand stays solid - Ad-hoc-news.de

Edwards Lifesciences focuses on heart valve growth as US cardiac demand stays solid&nbsp;&nbsp;Ad-hoc-news.de

What you need to know ahead of Edwards Lifesciences' earnings release - MSN

What you need to know ahead of Edwards Lifesciences' earnings release&nbsp;&nbsp;MSN

Boston Scientific (NYSE:BSX) Climbs As Cardiology Demand Expands - Kalkine Media

Boston Scientific (NYSE:BSX) Climbs As Cardiology Demand Expands&nbsp;&nbsp;Kalkine Media

The Edwards SAPIEN 3 Ultra Valve - Precision Transcatheter Option For US Heart Patients - AD HOC NEWS

The Edwards SAPIEN 3 Ultra Valve - Precision Transcatheter Option For US Heart Patients&nbsp;&nbsp;AD HOC NEWS

Jenscare Scientific Says Lux-Valve Plus Obtains EU MDR CE Certification - TradingView

Jenscare Scientific Says Lux-Valve Plus Obtains EU MDR CE Certification&nbsp;&nbsp;TradingView

Jenscare Wins EU MDR CE Mark for LuX-Valve Plus, Advancing Global Heart-Device Push - TipRanks

Jenscare Wins EU MDR CE Mark for LuX-Valve Plus, Advancing Global Heart-Device Push&nbsp;&nbsp;TipRanks

The Edwards SAPIEN 3 Ultra Valve - Precision Transcatheter Option For US Heart Patients - AD HOC NEWS

The Edwards SAPIEN 3 Ultra Valve - Precision Transcatheter Option For US Heart Patients&nbsp;&nbsp;AD HOC NEWS

Boston Scientific highlights its medical device role as investor interest stays steady - AD HOC NEWS

Boston Scientific highlights its medical device role as investor interest stays steady&nbsp;&nbsp;AD HOC NEWS

Form 4 Edwards Lifesciences Corp For: 7 July By Investing.com - Investing.com Nigeria

Form 4 Edwards Lifesciences Corp For: 7 July By Investing.com&nbsp;&nbsp;Investing.com Nigeria

Leptospirosis occurs as frequently as malaria among adolescent and adult acute febrile patients in Hoima, Uganda: A prospective health facility-based study

Background Leptospirosis is substantially underdiagnosed across sub-Saharan Africa, with its contribution to acute undifferentiated fever (AUF) poorly characterized. We determined the prevalence, risk factors, and clinical profile of leptospirosis among adolescents and adults presenting with AUF at a referral hospital and health centre in Hoima, western Uganda. Methods: In a prospective health facility-based study with convalescent follow-up, blood and urine from AUF patients were tested by LipL32 real-time PCR (qPCR) and microscopic agglutination (MAT). Leptospirosis was confirmed by qPCR positivity, a single test MAT titre of 1:800, or at least a fourfold titre rise or seroconversion in paired sera. Seroconversion was defined as a change from negative or 1:50 to 1:100 (conservative) or 1:200 (lenient). Seroprevalence was defined as a MAT titre of 1:100 or above in any sample. Risk factors were identified by multivariable logistic regression. Results: Among 330 AUF patients, acute leptospirosis prevalence was 27.0% (95% CI 22.3 to 32.1; conservative) and 32.7% (95% CI 27.7 to 38.1; lenient), comparable to malaria at 30.3% (95% CI 25.3 to 35.3), with co-infection in 8.8% (95% CI 5.7 to 11.8). qPCR detected Leptospira DNA in 9.1%, with 63.3% of qPCR-positive cases serologically confirmed and 24.4% of serological cases, qPCR-positive. Seroprevalence was 35.8% (95% CI 30.6 to 41.2); L. interrogans serovar Bataviae was predominant (18.2% of serological cases), reported here for the first time in Uganda. Skinning animals (aOR 5.19, 95% CI 1.40 to 21.16) and mosquito exposure (aOR 2.31, 95% CI 1.17 to 4.70) were the only independent risk factors in multivariable analysis. Discussion: Leptospirosis occurs as frequently as malaria among AUF patients in Hoima and warrants inclusion in Uganda's national febrile illness guidelines. The association of leptospirosis with skinning of animals suggests a potential role of animal exposure in leptospirosis transmission. Poor qPCR-MAT concordance confirms that accurate case ascertainment requires combined molecular and serological diagnostics.

Mechanical Leaflet Splitting is Feasible in High-Risk Patients Undergoing Valve-in-Valve TAVR - American College of Cardiology

Mechanical Leaflet Splitting is Feasible in High-Risk Patients Undergoing Valve-in-Valve TAVR&nbsp;&nbsp;American College of Cardiology

CMS Proposes TAVR Coverage Framework - Medscape

CMS Proposes TAVR Coverage Framework&nbsp;&nbsp;Medscape

Karpus Management (TAVI) discloses 1.89M shares, 21.63% stake - Stock Titan

Karpus Management (TAVI) discloses 1.89M shares, 21.63% stake&nbsp;&nbsp;Stock Titan

Edwards Lifesciences (EW) executive has shares withheld for tax on vesting - Stock Titan

Edwards Lifesciences (EW) executive has shares withheld for tax on vesting&nbsp;&nbsp;Stock Titan

Edwards Lifesciences’ SWOT analysis: stock gains momentum on market share opportunity - Investing.com

Edwards Lifesciences’ SWOT analysis: stock gains momentum on market share opportunity&nbsp;&nbsp;Investing.com

Edwards Lifesciences (EW) Has a Structural-Heart Platform Bigger Than a Single-Procedure Trade - AlphaStreet

Edwards Lifesciences (EW) Has a Structural-Heart Platform Bigger Than a Single-Procedure Trade&nbsp;&nbsp;AlphaStreet

Form 4 Edwards Lifesciences Corp For: 7 July By Investing.com - Investing.com Canada

Form 4 Edwards Lifesciences Corp For: 7 July By Investing.com&nbsp;&nbsp;Investing.com Canada

Edwards Lifesciences highlights structural heart portfolio as investors track long-term growth prosp - AD HOC NEWS

Edwards Lifesciences highlights structural heart portfolio as investors track long-term growth prosp&nbsp;&nbsp;AD HOC NEWS

Medtronic recalls heart valve delivery system due to safety risk - Cardiovascular Business

Medtronic recalls heart valve delivery system due to safety risk&nbsp;&nbsp;Cardiovascular Business

EW - Edwards Lifesciences Corp Options - Finviz

EW - Edwards Lifesciences Corp Options&nbsp;&nbsp;Finviz

SAFER-TAVI: Radial Eases Secondary Access Site Problems - TCTMD.com

SAFER-TAVI: Radial Eases Secondary Access Site Problems&nbsp;&nbsp;TCTMD.com

SAFER-TAVI: Radial Eases Secondary Access Site Problems

SAFER-TAVI: Radial Eases Secondary Access Site Problems cmacahilig@crf.org Mon, 07/06/2026 - 15:41 Todd Neale The findings should lead to changes in practice, David Cohen says, but as seen in the setting of PCI, “old habits die hard.”

Edwards Lifesciences Investors Seek 1st OK For $39M Deal - Law360

Edwards Lifesciences Investors Seek 1st OK For $39M Deal&nbsp;&nbsp;Law360

EW - Edwards Lifesciences Corp Latest SEC Filings - Finviz

EW - Edwards Lifesciences Corp Latest SEC Filings&nbsp;&nbsp;Finviz

EW Maintained by Evercore ISI Group -- Price Target Raised to $1 - GuruFocus

EW Maintained by Evercore ISI Group -- Price Target Raised to $1&nbsp;&nbsp;GuruFocus

Edwards Lifesciences Corp (EW): Analyst Consensus Points to Growth Potential in the Medical Device Sector - DirectorsTalk Interviews

Edwards Lifesciences Corp (EW): Analyst Consensus Points to Growth Potential in the Medical Device Sector&nbsp;&nbsp;DirectorsTalk Interviews

Medtronic recalls heart valve delivery system due to safety risk - Cardiovascular Business

Medtronic recalls heart valve delivery system due to safety risk&nbsp;&nbsp;Cardiovascular Business

Boston Scientific Corp. highlights minimally invasive care. Long-term demand supports its medical te - AD HOC NEWS

Boston Scientific Corp. highlights minimally invasive care. Long-term demand supports its medical te&nbsp;&nbsp;AD HOC NEWS

The WATCHMAN FLX Pro. Boston Scientific bets on stroke risk reduction for US heart patients - AD HOC NEWS

The WATCHMAN FLX Pro. Boston Scientific bets on stroke risk reduction for US heart patients&nbsp;&nbsp;AD HOC NEWS

Midterm Clinical and Echocardiographic Outcomes After Transcatheter Aortic Valve Replacement in Patients With Severe Bicuspid Aortic Valve Stenosis - American Heart Association Journals

Midterm Clinical and Echocardiographic Outcomes After Transcatheter Aortic Valve Replacement in Patients With Severe Bicuspid Aortic Valve Stenosis&nbsp;&nbsp;American Heart Association Journals

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R) - Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R)&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

EW - Edwards Lifesciences Corp Volatility & Greeks - Finviz

EW - Edwards Lifesciences Corp Volatility & Greeks&nbsp;&nbsp;Finviz

Price to earnings forward of Edwards Lifesciences Corporation – NYSE:EW - TradingView

Price to earnings forward of Edwards Lifesciences Corporation – NYSE:EW&nbsp;&nbsp;TradingView

Boston Scientific focuses on cardiovascular devices as investors look at long-term growth - AD HOC NEWS

Boston Scientific focuses on cardiovascular devices as investors look at long-term growth&nbsp;&nbsp;AD HOC NEWS

LCD - Temporary Nontherapeutic Ambulatory Cardiac Monitoring Devices (L40244) - Centers for Medicare & Medicaid Services | CMS (.gov)

LCD - Temporary Nontherapeutic Ambulatory Cardiac Monitoring Devices (L40244)&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

How Recall and Watchman Concerns Will Impact Boston Scientific (BSX) Investors - simplywall.st

How Recall and Watchman Concerns Will Impact Boston Scientific (BSX) Investors&nbsp;&nbsp;simplywall.st

The Shape Of Her Heart: The Inspiration Behind the DurAVR Valve From Anteris Technologies - insights.citeline.com

The Shape Of Her Heart: The Inspiration Behind the DurAVR Valve From Anteris Technologies&nbsp;&nbsp;insights.citeline.com

Cardiologists highlight early success with leaflet modification device for valve-in-valve TAVR - Cardiovascular Business

Cardiologists highlight early success with leaflet modification device for valve-in-valve TAVR&nbsp;&nbsp;Cardiovascular Business

Looking Back: Is coffee bad for the heart? | Procedure kit recalls | Cardiologist gets wake-up call | TAVR policy changes - Cardiovascular Business

Looking Back: Is coffee bad for the heart? | Procedure kit recalls | Cardiologist gets wake-up call | TAVR policy changes&nbsp;&nbsp;Cardiovascular Business

Cardiologists highlight early success with leaflet modification device for valve-in-valve TAVR

&lt;p&gt;The FDA-cleared ShortCut leaflet modification device has been linked to positive real-world outcomes.&lt;/p&gt;

Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains&nbsp;&nbsp;MarketWatch

EW - Edwards Lifesciences Corp Latest SEC Filings - Finviz

EW - Edwards Lifesciences Corp Latest SEC Filings&nbsp;&nbsp;Finviz

TD Cowen Names Edwards Lifesciences as Top Medical Device Pick By Investing.com - Investing.com Australia

TD Cowen Names Edwards Lifesciences as Top Medical Device Pick By Investing.com&nbsp;&nbsp;Investing.com Australia

Edwards Lifesciences stock hits 52-week high at 92.94 USD By Investing.com - Investing.com Australia

Edwards Lifesciences stock hits 52-week high at 92.94 USD By Investing.com&nbsp;&nbsp;Investing.com Australia

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day&nbsp;&nbsp;MSN

Edwards Lifesciences stock hits 52-week high at 92.94 USD By Investing.com - Investing.com India

Edwards Lifesciences stock hits 52-week high at 92.94 USD By Investing.com&nbsp;&nbsp;Investing.com India

Boston Scientific focuses on cardiovascular growth as medical device demand stays resilient - Ad-hoc-news.de

Boston Scientific focuses on cardiovascular growth as medical device demand stays resilient&nbsp;&nbsp;Ad-hoc-news.de

Edwards Lifesciences highlights heart valve innovation as demand for structural heart therapies grow - AD HOC NEWS

Edwards Lifesciences highlights heart valve innovation as demand for structural heart therapies grow&nbsp;&nbsp;AD HOC NEWS

Edwards Lifesciences highlights heart valve innovation as demand for structural heart therapies grow - AD HOC NEWS

Edwards Lifesciences highlights heart valve innovation as demand for structural heart therapies grow&nbsp;&nbsp;AD HOC NEWS

Second Universal Definition of HF Focuses on Phenotypes and Etiology - TCTMD.com

Second Universal Definition of HF Focuses on Phenotypes and Etiology&nbsp;&nbsp;TCTMD.com

What You Need To Know Ahead of Edwards Lifesciences' Earnings Release - inkl

What You Need To Know Ahead of Edwards Lifesciences' Earnings Release&nbsp;&nbsp;inkl

JenaValve data backs Trilogy TAVR in AR, LVAD patients - MassDevice

JenaValve data backs Trilogy TAVR in AR, LVAD patients&nbsp;&nbsp;MassDevice

TCTMD’s Top 10 Most Popular Stories for June 2026 - TCTMD.com

TCTMD’s Top 10 Most Popular Stories for June 2026&nbsp;&nbsp;TCTMD.com

TCTMD’s Top 10 Most Popular Stories for June 2026

TCTMD’s Top 10 Most Popular Stories for June 2026 cmacahilig@crf.org Wed, 07/01/2026 - 15:13 Todd Neale TAVI news, including stories from the recent New York Valves conference, claimed several of the top spots.

New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI

New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI cmacahilig@crf.org Wed, 07/01/2026 - 13:47 Publish Date --> 15 hours 2 minutes ago Teaser --> In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day&nbsp;&nbsp;MarketWatch

What You Need To Know Ahead of Edwards Lifesciences' Earnings Release - Yahoo Finance

What You Need To Know Ahead of Edwards Lifesciences' Earnings Release&nbsp;&nbsp;Yahoo Finance

EW - Edwards Lifesciences Corp Latest SEC Filings - Finviz

EW - Edwards Lifesciences Corp Latest SEC Filings&nbsp;&nbsp;Finviz

TAX MANAGED MULTI CAP GROWTH PORTFOLIO's Edwards Lifesciences Corp(EW) Holding History - GuruFocus

TAX MANAGED MULTI CAP GROWTH PORTFOLIO's Edwards Lifesciences Corp(EW) Holding History&nbsp;&nbsp;GuruFocus

Edwards Lifesciences CVP Daniel Lippis sells $56k in stock By Investing.com - Investing.com South Africa

Edwards Lifesciences CVP Daniel Lippis sells $56k in stock By Investing.com&nbsp;&nbsp;Investing.com South Africa

Edwards Lifesciences CVP Daniel Lippis sells $56k in stock - Investing.com UK

Edwards Lifesciences CVP Daniel Lippis sells $56k in stock&nbsp;&nbsp;Investing.com UK

TAVR and Surgery Show Comparable Valve Durability at 7 Years in severe aortic stenosis: JAMA - Medical Dialogues

TAVR and Surgery Show Comparable Valve Durability at 7 Years in severe aortic stenosis: JAMA&nbsp;&nbsp;Medical Dialogues

Two new artificial intelligence products that can improve cardiac care - Substack

Two new artificial intelligence products that can improve cardiac care&nbsp;&nbsp;Substack

Top Transcatheter Heart Valve Replacement Market Companies - SNS Insider

Top Transcatheter Heart Valve Replacement Market Companies&nbsp;&nbsp;SNS Insider

Edwards Lifesciences (NYSE: EW) exec sells 619 shares under 10b5-1 plan - Stock Titan

Edwards Lifesciences (NYSE: EW) exec sells 619 shares under 10b5-1 plan&nbsp;&nbsp;Stock Titan

Edwards Lifesciences CVP Daniel Lippis sells $56k in stock By Investing.com - Investing.com Nigeria

Edwards Lifesciences CVP Daniel Lippis sells $56k in stock By Investing.com&nbsp;&nbsp;Investing.com Nigeria

Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc - GuruFocus

Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc&nbsp;&nbsp;GuruFocus

Form 4 Edwards Lifesciences Corp For: 30 June By Investing.com - Investing.com Nigeria

Form 4 Edwards Lifesciences Corp For: 30 June By Investing.com&nbsp;&nbsp;Investing.com Nigeria

Top Transcatheter Heart Valve Replacement Market Companies - SNS Insider

Top Transcatheter Heart Valve Replacement Market Companies&nbsp;&nbsp;SNS Insider

Heart failure drug recalled due to risk of contamination - Cardiovascular Business

Heart failure drug recalled due to risk of contamination&nbsp;&nbsp;Cardiovascular Business

Early Data Look Promising for Nickel-Free Siegel TAVI Valve - TCTMD.com

Early Data Look Promising for Nickel-Free Siegel TAVI Valve&nbsp;&nbsp;TCTMD.com

Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option - Yahoo Finance

Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option&nbsp;&nbsp;Yahoo Finance

Mining Margins Beat Google’s. Here’s What That Tells You About Gold. - GoldSilver

Mining Margins Beat Google’s. Here’s What That Tells You About Gold.&nbsp;&nbsp;GoldSilver

Early Data Look Promising for Nickel-Free Siegel TAVI Valve

Early Data Look Promising for Nickel-Free Siegel TAVI Valve cmacahilig@crf.org Tue, 06/30/2026 - 12:45 Yael L. Maxwell The novel balloon-expandable device had good clinical outcomes and favorable hemodynamics out to 2 years.

EW - Edwards Lifesciences Corp Latest SEC Filings - Finviz

EW - Edwards Lifesciences Corp Latest SEC Filings&nbsp;&nbsp;Finviz

Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference - Yahoo Finance

Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference&nbsp;&nbsp;Yahoo Finance

Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference - Yahoo Finance

Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference&nbsp;&nbsp;Yahoo Finance

Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says - Moomoo

Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says&nbsp;&nbsp;Moomoo

Enteric pathogen infections among infants in rural Bangladesh: prevalence, trial impact, and associations with enteric dysfunction and growth.

Background: Repeated enteric infections and chronic enteric dysfunction have been associated with undernutrition in children. Interventions that reduce enteric pathogen exposure in young children could thereby improve growth and developmental outcomes. We assessed enteric pathogen prevalence in Bangladeshi infants, the impact of a combined homestead food production and food hygiene intervention on pathogen infections, and associations between pathogen infections, enteric dysfunction markers, and child growth outcomes. Methods: We analyzed panel data from 231 children born between April and December 2018 within the Food and Agricultural Approaches to Reducing Malnutrition (FAARM) cluster-randomized trial in Sylhet, Bangladesh. Stool samples were collected at 0-3, 6-8, and 10-13 months of age and assessed for enteric dysfunction biomarkers (myeloperoxidase, alpha-1 antitrypsin, and neopterin) by ELISA and 14 enteric pathogens by multiplex RT-PCR. Diarrhea prevalence was recorded using 7-day recall. Child length and weight were measured at birth and trial endline. Multilevel regression assessed the intervention effect and quantified associations between pathogen exposure, enteric dysfunction, and growth outcomes. Findings: Enteric pathogen prevalence was high (84%) despite low 7-day diarrhea prevalence (5%), and co-infections were common. There was no intervention effect on the prevalence of enteric pathogens. Shigella spp. and Giardia lamblia were associated with higher myeloperoxidase concentrations, while sapovirus was associated with higher alpha-1 antitrypsin concentrations. Repeated protozoan infections (mainly Giardia lamblia) were associated with lower length-for-age, while repeated viral infections (mainly rotavirus and sapovirus) and Cryptosporidium infections were associated with lower weight-for-height and weight-for-age. There was marginal evidence that bacterial infections were associated with lower length-for-age. Conclusion: The intervention was insufficient to reduce the high burden of enteric pathogens in infants, and subclinical infections were associated with enteric dysfunction and poorer growth outcomes. Comprehensive strategies addressing all key exposure pathways are needed to limit pathogen infections and their consequences for child development.

JenaValve TAVR Device Promising for LVAD-Associated Aortic Regurgitation - MedPage Today

JenaValve TAVR Device Promising for LVAD-Associated Aortic Regurgitation&nbsp;&nbsp;MedPage Today

A Buddy When You Need One: Buddy Balloon-Assisted Bailout for Failed Valve Crossing During Transfemoral Transcatheter Aortic Valve Implantation - Cureus

A Buddy When You Need One: Buddy Balloon-Assisted Bailout for Failed Valve Crossing During Transfemoral Transcatheter Aortic Valve Implantation&nbsp;&nbsp;Cureus

EARLY-TAVR Returns, WISeR’s Funding Cuts, and IL-6 Biomarker - Cardiac Wire

EARLY-TAVR Returns, WISeR’s Funding Cuts, and IL-6 Biomarker&nbsp;&nbsp;Cardiac Wire

New cardiac procedure changing lives in Southwest Michigan - MLive.com

New cardiac procedure changing lives in Southwest Michigan&nbsp;&nbsp;MLive.com

Americans keep poisoning themselves with semaglutide, other weight loss drugs - Cardiovascular Business

Americans keep poisoning themselves with semaglutide, other weight loss drugs&nbsp;&nbsp;Cardiovascular Business

General Payment - openpaymentsdata.cms.gov

General Payment&nbsp;&nbsp;openpaymentsdata.cms.gov

Alkem Laboratories Surges into Structural Heart Segment with 51%-55% Stake in Occlutech Holding AG - sahi.com

Alkem Laboratories Surges into Structural Heart Segment with 51%-55% Stake in Occlutech Holding AG&nbsp;&nbsp;sahi.com

Edwards Lifesciences: The Heart of OC Medtech - Orange County Business Journal

Edwards Lifesciences: The Heart of OC Medtech&nbsp;&nbsp;Orange County Business Journal

Edwards Lifesciences Corporation(NYSE: EW) added to Russell Midcap Value Benchmark - marketscreener.com

Edwards Lifesciences Corporation(NYSE: EW) added to Russell Midcap Value Benchmark&nbsp;&nbsp;marketscreener.com

Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says - 富途牛牛

Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says&nbsp;&nbsp;富途牛牛

Boston Scientific strategy focus, shares hold in S&P 500 healthcare group - AD HOC NEWS

Boston Scientific strategy focus, shares hold in S&amp;P 500 healthcare group&nbsp;&nbsp;AD HOC NEWS

Boston Scientific cautious consensus picture, shares near 1-year low on NYSE - AD HOC NEWS

Boston Scientific cautious consensus picture, shares near 1-year low on NYSE&nbsp;&nbsp;AD HOC NEWS

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - View Public Comments - Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - View Public Comments&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

Edwards Lifesciences (EW) Stock Weighs DCF Fair Value Against High P/E Multiple - simplywall.st

Edwards Lifesciences (EW) Stock Weighs DCF Fair Value Against High P/E Multiple&nbsp;&nbsp;simplywall.st

TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data - Cardiovascular Business

TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data&nbsp;&nbsp;Cardiovascular Business

Why Is Silver’s Mining Margin So Wide? Tavi Costa Explains - GoldSilver

Why Is Silver’s Mining Margin So Wide? Tavi Costa Explains&nbsp;&nbsp;GoldSilver

Transcatheter Heart Valve Replacement Market to Reach US$24.07 Billion by 2034 as Minimally Invasive Cardiac Procedures Transform Heart Valve Treatment - vocal.media

Transcatheter Heart Valve Replacement Market to Reach US$24.07 Billion by 2034 as Minimally Invasive Cardiac Procedures Transform Heart Valve Treatment&nbsp;&nbsp;vocal.media

TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data

&lt;p&gt;All patients presented with severe aortic regurgitation. The study's findings were presented at New York Valves 2026 and published in &lt;em&gt;JSCAI&lt;/em&gt;.&lt;/p&gt;

TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data - Cardiovascular Business

TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data&nbsp;&nbsp;Cardiovascular Business

Boston Scientific (NYSE:BSX) Gains Fresh Market Attention - Kalkine Media

Boston Scientific (NYSE:BSX) Gains Fresh Market Attention&nbsp;&nbsp;Kalkine Media

TAVR for Asymptomatic Severe AS: Updated Results from the EARLY-TAVR trial - TCTMD.com

TAVR for Asymptomatic Severe AS: Updated Results from the EARLY-TAVR trial&nbsp;&nbsp;TCTMD.com

Outcomes of TAVR with the Evolut Platform: Results from the VA-CART Program - TCTMD.com

Outcomes of TAVR with the Evolut Platform: Results from the VA-CART Program&nbsp;&nbsp;TCTMD.com

Edwards Lifesciences stock hits 52-week high at 89.7 USD By Investing.com - Investing.com South Africa

Edwards Lifesciences stock hits 52-week high at 89.7 USD By Investing.com&nbsp;&nbsp;Investing.com South Africa

EARLY TAVR: 5-Year Data Still Support TAVI Over Surveillance in Asymptomatic AS - TCTMD.com

EARLY TAVR: 5-Year Data Still Support TAVI Over Surveillance in Asymptomatic AS&nbsp;&nbsp;TCTMD.com

Midterm TAVR Data Turn Muddy: Will 10 Years Even Suffice for a Verdict? - MedPage Today

Midterm TAVR Data Turn Muddy: Will 10 Years Even Suffice for a Verdict?&nbsp;&nbsp;MedPage Today

RCT, Real-World Data Show TAVI Durability Up to 7 Years in Low-risk Patients - TCTMD.com

RCT, Real-World Data Show TAVI Durability Up to 7 Years in Low-risk Patients&nbsp;&nbsp;TCTMD.com

Is the Silver Rally Over? Tavi Costa Breaks Down the Selloff - GoldSilver

Is the Silver Rally Over? Tavi Costa Breaks Down the Selloff&nbsp;&nbsp;GoldSilver

Sweeping TAVR changes on the way | Pushing back against AI-powered prior authorization | FDA highlights recall after injuries - Cardiovascular Business

Sweeping TAVR changes on the way | Pushing back against AI-powered prior authorization | FDA highlights recall after injuries&nbsp;&nbsp;Cardiovascular Business

RCT, Real-World Data Show TAVI Durability Up to 7 Years in Low-risk Patients

RCT, Real-World Data Show TAVI Durability Up to 7 Years in Low-risk Patients hdellabella@crf.org Wed, 06/24/2026 - 16:48 Todd Neale The results were framed as reassuring, although experts made it clear that longer-term follow-up is needed.

EARLY TAVR: 5-Year Data Still Support TAVI Over Surveillance in Asymptomatic AS

EARLY TAVR: 5-Year Data Still Support TAVI Over Surveillance in Asymptomatic AS hdellabella@crf.org Wed, 06/24/2026 - 16:27 Yael L. Maxwell While the dataset is incomplete, the death and stroke curves appear to separate at 2 years, notes Philippe Généreux.

Top Cardiology News for June 2026

Top Cardiology News for June 2026 cmacahilig@crf.org Wed, 06/24/2026 - 07:38 Publish Date --> 20 hours 57 minutes ago Teaser --> The TCTMD journalists talk about 10-year TAVI data, a FLOW subanalysis, and women's heart centers in Europe. NY Valves co-director David Cohen joins as a guest.

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day&nbsp;&nbsp;MarketWatch

Edwards Lifesciences stock hits 52-week high at 89.7 USD - Investing.com

Edwards Lifesciences stock hits 52-week high at 89.7 USD&nbsp;&nbsp;Investing.com

A Look at Edwards Lifesciences Corp (EW) After 3.1% Gain -- GF V - GuruFocus

A Look at Edwards Lifesciences Corp (EW) After 3.1% Gain -- GF V&nbsp;&nbsp;GuruFocus

Why Boston Scientific is betting $1.5B on this TAVR superalloy - Medical Design & Outsourcing

Why Boston Scientific is betting $1.5B on this TAVR superalloy&nbsp;&nbsp;Medical Design & Outsourcing

Agentic Autodiscovery of Diastolic Dysfunction Phenotypes from Surface Electrocardiogram

Background: Left ventricular diastolic dysfunction (LVDD) is a major determinant of heart failure (HF), yet its assessment relies on multiparametric echocardiography, limiting scalability. We previously demonstrated that generative artificial intelligence (AI) can synthesize tissue Doppler imaging (TDI) waveforms from the 12-lead ECG. The growing complexity of candidate architecture creates a need for automated model-discovery frameworks. Objectives: To evaluate agentic AI-based auto-discovery for ECG-based LVDD assessment using either raw ECG or synthetic TDI waveforms. Methods: Two attention-based agentic AI architectures were developed using an automated large language model-driven refinement framework that optimized transfer-learning and multimodal architectures through autonomous proposal, validation, and selection of candidate model configurations. Development was performed in 1,011 paired ECG-echocardiography studies and externally validated in 983 patients using two reference frameworks: (i) data-driven phenogroups and (ii) the 2025 ASE Diastolic Function Guidelines. External validation was performed in CODE-15% (n=219,567) for HF-related mortality and EchoNext (n=35,718) for structural heart disease associations. Results: Despite the modest cohort size, the ECG-based agentic search achieved area under the receiver operating characteristic curve (AUCs) of 0.87 (95% CI: 0.85-0.89) and 0.83 (95% CI: 0.80-0.86) for phenogroup and guideline-based LVDD severity classification. Corresponding AUCs for the synthetic TDI-based model were 0.82 (95% CI: 0.80-0.85) and 0.80 (95% CI: 0.77-0.84), respectively. In large-scale external validation, both models stratified incident HF mortality with subdistribution hazard ratios ranging 5.5 to 9.5 (Gray's p<0.001 for all). Time-dependent discrimination for incident HF mortality exceeded a publicly available convolutional neural network model (ECG2HF) ({Delta}AUC range: +0.14 to +0.20). Both models demonstrated consistent associations with structural heart disease outcomes. Conclusions: Agentic auto-discovery enabled data-efficient assessment of LVDD from surface ECG by combining physiologically informed transfer learning with autonomous architecture optimization, achieving robust external generalizability. This approach may facilitate broader access to diastolic function assessment beyond conventional echocardiography.

Is the Silver Rally Over? Tavi Costa Breaks Down the Selloff - GoldSilver

Is the Silver Rally Over? Tavi Costa Breaks Down the Selloff&nbsp;&nbsp;GoldSilver

Price-Driven Insight from (TAVI) for Rule-Based Strategy - Stock Traders Daily

Price-Driven Insight from (TAVI) for Rule-Based Strategy&nbsp;&nbsp;Stock Traders Daily

Hundreds of cardiologists incorrectly added to new mandatory payment model - Cardiovascular Business

Hundreds of cardiologists incorrectly added to new mandatory payment model&nbsp;&nbsp;Cardiovascular Business

Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains&nbsp;&nbsp;MarketWatch

The real impact of RVU cuts in electrophysiology | TAVR changes on the way | Cardiology groups celebrate bill | BP drug recalled - Cardiovascular Business

The real impact of RVU cuts in electrophysiology | TAVR changes on the way | Cardiology groups celebrate bill | BP drug recalled&nbsp;&nbsp;Cardiovascular Business

A sweeping new AI to detect heart conditions is coming to OpenEvidence - statnews.com

A sweeping new AI to detect heart conditions is coming to OpenEvidence&nbsp;&nbsp;statnews.com

Cardiothoracic surgeon Joseph Woo takes over as new AATS president - Cardiovascular Business

Cardiothoracic surgeon Joseph Woo takes over as new AATS president&nbsp;&nbsp;Cardiovascular Business

Cardiology groups strongly oppose expansion of Medicare AI prior authorization model - Cardiovascular Business

Cardiology groups strongly oppose expansion of Medicare AI prior authorization model&nbsp;&nbsp;Cardiovascular Business

CMS Proposes TAVR Medicare Coverage is Potential Boost for Edwards Lifesciences - MedTech Intelligence

CMS Proposes TAVR Medicare Coverage is Potential Boost for Edwards Lifesciences&nbsp;&nbsp;MedTech Intelligence

Edwards Lifesciences strategy focus, S&P 500 stock anchored in heart valve growth - AD HOC NEWS

Edwards Lifesciences strategy focus, S&amp;P 500 stock anchored in heart valve growth&nbsp;&nbsp;AD HOC NEWS

Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors - MarketWatch

Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors&nbsp;&nbsp;MarketWatch

CMS Proposes TAVR Medicare Coverage is Potential Boost for Edwards Lifesciences - MedTech Intelligence

CMS Proposes TAVR Medicare Coverage is Potential Boost for Edwards Lifesciences&nbsp;&nbsp;MedTech Intelligence

Mumbai Sees 25 persent Rise in TAVI and Other Minimally Invasive Heart Procedures YoY, Reinforcing Its Position as India’s Most Mature Cardiac Care Ecosystem - TheWire.in

Mumbai Sees 25 persent Rise in TAVI and Other Minimally Invasive Heart Procedures YoY, Reinforcing Its Position as India’s Most Mature Cardiac Care Ecosystem&nbsp;&nbsp;TheWire.in

Elite CT cyclist, 81, isn’t letting heart surgery slow him down. Up next? A grueling mountain ride - Hartford Courant

Elite CT cyclist, 81, isn’t letting heart surgery slow him down. Up next? A grueling mountain ride&nbsp;&nbsp;Hartford Courant

Raluca Ileana Mincu: Excellent Presentation on TAVI in Patients With Cancer at ESC Cardio-Oncology 2026 - Oncodaily

Raluca Ileana Mincu: Excellent Presentation on TAVI in Patients With Cancer at ESC Cardio-Oncology 2026&nbsp;&nbsp;Oncodaily

Week in Review: CCTA on ACC expo floor gives cardiologist wake-up call | Reaction to CMS TAVR changes | Recalls and new AI - Cardiovascular Business

Week in Review: CCTA on ACC expo floor gives cardiologist wake-up call | Reaction to CMS TAVR changes | Recalls and new AI&nbsp;&nbsp;Cardiovascular Business

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2)&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

[Jul30@6:50PM] -$EW (Edwards Lifesciences) $BSX (Boston Scientific) Olivia Andre Dilley Detention Release (pdXmm2AYCq) - Mshale

[Jul30@6:50PM] -$EW (Edwards Lifesciences) $BSX (Boston Scientific) Olivia Andre Dilley Detention Release (pdXmm2AYCq)&nbsp;&nbsp;Mshale

Edwards Lifesciences hits 52-week high after Medicare coverage proposal - MSN

Edwards Lifesciences hits 52-week high after Medicare coverage proposal&nbsp;&nbsp;MSN

Edwards Lifesciences hits 52-week high after Medicare coverage proposal - MSN

Edwards Lifesciences hits 52-week high after Medicare coverage proposal&nbsp;&nbsp;MSN

High-intensity ultrasound technology for calcified valve leaflets makes debut in Europe - Cardiovascular Business

High-intensity ultrasound technology for calcified valve leaflets makes debut in Europe&nbsp;&nbsp;Cardiovascular Business

Bovine Pericardial Valve Market to Reach US$ 6.08 Billion - openPR.com

Bovine Pericardial Valve Market to Reach US$ 6.08 Billion&nbsp;&nbsp;openPR.com

Why Edwards Lifesciences Corporation (NYSE:EW) Could Be Worth Watching - Moomoo

Why Edwards Lifesciences Corporation (NYSE:EW) Could Be Worth Watching&nbsp;&nbsp;Moomoo

10-Year TAVR Data, PA Scope Creep, and Vitamin K for CAC - Cardiac Wire

10-Year TAVR Data, PA Scope Creep, and Vitamin K for CAC&nbsp;&nbsp;Cardiac Wire

CMS proposes major TAVR changes | The real impact of RVU cuts in electrophysiology | Girl’s heart valve implanted upside down - Cardiovascular Business

CMS proposes major TAVR changes | The real impact of RVU cuts in electrophysiology | Girl’s heart valve implanted upside down&nbsp;&nbsp;Cardiovascular Business

Edwards Lifesciences CEO Zovighian sells $45,982 of stock - Investing.com

Edwards Lifesciences CEO Zovighian sells $45,982 of stock&nbsp;&nbsp;Investing.com

Edwards Lifesciences (EW) CEO sells 523 shares under Rule 10b5-1 plan - Stock Titan

Edwards Lifesciences (EW) CEO sells 523 shares under Rule 10b5-1 plan&nbsp;&nbsp;Stock Titan

Edwards Lifesciences Corp (EW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Edwards Lifesciences Corp (EW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution&nbsp;&nbsp;TradingKey

Edwards Lifesciences Corp (EW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Edwards Lifesciences Corp (EW) Shareholder Structure: Major Shareholders & Institutional Holdings&nbsp;&nbsp;TradingKey

More than 11K bottles of blood pressure drug recalled - Cardiovascular Business

More than 11K bottles of blood pressure drug recalled&nbsp;&nbsp;Cardiovascular Business

Characterisation of disease progression in hantavirus haemorrhagic fever with renal syndrome

Hantaviruses can cause haemorrhagic fever with renal syndrome (HFRS). This is a clinically variable disease in which severe outcomes are hypothesized to arise from dysregulated host responses. To characterise this, longitudinal, label-free plasma proteomics was used to compare disease progression in a unique well-defined cohort of patients infected with either Dobrava virus (DOBV) or Puumala virus (PUUV) hantaviruses. Patients were stratified by clinical severity. The average viral load in the first available sample from hospitalized patients was higher in those who went on to have severe infection, and higher in patients infected with DOBV. There was marked separation of infected patients from controls across early, mid and late disease, including after viral RNA clearance, suggesting a sustained systemic host-response signature. Proteomic signatures were consistent with a strong acute-phase response in both mild and severe disease. There was evidence of activation of the adaptive humoral response at later stages. Hierarchical clustering identified severity-associated pathways linked to endothelial dysfunction, thrombocytopenia, vascular leakage and renal injury. These findings define a durable plasma proteomic signature of hantavirus disease and support a model in which severe HFRS is driven by persistent inflammatory, complement and platelet/coagulation pathway activation rather than viral burden alone.

Cardio Heart Connect: Protocol for a Randomized Trial of a Commercially Available mHealth Fitness Intervention for Cardiac Rehabilitation After Transcatheter Aortic Valve Replacement

Background: Despite ample evidence of the benefits of cardiac rehabilitation (CR), few transcatheter aortic valve replacement (TAVR) patients participate. Commercially available mobile health offers an opportunity to deliver activity-promotion content to populations that are challenged to participate in CR. This study aims to test the efficacy of clinically controlled, commercially available fitness programming for improving physical activity and cardiovascular health outcomes designed to be initiated while patients are on waitlists for traditional CR. Methods: The Cardio Heart Connect study is a hybrid type I effectiveness-implementation trial aiming to enroll N=200 patients who have been placed on a cardiac rehab waitlist following a TAVR procedure from the University of Colorado Hospital Heart and Vascular Center. Participants will be randomized 1:1 to the Cardio Heart Connect intervention with commercially available fitness or attention control, designed to control for technology access. At baseline, post-intervention (8 weeks), and follow-up (12 months), we will assess the primary outcome of participants? daily steps as measured by smartwatch accelerometer and secondary outcomes of interest including functional capacity (Duke Activity Status Index; VO2max), quality of life (Kansas City Cardiomyopathy Questionnaire), and cardiovascular health status (Life Essential 8). In addition, we will use mixed methodologies to evaluate the implementation of intervention using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) Framework. Conclusions: Commercially available fitness programs have the potential to provide more accessible opportunities for patients recovering from TAVR to engage in physical activity and may be preferred due to their customizability, convenience, and ease of scheduling. Overall, this study will provide insight into the use of commercial mHealth to promote activity following TAVR.

Cardiologists and surgeons share early feedback after CMS proposed sweeping TAVR changes - Cardiovascular Business

Cardiologists and surgeons share early feedback after CMS proposed sweeping TAVR changes&nbsp;&nbsp;Cardiovascular Business

Draft CMS TAVR Memo ‘Clear Win’ For Edwards But Leaves Regurgitation Players Waiting - Citeline News & Insights

Draft CMS TAVR Memo ‘Clear Win’ For Edwards But Leaves Regurgitation Players Waiting&nbsp;&nbsp;Citeline News & Insights

CMS Proposes Major Expansion of Medicare Coverage for TAVR - Medical Device and Diagnostic industry

CMS Proposes Major Expansion of Medicare Coverage for TAVR&nbsp;&nbsp;Medical Device and Diagnostic industry

Does Expanded CMS TAVR Coverage Alter the Bull Case for Edwards Lifesciences (EW)? - simplywall.st

Does Expanded CMS TAVR Coverage Alter the Bull Case for Edwards Lifesciences (EW)?&nbsp;&nbsp;simplywall.st

CMS Proposes Expanding TAVI Coverage to Asymptomatic Patients - TCTMD.com

CMS Proposes Expanding TAVI Coverage to Asymptomatic Patients&nbsp;&nbsp;TCTMD.com

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - View Public Comments - Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - View Public Comments&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - Tracking Sheet - Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - Tracking Sheet&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - Submit Public Comments - Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - Submit Public Comments&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

CMS Proposes Expanding TAVI Coverage to Asymptomatic Patients

CMS Proposes Expanding TAVI Coverage to Asymptomatic Patients cmacahilig@crf.org Wed, 06/17/2026 - 10:29 L.A. McKeown The proposed decision memo also paves the way for triaging by chart review and enhancing flexibility for heart team decisions.

Cardiologists and surgeons share early feedback after CMS proposed sweeping TAVR changes

&lt;p&gt;Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.&lt;/p&gt;

Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch

Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day&nbsp;&nbsp;MarketWatch

Does Expanded CMS TAVR Coverage Alter the Bull Case for Edwards Lifesciences (EW)? - simplywall.st

Does Expanded CMS TAVR Coverage Alter the Bull Case for Edwards Lifesciences (EW)?&nbsp;&nbsp;simplywall.st

CMS Proposes Major Expansion of Medicare Coverage for TAVR - Medical Device and Diagnostic industry

CMS Proposes Major Expansion of Medicare Coverage for TAVR&nbsp;&nbsp;Medical Device and Diagnostic industry

Draft CMS TAVR Memo ‘Clear Win’ For Edwards But Leaves Regurgitation Players Waiting - Citeline News & Insights

Draft CMS TAVR Memo ‘Clear Win’ For Edwards But Leaves Regurgitation Players Waiting&nbsp;&nbsp;Citeline News & Insights

Edwards Lifesciences Corp (EW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Edwards Lifesciences Corp (EW) Earnings Forecast: Future EPS & Revenue Growth Estimates&nbsp;&nbsp;TradingKey

Edwards Lifesciences Sapien 3 Ultra shines as trusted TAVI classic for Sunday heart patients - AD HOC NEWS

Edwards Lifesciences Sapien 3 Ultra shines as trusted TAVI classic for Sunday heart patients&nbsp;&nbsp;AD HOC NEWS

CMS proposes Medicare coverage expansion for TAVR - Healthcare Dive

CMS proposes Medicare coverage expansion for TAVR&nbsp;&nbsp;Healthcare Dive

CMS proposes Medicare coverage expansion for TAVR - Healthcare Dive

CMS proposes Medicare coverage expansion for TAVR&nbsp;&nbsp;Healthcare Dive

Edwards Lifesciences (EW) Hits 52-Week High on Medicare Coverage Proposal - GuruFocus

Edwards Lifesciences (EW) Hits 52-Week High on Medicare Coverage Proposal&nbsp;&nbsp;GuruFocus

Why is Edwards Lifesciences stock climbing today? By Investing.com - Investing.com Canada

Why is Edwards Lifesciences stock climbing today? By Investing.com&nbsp;&nbsp;Investing.com Canada

CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients - Cardiovascular Business

CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients&nbsp;&nbsp;Cardiovascular Business

CMS proposes TAVR coverage update that benefits Edwards, Medtronic, Abbott - MassDevice

CMS proposes TAVR coverage update that benefits Edwards, Medtronic, Abbott&nbsp;&nbsp;MassDevice

CMS proposes Medicare coverage expansion for TAVR - MedTech Dive

CMS proposes Medicare coverage expansion for TAVR&nbsp;&nbsp;MedTech Dive

New 10-Year TAVI Data Generally ‘Reassuring’ But Highlight Challenges - TCTMD.com

New 10-Year TAVI Data Generally ‘Reassuring’ But Highlight Challenges&nbsp;&nbsp;TCTMD.com

Balloon-Expandable TAVR Has Struggles Evident at 10-Year Follow-Up - MedPage Today

Balloon-Expandable TAVR Has Struggles Evident at 10-Year Follow-Up&nbsp;&nbsp;MedPage Today

Edwards Lifesciences stock jumps on TAVR coverage proposal - Investing.com

Edwards Lifesciences stock jumps on TAVR coverage proposal&nbsp;&nbsp;Investing.com

Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device - Benzinga

Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device&nbsp;&nbsp;Benzinga

Leerink reiterates Edwards Lifesciences stock rating on TAVR policy - Investing.com

Leerink reiterates Edwards Lifesciences stock rating on TAVR policy&nbsp;&nbsp;Investing.com

Edwards Lifesciences (EW) Stock Could Be 11% Undervalued on Its TAVR and EVOQUE Story - simplywall.st

Edwards Lifesciences (EW) Stock Could Be 11% Undervalued on Its TAVR and EVOQUE Story&nbsp;&nbsp;simplywall.st

Sapien 3 Ultra Transcatheter Heart Valve aims to raise the bar in minimally invasive TAVR care - AD HOC NEWS

Sapien 3 Ultra Transcatheter Heart Valve aims to raise the bar in minimally invasive TAVR care&nbsp;&nbsp;AD HOC NEWS

News Alert: CMS proposes major TAVR changes - Cardiovascular Business

News Alert: CMS proposes major TAVR changes&nbsp;&nbsp;Cardiovascular Business

CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients

&lt;p&gt;After months of consideration, CMS has proposed sweeping changes to its TAVR coverage policies. The agency is accepting public comments until July 15.&lt;/p&gt;

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day&nbsp;&nbsp;MarketWatch

Edwards Lifesciences stock gains on Medicare proposal (EW:NYSE) - Seeking Alpha

Edwards Lifesciences stock gains on Medicare proposal (EW:NYSE)&nbsp;&nbsp;Seeking Alpha

Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device - Benzinga

Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device&nbsp;&nbsp;Benzinga

Edwards Lifesciences stock hits 52-week high at $89.50 - Investing.com

Edwards Lifesciences stock hits 52-week high at $89.50&nbsp;&nbsp;Investing.com

Edwards Lifesciences jumps as CMS posts proposed TAVR coverage update - Quiver Quantitative

Edwards Lifesciences jumps as CMS posts proposed TAVR coverage update&nbsp;&nbsp;Quiver Quantitative

CMS proposes TAVR coverage update that benefits Edwards, Medtronic, Abbott - MassDevice

CMS proposes TAVR coverage update that benefits Edwards, Medtronic, Abbott&nbsp;&nbsp;MassDevice

Edwards Lifesciences (EW) Stock Could Be 11% Undervalued on Its TAVR and EVOQUE Story - simplywall.st

Edwards Lifesciences (EW) Stock Could Be 11% Undervalued on Its TAVR and EVOQUE Story&nbsp;&nbsp;simplywall.st

CMS proposes Medicare coverage expansion for TAVR - MedTech Dive

CMS proposes Medicare coverage expansion for TAVR&nbsp;&nbsp;MedTech Dive

Edwards Lifesciences (EW) Gains Analyst Support Amid Coverage Up - GuruFocus

Edwards Lifesciences (EW) Gains Analyst Support Amid Coverage Up&nbsp;&nbsp;GuruFocus

Edwards Lifesciences (EW) Sees Positive Coverage Update Boosting Stock Prospects - GuruFocus

Edwards Lifesciences (EW) Sees Positive Coverage Update Boosting Stock Prospects&nbsp;&nbsp;GuruFocus

Leerink reiterates Edwards Lifesciences stock rating on TAVR policy - Investing.com

Leerink reiterates Edwards Lifesciences stock rating on TAVR policy&nbsp;&nbsp;Investing.com

Edwards Lifesciences (EW) Set to Gain from Medicare Coverage Exp - GuruFocus

Edwards Lifesciences (EW) Set to Gain from Medicare Coverage Exp&nbsp;&nbsp;GuruFocus

Edwards Lifesciences (EW) Hits 52-Week High on Medicare Coverage Proposal - GuruFocus

Edwards Lifesciences (EW) Hits 52-Week High on Medicare Coverage Proposal&nbsp;&nbsp;GuruFocus

Edwards Lifesciences (EW) Sees 3% Rise Following CMS Coverage An - GuruFocus

Edwards Lifesciences (EW) Sees 3% Rise Following CMS Coverage An&nbsp;&nbsp;GuruFocus

Edwards Lifesciences (EW) Sees Gains Following CMS Coverage Prop - GuruFocus

Edwards Lifesciences (EW) Sees Gains Following CMS Coverage Prop&nbsp;&nbsp;GuruFocus

Why is Edwards Lifesciences stock climbing today? - Investing.com UK

Why is Edwards Lifesciences stock climbing today?&nbsp;&nbsp;Investing.com UK

Edwards Lifesciences stock jumps on TAVR coverage proposal - Investing.com UK

Edwards Lifesciences stock jumps on TAVR coverage proposal&nbsp;&nbsp;Investing.com UK

A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $98 to $101 - 富途牛牛

A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $98 to $101&nbsp;&nbsp;富途牛牛

Is Edwards Lifesciences Ready For Its Next Growth Phase? - Kalkine Media

Is Edwards Lifesciences Ready For Its Next Growth Phase?&nbsp;&nbsp;Kalkine Media

Co-Circulation of Multiple Kolmiovirus Lineages Through Vertebrate Evolution

Although once only characterised by human hepatitis deltavirus (HDV), membership of the family Kolmioviridae has dramatically expanded in recent years. Despite this transformation in our understanding of the host range of the kolmioviruses, the evolutionary history of this enigmatic group of RNA viruses is unclear. Kolmioviruses are characterised as small (~1.7kb) satellite viruses that require unrelated helper viruses for replication and encode a single ~200 amino acid delta antigen (DAg). Here, we describe eight novel kolmioviruses from metatranscriptomic studies of the American alligator (Alligator missippiensis), red kangaroo (Osphranter rufus), and central bearded dragon (Pogona vitticeps), as well as avian kolmioviruses mined from the Sequence Read Archive (SRA). Although the novel kolmioviruses were often found in samples co-infected by other viruses, there was no evidence for the presence of hepatitis B virus as seen in HDV. By employing a range of sequence data sets, alignment methods, alignment trimming methods, and substitution models, we provide an evolutionary history of the Kolmioviridae that maximises the extent of virus-host co-divergence and refines estimates of their evolutionary timescale. Although DAg amino acid sequences are more conserved than nucleotide sequences and hence might be expected to result in more accurate phylogenetic trees, we show that full genome nucleotide sequences likely provide the best representation of kolmiovirus evolution. More broadly, our results reveal that irrespective of the data set used, multiple distinct kolmiovirus lineages have co-circulated throughout vertebrate evolution over timescales spanning hundreds of millions of years, with the association between HDV and HBV only appearing recently.

TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge - Yahoo Finance

TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge&nbsp;&nbsp;Yahoo Finance

Edwards Lifesciences Corp. stock rises Monday, still underperforms market - MarketWatch

Edwards Lifesciences Corp. stock rises Monday, still underperforms market&nbsp;&nbsp;MarketWatch

Prevalence and Clinical Impact of Pathogenic Variants in Cardiomyopathy Genes Among Individuals with Cardiac Conduction Disorders

Importance: Cardiac conduction disorders have traditionally been regarded as a secondary manifestation of underlying structural heart diseases. However, isolated conduction disorders may precede the onset of heart failure (HF) suggesting shared mechanisms. Objective: To evaluate the prevalence and clinical significance of pathogenic/likely pathogenic (P/LP) rare variants in cardiomyopathy genes among individuals with conduction disorders. Design, Setting, and Participants: Biobank analysis of 192,834 participants with whole genome sequence data from Vanderbilt's BioVU and 353,092 participants from the All of Us Research Program (AoU). Participants with primary conduction disorder (left bundle branch block [LBBB], right bundle branch block [RBBB], high-grade atrioventricular block [AVB]) were identified after excluding secondary causes. Exposures: P/LP variants in cardiomyopathy genes. Main Outcomes and Measures: Primary outcome was P/LP carrier status by age and HF status. Secondary outcomes included incident HF and composite ventricular arrhythmias/sudden cardiac death/mortality (VA/SCD/mortality). Results: Among 16,959 participants with conduction disorders in BioVU and 13,442 in AoU, 432 (2.6%) and 206 (1.5%) were P/LP carriers, respectively. Conduction disorder was independently associated with carrier status (BioVU p<0.001; AoU p=0.005). Carrier probability varied by age at conduction disorder onset and HF status. Among participants with HF at age 30 years, predicted carrier probability for LBBB was 7.5% in BioVU and 20.2% in AoU; for high-grade AVB, 7.7% and 8.5%, respectively, compared with 3.7% and 2.9% among those with HF without conduction disorder. P/LP carrier status among participants with conduction disorders was associated with increased risk of incident HF (BioVU p<0.001; AoU p<0.001) and ventricular arrhythmia/sudden death/mortality (BioVU p<0.001; AoU p<0.001). Carriers also demonstrated increased susceptibility to conduction disorder following HF diagnosis, including more than two-fold higher risk of third-degree AVB (BioVU aOR 2.48, 95% CI 1.85-3.32; AoU aOR 2.26, 95% CI 1.35-3.80). Conclusions: Adults with primary conduction disorders have an increased prevalence of P/LP variants in cardiomyopathy genes, which is most pronounced with diagnoses at early ages of adulthood. Furthermore, there is evidence of an interaction between P/LP carrier status and conduction disorder to increase HF risk and composite cardiovascular outcomes, underscoring the potential role of genetic evaluation in patients with primary conduction disorders to inform long-term outcomes.

Anteris outlines future challenges of TAVR therapy - MassDevice

Anteris outlines future challenges of TAVR therapy&nbsp;&nbsp;MassDevice

TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge - PR Newswire

TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge&nbsp;&nbsp;PR Newswire

From operating room to recovery: how Edwards’ SAPIEN 3 Ultra Resilia raises the bar for TAVR - AD HOC NEWS

From operating room to recovery: how Edwards’ SAPIEN 3 Ultra Resilia raises the bar for TAVR&nbsp;&nbsp;AD HOC NEWS

Abbott recalls heart monitoring tech | Redo TAVR with balloon-expandable valves | FDA clears new clot-removing device - Cardiovascular Business

Abbott recalls heart monitoring tech | Redo TAVR with balloon-expandable valves | FDA clears new clot-removing device&nbsp;&nbsp;Cardiovascular Business

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - Submit Public Comments - Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - Submit Public Comments&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

Edwards Lifesciences Corp. stock rises Monday, still underperforms market - MarketWatch

Edwards Lifesciences Corp. stock rises Monday, still underperforms market&nbsp;&nbsp;MarketWatch

Edwards Lifesciences (EW) Stock Analysis: Strong Buy Ratings Point To A 13.88% Upside - DirectorsTalk Interviews

Edwards Lifesciences (EW) Stock Analysis: Strong Buy Ratings Point To A 13.88% Upside&nbsp;&nbsp;DirectorsTalk Interviews

Boston Scientific Corp. Stock (US10117L1017): Short interest jumps while analysts stay positive - AD HOC NEWS

Boston Scientific Corp. Stock (US10117L1017): Short interest jumps while analysts stay positive&nbsp;&nbsp;AD HOC NEWS

From chronic reflux relief to durability claims, Boston Scientific’s LINX system under the microsc - AD HOC NEWS

From chronic reflux relief to durability claims, Boston Scientific’s LINX system under the microsc&nbsp;&nbsp;AD HOC NEWS

CKM Guidelines, Plaque Test, and TAVR Mortality Clarified - Cardiac Wire

CKM Guidelines, Plaque Test, and TAVR Mortality Clarified&nbsp;&nbsp;Cardiac Wire

Public Employees Retirement Association of Colorado Increases Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat

Public Employees Retirement Association of Colorado Increases Stock Holdings in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Entropy Technologies LP Takes Position in Edwards Lifesciences Corporation $EW - MarketBeat

Entropy Technologies LP Takes Position in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Epoch Investment Partners Inc. Has $18.82 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat

Epoch Investment Partners Inc. Has $18.82 Million Position in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Brown Advisory Inc. Decreases Stake in Edwards Lifesciences Corporation $EW - MarketBeat

Brown Advisory Inc. Decreases Stake in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Week in Review: Star Trek star's family awarded $13M | AI for cardiac amyloidosis | TAVR concerns | New CKM syndrome guidelines - Cardiovascular Business

Week in Review: Star Trek star's family awarded $13M | AI for cardiac amyloidosis | TAVR concerns | New CKM syndrome guidelines&nbsp;&nbsp;Cardiovascular Business

Parnassus Investments LLC Acquires 111,843 Shares of Edwards Lifesciences Corporation $EW - MarketBeat

Parnassus Investments LLC Acquires 111,843 Shares of Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Hantavirus Disease in Uruguay: Trends and Mortality Before and During the COVID-19 Pandemic.

Introduction: Hantavirus disease is an emerging and potentially severe zoonosis of global distribution. In Uruguay, it is transmitted by rodents inhabiting peridomestic, suburban, and rural areas. Global incidence is estimated at 150,000 to 200,000 cases per year, with up to 300 annual cases in the Americas. Since 1997, Uruguay's Ministry of Public Health (MPH) has monitored Hantavirus cardiopulmonary syndrome (HCPS), the most common clinical presentation in the region. By 2019, a total of 271 cases had been identified in the country, with an estimated mortality rate of nearly 50%. Objectives: To describe the clinical, epidemiological, and occupational characteristics of patients with Hantavirus disease in Uruguay during the pre-pandemic (2018-2019) and pandemic (2020-2021) periods. Methods: A descriptive, cross-sectional, observational study was conducted, including all serologically confirmed cases of Hantavirus infection reported to the MPH between 2018 and 2021. Clinical and demographic data were extracted from the mandatory reporting form for zoonotic diseases. Incidence and case fatality rates were calculated, and factors associated with fatal outcomes were analyzed. Results: A total of 58 confirmed cases were identified between 2018 and 2021. Most patients were male (62%), with a mean age of 36.5 years (SD 16). A decline in incidence was observed during 2020-2021, with no significant change in case fatality. Direct rodent exposure was the most frequently associated risk factor. Montevideo and Canelones were the most affected departments. Renal and pulmonary involvement were significantly associated with mortality. Conclusion: Hantavirus remains a relevant public health concern in Uruguay. Although a decrease in incidence was observed during the COVID-19 pandemic years, case fatality rates remained high. The findings underscore the need for sustained surveillance and early recognition, particularly in urbanizing regions.

TAVR concerns: Cardiologists, patient family members question quality of care at rural hospital - Cardiovascular Business

TAVR concerns: Cardiologists, patient family members question quality of care at rural hospital&nbsp;&nbsp;Cardiovascular Business

Death after TAVR: New data support use of better patient assessments - Cardiovascular Business

Death after TAVR: New data support use of better patient assessments&nbsp;&nbsp;Cardiovascular Business

Rabbit Fever Alert; Med School Faces Bias Claim; TAVR Program Still Under Fire - MedPage Today

Rabbit Fever Alert; Med School Faces Bias Claim; TAVR Program Still Under Fire&nbsp;&nbsp;MedPage Today

Death after TAVR: New data support use of better patient assessments

&lt;p&gt;A vast majority of patient deaths in the first year after TAVR have nothing to do with heart health. Could care teams be doing more to identify high-risk patients?&amp;nbsp;&lt;/p&gt;

TAVR concerns: Cardiologists, patient family members question quality of care at rural hospital

&lt;p&gt;A failed TAVR procedure has left one family unsure about where things went wrong.&amp;nbsp;&lt;/p&gt;

Edwards Lifesciences Stock Watched As Procedure Recovery Matters - Kalkine Media

Edwards Lifesciences Stock Watched As Procedure Recovery Matters&nbsp;&nbsp;Kalkine Media

Deutsche Bank AG Has $475.59 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat

Deutsche Bank AG Has $475.59 Million Stock Holdings in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Promera: a unified model for biomolecular structure prediction, filtering, and design

Generative models have become staple tools for modeling and designing biomolecular structures. However, although these tools have improved in structural prediction accuracy, their ability to filter designed binders---an essential use case---remains insufficient; whereas design methods have focused more on unconstrained binder generation rather than capabilities enabled by controllable design. We introduce Promera, a unified generative model that combines all-atom structure prediction with improved filtering and controllable design. We find that Promera's confidence metrics are more accurate for filtering binders from non-binders for both miniproteins and nanobodies, while its co-folding performance surpasses popular open-source models (OpenFold3-p2, Boltz-2) on therapeutically relevant categories. As a design model, Promera generates binders by predicting masked protein sequences with optional epitope, paratope, and template constraints. Remarkably, our nanobody designs match the in silico success rates from backprop-based techniques (mBER) when evaluated under co-folding confidence filters. We further provide two in silico demonstrations of the the versatile capabilities of our design method: epitope targeting of the Andes hantavirus glycoprotein with VHHs and active state stabilization of the beta-2 andrenergic GPCR. We conclude by proposing a scaling law for co-folding models, suggesting a path for further performance improvement.

In Great Falls, a hospital tried to build a cutting-edge heart program. Doctors left in the process. - Montana Free Press

In Great Falls, a hospital tried to build a cutting-edge heart program. Doctors left in the process.&nbsp;&nbsp;Montana Free Press

One in 25 TAVI Patients Die Within a Year, Mostly From Noncardiovascular Causes: Study - Medical Dialogues

One in 25 TAVI Patients Die Within a Year, Mostly From Noncardiovascular Causes: Study&nbsp;&nbsp;Medical Dialogues

NYC Health + Hospitals/Bellevue Marks 200th Transcatheter Aortic Valve Replacement - NYC Health + Hospitals

NYC Health + Hospitals/Bellevue Marks 200th Transcatheter Aortic Valve Replacement&nbsp;&nbsp;NYC Health + Hospitals

TAVI also offers new treatment options for patients with aortic regurgitation - Il Sole 24 ORE

TAVI also offers new treatment options for patients with aortic regurgitation&nbsp;&nbsp;Il Sole 24 ORE

How Heart Specialists Benefit From Medicare’s TAVR Restrictions - Forbes

How Heart Specialists Benefit From Medicare’s TAVR Restrictions&nbsp;&nbsp;Forbes

TAVI: what it is, how it is done and how it changes life after surgery - Il Sole 24 ORE

TAVI: what it is, how it is done and how it changes life after surgery&nbsp;&nbsp;Il Sole 24 ORE

Star Trek star's family awarded $13M in heart failure malpractice case - Cardiovascular Business

Star Trek star's family awarded $13M in heart failure malpractice case&nbsp;&nbsp;Cardiovascular Business

Is Edwards Lifesciences stock underperforming the Nasdaq? - MSN

Is Edwards Lifesciences stock underperforming the Nasdaq?&nbsp;&nbsp;MSN

Multi-Pathogen Wastewater Surveillance enables Real-Time Targeted Public Health Interventions During the 2025 African Nations Championship Football Tournament

Mass gatherings pose significant public health risks by facilitating the spread of infectious diseases. While wastewater-based surveillance (WBS) has been widely used to monitor pathogens in high-income settings, its use as a practical, multi-pathogen surveillance tool during mass gatherings in low- and middle-income countries remains limited. This study aimed to assess the operational feasibility, epidemiological significance, and public health utility of multi-pathogen WBS during the African Nations Championship (CHAN) football tournament in Uganda. Wastewater surveillance was conducted at Mandela National Stadium during eight match days in August 2025. Moore swabs were deployed at 38 manholes receiving wastewater from different toilet facilities across the stadium to capture representative wastewater samples. Samples were processed using Nanotrap(R) microbiome virus particles to concentrate pathogens, followed by nucleic acid extraction. Samples were analyzed for multiple enteric and respiratory pathogens, including Mpox, using quantitative PCR (qPCR). Descriptive analyses were performed to characterize pathogen detection patterns, positivity rates, and temporal distribution across surveillance sites. A total of 304 wastewater samples were collected and analyzed, of which 259 (85.2%) tested positive for at least one pathogen. Multiple pathogens were consistently detected across sampling days, with enteric pathogens predominating, particularly Shigella spp. (53.6%), Rotavirus A (35.9%) and Enterovirus (32.2%). The mpox virus was also detected in a notable proportion of samples (28.6%) across several sampling days. Respiratory pathogens, including SARS-CoV-2 (11.8%) and Influenza B (8.2%), were identified intermittently at lower frequencies. Pathogen diversity varied over time, with up to eight pathogens detected on a single day, and co-detection of multiple pathogens observed in the majority of positive samples. Cq value distributions further demonstrated variability in detected signal patterns across pathogens. Surveillance findings informed real-time public health interventions, including sanitation reinforcement, intensified hygiene promotion, environmental disinfection, and targeted risk communication, strengthened syndromic surveillance with on-site triage, and targeted environmental health assessments of food handling and wastewater infrastructure. These findings demonstrate the operational feasibility and public health utility of integrating multi-pathogen wastewater-based surveillance into mass-gathering preparedness and response frameworks in low-resource settings. By capturing diverse pathogen signals and informing targeted interventions during the CHAN football tournament, WBS can provide actionable population-level insights that can support outbreak preparedness and response. Scaling WBS within national preparedness systems could strengthen epidemic intelligence, enhance early warning capacity, and support data-driven public health decision-making during future mass gatherings and emerging infectious disease threats.

Detection and genomic characterisation of a novel hantavirus in Australian dolphins

We report the detection of a novel hantavirus in the lung tissue of two diseased Australian dolphins with histopathological changes. Phylogenetic analysis placed this virus within the genus Mobatvirus. This highlights the ability of hantaviruses to infect non-terrestrial mammals and the potential role of marine mammals as one health sentinels.

Following Successful TAVI, 4% Die between 1 and 12 months: TRITAVI - TCTMD.com

Following Successful TAVI, 4% Die between 1 and 12 months: TRITAVI&nbsp;&nbsp;TCTMD.com

Structural Heart Disease - Cardiovascular Business

Structural Heart Disease&nbsp;&nbsp;Cardiovascular Business

Following Successful TAVI, 4% Die between 1 and 12 months: TRITAVI

Following Successful TAVI, 4% Die between 1 and 12 months: TRITAVI cmacahilig@crf.org Mon, 06/08/2026 - 12:39 Yael L. Maxwell The data should help with conversations around patient selection and futility, researchers say.

Edwards Lifesciences Corporation (EW) Stock Analysis: 12.75% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews

Edwards Lifesciences Corporation (EW) Stock Analysis: 12.75% Potential Upside with Robust Revenue Growth&nbsp;&nbsp;DirectorsTalk Interviews

Edwards Lifesciences Corporation - MLQ.ai

Edwards Lifesciences Corporation&nbsp;&nbsp;MLQ.ai

Did Higher 2026 TAVR Guidance and Autus Deal Just Shift Edwards Lifesciences' (EW) Investment Narrative? - simplywall.st

Did Higher 2026 TAVR Guidance and Autus Deal Just Shift Edwards Lifesciences' (EW) Investment Narrative?&nbsp;&nbsp;simplywall.st

Did Higher 2026 TAVR Guidance and Autus Deal Just Shift Edwards Lifesciences' (EW) Investment Narrative? - simplywall.st

Did Higher 2026 TAVR Guidance and Autus Deal Just Shift Edwards Lifesciences' (EW) Investment Narrative?&nbsp;&nbsp;simplywall.st

Arrowpoint Investment Partners Singapore Pte. Ltd. Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat

Arrowpoint Investment Partners Singapore Pte. Ltd. Makes New Investment in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

KESOZI Digital Twin: Physics-Informed Neural Network for Independent Estimation and Prediction of Childhood Diarrheal Disease Burden in Kenya, Somaliland, and Zimbabwe

Childhood diarrheal disease remains a leading cause of morbidity and mortality among children under five years in sub-Saharan Africa, particularly in settings affected by inadequate sanitation, climate variability, malnutrition, and limited healthcare access. Conventional forecasting approaches are often constrained by sparse surveillance data, weak spatial representation, and limited incorporation of mechanistic disease dynamics. This study presents a Physics-Informed Multimodal Artificial Intelligence Digital Twin framework that integrates Physics-Informed Neural Networks, Graph Neural Networks, diffusion-reaction epidemiological modeling, multimodal fusion learning, and Digital Twin simulation to estimate and predict childhood diarrheal disease burden in Kenya, Somaliland, and Zimbabwe. Using public epidemiological, environmental, climate, sanitation, and synthetic proof-of-concept datasets, the framework modeled temporal disease dynamics, spatial transmission, pathogen-attributed burden, and outbreak trajectories while enforcing epidemiological consistency through physics-informed optimization. Results demonstrated robust forecasting performance, enhanced spatial transmission modeling, uncertainty-aware predictions, and realistic outbreak simulations across the three countries. Rotavirus, Shigella, and Cryptosporidium were identified as major contributors to modeled mortality burden, while unsafe water exposure, poor sanitation, malnutrition, and climate-sensitive transmission substantially increased disease risk. Compared with a Bayesian baseline model, the multimodal framework achieved superior nonlinear risk characterization, geospatial learning, and temporal prediction. These findings highlight the potential of scientific machine learning and digital twin systems for infectious disease surveillance, outbreak forecasting, climate-health analytics, and evidence-based public health decision-making in low-resource African settings. Keywords: Physics-Informed Neural Networks, Graph Neural Networks, Digital Twin, Childhood Diarrheal Disease, Epidemiology, Kenya, Somaliland, Zimbabwe, Scientific Machine Learning, Spatial Epidemiology, Multimodal Fusion

Viral reservoir status in small mammals emerges as a predictable life-history trait after correcting for surveillance bias

Small mammals, particularly rodents and shrews, act as primary reservoirs for Arenaviruses and Hantaviruses, zoonotic pathogens causing substantial global morbidity. However, our understanding of reservoir ecology is obscured by biased surveillance efforts, where sampling preferentially targets synanthropic species and high-income regions. It remains unclear whether observed patterns of reservoir competence, such as the association with synanthropy, are biological realities or artefacts of surveillance bias. We conducted a systematic review and data synthesis of global surveillance efforts (1960-2023), creating a harmonised database of over 590,000 recorded small mammals contributing 716,000 assay results. We then integrated this with macroecological trait data and phylogenetics to model reservoir probability using Bayesian phylogenetic dyadic generalised linear mixed models. We identified substantial taxonomic and geographic biases; surveillance is heavily skewed towards the Palearctic and widespread, large-bodied species, while 46% of host genera remain entirely unsampled. Geographically, surveillance intensity correlates strongly with accessibility and night-light intensity rather than host biodiversity. After statistically correcting for historical sampling volume, we demonstrate that reservoir status is a predictable biological trait. A fast pace of life (e.g., early maturity, large litters) is associated with an increased probability of reservoir status, independent of sampling effort. Synanthropy also remains a strong, independent predictor, indicating that commensal species act as genuine biological amplifiers in modified landscapes. Evolutionary analyses reveal a mosaic of broad lineage-level co-divergence punctuated by frequent, reactive host-switching. By projecting these models globally, we demonstrate that anthropogenic disturbance acts as an ecological filter, fundamentally challenging the assumption that pristine tropical ecosystems represent the highest intrinsic hazard for viral emergence.

TAVR: ‘If you need it, get it done’ - UCI Health

TAVR: ‘If you need it, get it done’&nbsp;&nbsp;UCI Health

Deaconess Heart Hospital celebrates 1,000th TAVR procedure - wevv.com

Deaconess Heart Hospital celebrates 1,000th TAVR procedure&nbsp;&nbsp;wevv.com

Azuria's Tavi Costa: The AI 'build phase' is an inflation trap - here is the metals playbook the market is missing - KITCO

Azuria's Tavi Costa: The AI 'build phase' is an inflation trap - here is the metals playbook the market is missing&nbsp;&nbsp;KITCO

Videos - KITCO

Videos&nbsp;&nbsp;KITCO

Plaque imaging, AI and structural heart disease in the spotlight at SCCT 2026 meeting - Cardiovascular Business

Plaque imaging, AI and structural heart disease in the spotlight at SCCT 2026 meeting&nbsp;&nbsp;Cardiovascular Business

Plaque imaging, AI and structural heart disease in the spotlight at SCCT 2026 meeting

&lt;p&gt;Coronary plaque imaging is an area many experts believe is driving a shift toward earlier detection and prevention of heart disease.&lt;/p&gt;

Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Yahoo Finance

Is Edwards Lifesciences Stock Underperforming the Nasdaq?&nbsp;&nbsp;Yahoo Finance

Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains&nbsp;&nbsp;MarketWatch

TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $104 - 富途牛牛

TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $104&nbsp;&nbsp;富途牛牛

Boston Scientific Corp. stock (US10117L1017): Indiana expansion and sector backdrop in focus - AD HOC NEWS

Boston Scientific Corp. stock (US10117L1017): Indiana expansion and sector backdrop in focus&nbsp;&nbsp;AD HOC NEWS

Assessing Edwards Lifesciences (EW) Valuation As Short-Term Momentum Improves But Long-Term Returns Stay Mixed - simplywall.st

Assessing Edwards Lifesciences (EW) Valuation As Short-Term Momentum Improves But Long-Term Returns Stay Mixed&nbsp;&nbsp;simplywall.st

Is Boston Scientific (BSX) Quietly Rebalancing From Structural Heart To Coronary Strength? - simplywall.st

Is Boston Scientific (BSX) Quietly Rebalancing From Structural Heart To Coronary Strength?&nbsp;&nbsp;simplywall.st

TAVR Highlights: Self-expanding valves continue to impress | A new technique | Why implant depth matters | SAPT vs. DAPT - Cardiovascular Business

TAVR Highlights: Self-expanding valves continue to impress | A new technique | Why implant depth matters | SAPT vs. DAPT&nbsp;&nbsp;Cardiovascular Business

Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch

Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors&nbsp;&nbsp;MarketWatch

Edwards Lifesciences (EW) Still Looks Like a Structural Heart Growth Story, Not Just a TAVR Franchise - AlphaStreet

Edwards Lifesciences (EW) Still Looks Like a Structural Heart Growth Story, Not Just a TAVR Franchise&nbsp;&nbsp;AlphaStreet

Prevalence, Genetic Diversity, and Landscape Associations of Orthohantavirus puumalaense in Bank Voles (Clethrionomys glareolus) from Northern Sweden

Puumala hantavirus (PUUV, Orthohantavirus puumalaense) is one of the primary causative agents of haemorrhagic fever with renal syndrome in Europe and is maintained in natural populations of the bank vole (Clethrionomys glareolus, also known as Myodes glareolus). Despite public health relevance, we are only starting to understand the molecular properties and interplay between environmental and ecological factors of the pathogen that explain PUUV infection in bank voles. Here, we investigated PUUV occurrence, genetic structure, and environmental associations in bank voles sampled from two boreal forest areas in northern Sweden, during a complete vole population cycle (2020-2023). In total, 519 voles were screened for PUUV RNA using targeted reverse transcription PCR (RT-PCR). PUUV small (S-) segment RNA was detected in both study areas and observed infection patterns varied with sex, body weight, season and year. Specifically, we detected significant interactions between season and area and between season and body weight, with males showing consistently higher infection probabilities. Infection probability was also higher during periods of increased vole abundance and peaked in 2022. Phylogenetic analysis of partial S segment sequences demonstrated that all detected sequences clustered within the North-Scandinavian PUUV lineage, with no apparent spatial differentiation, indicating limited genetic structuring between the sampling areas. Habitat analyses at multiple spatial scales did not identify significant associations between PUUV occurrence and land-use variables, suggesting that infection dynamics were driven primarily by host demographic and temporal factors rather than broad-scale habitat composition. These findings highlight the importance of host demographics and temporal dynamics in shaping PUUV epidemiology in its reservoir, and provide additional insight into the molecular ecology of PUUV in northern Europe.

How to evaluate risk when TAVR patients require surgery later in life - Cardiovascular Business

How to evaluate risk when TAVR patients require surgery later in life&nbsp;&nbsp;Cardiovascular Business

Wealthspring/M. Simpson joint 13G/A for Tavia Acquisition Corp. (TAVI) - Stock Titan

Wealthspring/M. Simpson joint 13G/A for Tavia Acquisition Corp. (TAVI)&nbsp;&nbsp;Stock Titan

Edwards Lifesciences (EW) Still Looks Like a Structural Heart Growth Story, Not Just a TAVR Franchise - AlphaStreet

Edwards Lifesciences (EW) Still Looks Like a Structural Heart Growth Story, Not Just a TAVR Franchise&nbsp;&nbsp;AlphaStreet

Search - TCTMD.com

Search&nbsp;&nbsp;TCTMD.com

Edwards Lifesciences (EW) Still Looks Like a Structural Heart Growth Story, Not Just a TAVR Franchise - AlphaStreet

Edwards Lifesciences (EW) Still Looks Like a Structural Heart Growth Story, Not Just a TAVR Franchise&nbsp;&nbsp;AlphaStreet

Bank of New York Mellon Corp Sells 1,517,638 Shares of Edwards Lifesciences Corporation $EW - MarketBeat

Bank of New York Mellon Corp Sells 1,517,638 Shares of Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Mccarter Private Wealth Services LLC Has $2.25 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat

Mccarter Private Wealth Services LLC Has $2.25 Million Stock Position in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Edwards Lifesciences Appoints Theodora Mistras as Chief Financial Officer - thekeyexecutives.com

Edwards Lifesciences Appoints Theodora Mistras as Chief Financial Officer&nbsp;&nbsp;thekeyexecutives.com

Edwards Lifesciences stock (US28176E1082): NYSE-listed medtech share edges lower as investors digest - AD HOC NEWS

Edwards Lifesciences stock (US28176E1082): NYSE-listed medtech share edges lower as investors digest&nbsp;&nbsp;AD HOC NEWS

New York Valves 2026 To Unveil Late-Breaking Research in Structural Heart Disease | Newswise - Newswise

New York Valves 2026 To Unveil Late-Breaking Research in Structural Heart Disease | Newswise&nbsp;&nbsp;Newswise

New York Valves Summit to Present Structural Heart Disease Research June 24–26, 2026 - geneonline.com

New York Valves Summit to Present Structural Heart Disease Research June 24–26, 2026&nbsp;&nbsp;geneonline.com

Why Boston Scientific Faces New Questions Across Healthcare - Kalkine Media

Why Boston Scientific Faces New Questions Across Healthcare&nbsp;&nbsp;Kalkine Media

New York Valves 2026 to Reveal Groundbreaking Advances in Structural Heart Disease Research - Bioengineer.org

New York Valves 2026 to Reveal Groundbreaking Advances in Structural Heart Disease Research&nbsp;&nbsp;Bioengineer.org

TD Cowen Adjusts Price Target on Edwards Lifesciences to $104 From $97, Maintains Buy Rating - Moomoo

TD Cowen Adjusts Price Target on Edwards Lifesciences to $104 From $97, Maintains Buy Rating&nbsp;&nbsp;Moomoo

Nomura Asset Management Co. Ltd. Has $36.83 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat

Nomura Asset Management Co. Ltd. Has $36.83 Million Stake in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Edwards Lifesciences Corporation $EW Stake Lifted by MUFG Securities EMEA plc - MarketBeat

Edwards Lifesciences Corporation $EW Stake Lifted by MUFG Securities EMEA plc&nbsp;&nbsp;MarketBeat

Early Prediction of Post-TAVR Left Ventricular Remodeling Using CT-Derived Radiomics and Clinical Variables

Background: Adverse left ventricular (LV) remodeling after transcatheter aortic valve replacement (TAVR) is associated with impaired functional recovery and adverse long-term outcomes, yet imaging-based risk stratification remains limited. Objectives: This study sought to determine whether CT-derived radiomic and geometric myocardial features, integrated with procedural and clinical variables, can predict adverse LV remodeling after TAVR. Methods: We retrospectively analyzed 232 consecutive TAVR recipients with paired pre- and post-procedural LV mass index (LVMI) measurements. Adverse remodeling was defined as a [&ge;]10% increase in LVMI at follow-up. Pre-procedural CT was used to derive three-dimensional LV geometric descriptors, ray-tracing wall-thickness metrics, and myocardial texture radiomic features. Random forest classifiers were developed across six models of sequentially increasing complexity. Results: Adverse LV remodeling occurred in 52 patients (22.4%). Geometry-only model showed limited discrimination (AUC 0.62), whereas wall-thickness radiomics substantially improved performance (AUC 0.84). A multimodal pre-procedural model combining CT radiomics with pre-procedural LVMI, residual valve insufficiency, and prior coronary revascularization achieved an AUC of 0.86 (95% CI 0.73 to 0.98). Addition of post-procedural mean transvalvular gradient further improved discrimination (AUC 0.91, 95% CI 0.81 to 0.98). SHAP analysis identified post-procedural mean aortic gradient and radiomic markers of myocardial heterogeneity as the leading predictors. Conclusions: CT-derived radiomic characterization of myocardial heterogeneity provides incremental prognostic information beyond conventional geometric assessment for identifying patients at risk of adverse LV remodeling after TAVR. These findings extend the role of pre-procedural CT beyond anatomical planning toward quantitative myocardial phenotyping and individualized risk stratification, although prospective validation is required to establish clinical utility.

The AFRIDIARRHEA multimodal fusion framework for Estimating the Burden of Diarrheal Diseases Among Children Under Five in Kenya, Zimbabwe, and Somaliland

Background: Accurate estimation of childhood diarrheal disease burden in Africa remains challenging because of limited surveillance, incomplete mortality data, pathogen-attribution uncertainty, and complex environmental and socioeconomic drivers. This study developed the African Diarrheal Disease Integrated Risk Intelligence and Burden Estimation Architecture (AFRIDIARRHEA), a multimodal fusion framework for estimating under-five diarrheal burden in resource-constrained settings. Methods: AFRIDIARRHEA integrates Bayesian epidemiological modeling, machine learning, temporal forecasting, geospatial analytics, pathogen attribution, environmental intelligence, and uncertainty quantification within a unified framework. Synthetic datasets representing Kenya, Zimbabwe, and Somaliland were used to evaluate mortality, morbidity, hospitalization burden, pathogen-attributed mortality, and predictive performance. Results: The framework identified substantial heterogeneity in disease burden across countries, with Zimbabwe exhibiting the highest modeled mortality and morbidity burden and Somaliland the highest hospitalization burden. Rotavirus and Shigella were the dominant contributors to pathogen-attributed mortality. The multimodal fusion model outperformed the Bayesian baseline and individual component models, achieving improved predictive accuracy, robust uncertainty calibration, and strong agreement with benchmark estimates. Conclusions: AFRIDIARRHEA demonstrates the potential of multimodal fusion modeling for integrated estimation of childhood diarrheal burden, pathogen attribution, and uncertainty in African settings. The framework provides a scalable, transparent, and policy-relevant approach for supporting vaccine prioritization, WASH investments, outbreak preparedness, and child survival programs in data-limited environments. Keywords: Diarrheal disease, burden estimation, multimodal fusion, pathogen attribution, machine learning, uncertainty quantification, Africa

HARLINGEN MEDICAL CENTER PERFORMS HARLINGEN’s 1st “TRANSCATHETER AORTIC VALVE REPLACEMENT” PROCEDURE - MyRGV.com

HARLINGEN MEDICAL CENTER PERFORMS HARLINGEN’s 1st “TRANSCATHETER AORTIC VALVE REPLACEMENT” PROCEDURE&nbsp;&nbsp;MyRGV.com

TD Cowen raises Edwards Lifesciences stock price target on TAVR market share gains - Investing.com

TD Cowen raises Edwards Lifesciences stock price target on TAVR market share gains&nbsp;&nbsp;Investing.com

TD Cowen raises Edwards Lifesciences stock price target on TAVR market share gains - Investing.com

TD Cowen raises Edwards Lifesciences stock price target on TAVR market share gains&nbsp;&nbsp;Investing.com

UCHealth Parkview in Pueblo says they will no longer perform some cardiothoracic surgeries starting this month - KOAA News 5

UCHealth Parkview in Pueblo says they will no longer perform some cardiothoracic surgeries starting this month&nbsp;&nbsp;KOAA News 5

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2) - Centers for Medicare & Medicaid Services | CMS (.gov)

NCA - Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2)&nbsp;&nbsp;Centers for Medicare & Medicaid Services | CMS (.gov)

Edwards Lifesciences (EW) CFO Theodora Mistras files initial Form 3 report - Stock Titan

Edwards Lifesciences (EW) CFO Theodora Mistras files initial Form 3 report&nbsp;&nbsp;Stock Titan

Edwards Lifesciences (EW) Investor Outlook: A 11.78% Potential Upside in the Medical Device Sector - DirectorsTalk Interviews

Edwards Lifesciences (EW) Investor Outlook: A 11.78% Potential Upside in the Medical Device Sector&nbsp;&nbsp;DirectorsTalk Interviews

Eurizon Capital SGR S.p.A. Invests $13.69 Million in Edwards Lifesciences Corporation $EW - MarketBeat

Eurizon Capital SGR S.p.A. Invests $13.69 Million in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Norges Bank Purchases New Shares in Edwards Lifesciences Corporation $EW - MarketBeat

Norges Bank Purchases New Shares in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Intech Investment Management LLC Has $5.91 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat

Intech Investment Management LLC Has $5.91 Million Stake in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

LANDMARK: 2-Year Data Show Continued Safety and Efficacy of Unique TAVI Valve - TCTMD.com

LANDMARK: 2-Year Data Show Continued Safety and Efficacy of Unique TAVI Valve&nbsp;&nbsp;TCTMD.com

The high costs of robotic tech | Medtronic recalls thousands of devices | TAVR in younger patients | FDA approves next-gen valve - Cardiovascular Business

The high costs of robotic tech | Medtronic recalls thousands of devices | TAVR in younger patients | FDA approves next-gen valve&nbsp;&nbsp;Cardiovascular Business

Josh Brown's 'best stocks in the market': Edwards Lifesciences - CNBC

Josh Brown's 'best stocks in the market': Edwards Lifesciences&nbsp;&nbsp;CNBC

Edwards Lifesciences CVP Donald Bobo Jr. sells $2m in stock - Investing.com Australia

Edwards Lifesciences CVP Donald Bobo Jr. sells $2m in stock&nbsp;&nbsp;Investing.com Australia

Is Edwards Lifesciences (EW) Fairly Priced After Recent Share Price Strength? - Yahoo Finance UK

Is Edwards Lifesciences (EW) Fairly Priced After Recent Share Price Strength?&nbsp;&nbsp;Yahoo Finance UK

Narayana Health City performs India’s first TAVI for pure aortic valve leakage using Hanchor valve - The New Indian Express

Narayana Health City performs India’s first TAVI for pure aortic valve leakage using Hanchor valve&nbsp;&nbsp;The New Indian Express

Legal & General Group Plc Has $376.46 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat

Legal & General Group Plc Has $376.46 Million Stake in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Jefferies Financial Group Inc. Cuts Stake in Edwards Lifesciences Corporation $EW - MarketBeat

Jefferies Financial Group Inc. Cuts Stake in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Impact of Angina on Outcome After Percutaneous Coronary Intervention in Patients Undergoing Transcatheter Aortic Valve Implantation: Insights From the NOTION-3 Trial

Circulation, Volume 153, Issue 21, Page 1687-1690, May 26, 2026.

Conduction system pacing after TAVR linked to improved outcomes in new meta-analysis - Cardiovascular Business

Conduction system pacing after TAVR linked to improved outcomes in new meta-analysis&nbsp;&nbsp;Cardiovascular Business

Younger Adults Face Risks With ‘Quick-Fix’ for Heart Valve Surgery - University of Rochester Medicine

Younger Adults Face Risks With ‘Quick-Fix’ for Heart Valve Surgery&nbsp;&nbsp;University of Rochester Medicine

How TAVR implant depth impacts outcomes | A closer look at GLP-1 drugs & AFib | BATMAN technique to the rescue - Cardiovascular Business

How TAVR implant depth impacts outcomes | A closer look at GLP-1 drugs & AFib | BATMAN technique to the rescue&nbsp;&nbsp;Cardiovascular Business

Conduction system pacing after TAVR linked to improved outcomes in new meta-analysis

&lt;p&gt;Researchers explored data from nearly 800 patients, focusing on a wide variety of outcomes.&lt;/p&gt;

Edwards Lifesciences stock hits 52-week high at 87.89 USD - Investing.com

Edwards Lifesciences stock hits 52-week high at 87.89 USD&nbsp;&nbsp;Investing.com

Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth - Yahoo Finance

Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth&nbsp;&nbsp;Yahoo Finance

Boston Scientific Corp. stock (US10117L1017): Q1 beat and raised guidance keep medtech on investors - AD HOC NEWS

Boston Scientific Corp. stock (US10117L1017): Q1 beat and raised guidance keep medtech on investors&nbsp;&nbsp;AD HOC NEWS

Allen Hospital performs 300th all-time transcatheter aortic valve replacement procedure - Waterloo-Cedar Falls Courier

Allen Hospital performs 300th all-time transcatheter aortic valve replacement procedure&nbsp;&nbsp;Waterloo-Cedar Falls Courier

Swedbank AB Lowers Holdings in Edwards Lifesciences Corporation $EW - MarketBeat

Swedbank AB Lowers Holdings in Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth - Zacks Investment Research

Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth&nbsp;&nbsp;Zacks Investment Research

Artificial initiation codons and engineered initiator tRNAs enable N-terminal noncanonical amino acid incorporation in intact cell-free translation systems

Noncanonical amino acid (ncAA) incorporation at the protein N-terminus provides a powerful strategy for installing defined chemical handles while minimizing perturbation of internal protein sequences. However, highly efficient initiation-based ncAA incorporation systems suppress the native methionine pathway by removing methionine or methionyl-tRNA synthetase, limiting their use for proteins containing internal methionine residues. Here, we developed an orthogonal initiation system for selective N-terminal ncAA incorporation into proteins in intact cell-free translation systems. We systematically profiled background initiation from all 64 codons in reconstituted translation systems and identified low-background artificial initiation codons. Engineered initiator tRNAs, termed tRNAIniTx, were then designed to decode selected codons and support ncAA-dependent initiation. The optimized CAC/tRNAIniTx04GUG pair enabled efficient N-terminal incorporation of N-biotinyl-L-phenylalanine without removing methionine or methionyl-tRNA synthetase, reaching over 90% incorporation. The system was further extended to p-azido-L-phenylalanine and to an Escherichia coli extract-based cell-free translation system. Finally, N-terminally biotinylated proteins were directly immobilized on streptavidin biosensors for purification-free biolayer interferometry analysis of computationally designed Brd4BD2 binders. This work establishes a codon-guided orthogonal initiation strategy for N-terminal protein functionalization while preserving the native methionine translation pathway.

An engineered streptavidin condensate platform for chemically inducible control of endogenous proteins in mammalian cells

Inducible control of protein activity with temporal precision is essential for understanding and engineering dynamic cellular behaviors. However, current inducible molecular tools largely rely on overexpression of target proteins, which often disrupts the signaling pathways and cellular functions under investigation. A generalizable method to achieve inducible control of endogenous proteins in mammalian cells remains an unmet need. Here, we present a versatile platform based on engineered streptavidin biomolecular condensates to trap and release endogenously tagged proteins. By tagging endogenous loci with a short streptavidin-binding peptide via CRISPR knock-in, our synthetic streptavidin condensates efficiently partition and functionally inhibit the tagged endogenous proteins. The sequestered cargo protein is rapidly released upon the addition of biotin, restoring protein activity within minutes. We demonstrated the broad applicability of this system by controlling diverse endogenous targets: the anterograde motor KIF5B and retrograde motor DYNC1H1, which regulate intracellular vesicle trafficking, and the Arp2/3 complex subunit ARPC3, which regulates actin dynamics. Furthermore, we developed a dual-inducible system based on rapamycin-dependent condensation of streptavidin, enabling both rapid sequestration and release of endogenous proteins at user-defined time points. Altogether, this engineered streptavidin condensate platform provides a robust, rapid, and scalable approach for manipulating endogenous protein function under physiologically relevant conditions in both basic and translational research.

Edwards Lifesciences Corp. (EW) Stock Analysis: Healthcare Giant with 13% Upside Potential - DirectorsTalk Interviews

Edwards Lifesciences Corp. (EW) Stock Analysis: Healthcare Giant with 13% Upside Potential&nbsp;&nbsp;DirectorsTalk Interviews

Boston Scientific: $1.5 Billion Investment In MiRus To Advance Novel TAVR Technology - Pulse 2.0

Boston Scientific: $1.5 Billion Investment In MiRus To Advance Novel TAVR Technology&nbsp;&nbsp;Pulse 2.0

Transcatheter aortic valve implantation opens lifeline for critically patients - vietnamnews.vn

Transcatheter aortic valve implantation opens lifeline for critically patients&nbsp;&nbsp;vietnamnews.vn

Edwards Lifesciences Corporation $EW Shares Sold by PNC Financial Services Group Inc. - MarketBeat

Edwards Lifesciences Corporation $EW Shares Sold by PNC Financial Services Group Inc.&nbsp;&nbsp;MarketBeat

19,073 Shares in Edwards Lifesciences Corporation $EW Purchased by Fideuram Intesa Sanpaolo Private Banking S.P.A. - MarketBeat

19,073 Shares in Edwards Lifesciences Corporation $EW Purchased by Fideuram Intesa Sanpaolo Private Banking S.P.A.&nbsp;&nbsp;MarketBeat

Edwards Lifesciences stock (US28176E1082): investors eye upcoming earnings after recent beat - AD HOC NEWS

Edwards Lifesciences stock (US28176E1082): investors eye upcoming earnings after recent beat&nbsp;&nbsp;AD HOC NEWS

Boston Scientific: $1.5 Billion Investment In MiRus To Advance Novel TAVR Technology - Pulse 2.0

Boston Scientific: $1.5 Billion Investment In MiRus To Advance Novel TAVR Technology&nbsp;&nbsp;Pulse 2.0

A tomato fruit blotch viral replicon defines minimal requirements for cell autonomous replication and identifies functional RNA4-encoded movement and silencing suppression activities

Tomato fruit blotch virus (ToFBV) is an emerging multipartite positive-sense RNA virus associated with blotchy symptoms on tomato fruits and classified within the genus Blunervirus (family Kitaviridae). Despite its increasing agricultural relevance, the study of ToFBV has been hindered by the lack of mechanical transmissibility and the difficulty in reproducing infections under controlled conditions. In this work, we report a preliminary step toward the development of the first infectious agroclone system for ToFBV, based on full-length cDNA copies of its four genomic RNAs. We demonstrate that the cloned viral genome is capable of initiating cell autonomous replication in Nicotiana benthamiana, as indicated by the accumulation of negative-sense RNA intermediates in infiltrated tissues. To further validate the system, RNA3 was engineered to express GFP, enabling visualization of infection foci and confirming active viral replication in both N. benthamiana and tomato. Functional assays of RNA4-encoded proteins demonstrated that it encodes a movement protein capable of complementing movement-deficient viral vectors and a putative suppressor of post-transcriptional gene silencing (PTGS). Together, these results establish a versatile reverse genetics platform for ToFBV, providing new insights into the replication and functional organization of blunerviruses and enabling future studies on virus-host interactions, pathogenicity, and control strategies

Advocacy group wants TAVR changes, urging Trump admin to ‘stop getting in between patients and their doctors’ - Cardiovascular Business

Advocacy group wants TAVR changes, urging Trump admin to ‘stop getting in between patients and their doctors’&nbsp;&nbsp;Cardiovascular Business

PCI Prior to TAVI of Only Modest Benefit in Patients With CAD and Aortic Stenosis - TCTMD.com

PCI Prior to TAVI of Only Modest Benefit in Patients With CAD and Aortic Stenosis&nbsp;&nbsp;TCTMD.com

Women-Only Trial Supports Self-Expanding TAVR as the Way to Go - MedPage Today

Women-Only Trial Supports Self-Expanding TAVR as the Way to Go&nbsp;&nbsp;MedPage Today

After TAVI, Early Hemodynamic Valve Deterioration May Elude Detection - TCTMD.com

After TAVI, Early Hemodynamic Valve Deterioration May Elude Detection&nbsp;&nbsp;TCTMD.com

TAVI: Changing lives without open-heart surgery - Imperial College Healthcare NHS Trust

TAVI: Changing lives without open-heart surgery&nbsp;&nbsp;Imperial College Healthcare NHS Trust

Precision Trading with Edwards Lifesciences Corporation (EW) Risk Zones - Stock Traders Daily

Precision Trading with Edwards Lifesciences Corporation (EW) Risk Zones&nbsp;&nbsp;Stock Traders Daily

David Letterman Launches Urgent Heart Valve Failure Awareness Campaign - streamlinefeed.co.ke

David Letterman Launches Urgent Heart Valve Failure Awareness Campaign&nbsp;&nbsp;streamlinefeed.co.ke

Abbott study findings back Navitor TAVI system - MassDevice

Abbott study findings back Navitor TAVI system&nbsp;&nbsp;MassDevice

Abbott study findings back Navitor TAVI system - MassDevice

Abbott study findings back Navitor TAVI system&nbsp;&nbsp;MassDevice

FDA approves next-gen mitral valve | Doctors are first in world to use new TAVR technique | Preventing a common complication - Cardiovascular Business

FDA approves next-gen mitral valve | Doctors are first in world to use new TAVR technique | Preventing a common complication&nbsp;&nbsp;Cardiovascular Business

Boston Scientific invests $1.5 billion in MiRus, secures option for TAVR acquisition - DOTmed

Boston Scientific invests $1.5 billion in MiRus, secures option for TAVR acquisition&nbsp;&nbsp;DOTmed

Boston Scientific Pairs US$2b Buyback With MiRus TAVR Growth Bet - Yahoo Finance

Boston Scientific Pairs US$2b Buyback With MiRus TAVR Growth Bet&nbsp;&nbsp;Yahoo Finance

Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc - GuruFocus

Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc&nbsp;&nbsp;GuruFocus

Edwards Lifesciences stock (US28176E1082): heart-valve specialist in focus after latest earnings upd - AD HOC NEWS

Edwards Lifesciences stock (US28176E1082): heart-valve specialist in focus after latest earnings upd&nbsp;&nbsp;AD HOC NEWS

Boston Scientific stock (US10117L1017): New catalyst watch after recent company developments - AD HOC NEWS

Boston Scientific stock (US10117L1017): New catalyst watch after recent company developments&nbsp;&nbsp;AD HOC NEWS

Breastmilk antibody isotypes differentially protect against neonatal rotavirus infection and modulate the timing and clonal architecture of offspring B cell responses

Mother-to-offspring transfer of antibodies protects newborns during the critical phase of early life, preventing both infection and inflammation. Whether and how pre-existing passive immunity actively shapes immune memory formation in neonates remains unclear. Using a murine neonatal Rotavirus infection model in combination with cross-foster approaches and genetic models, we disentangled the contribution of maternal IgA and IgG to neonatal immune outcomes. While breastmilk antigen specific IgA is responsible for protection from Rotavirus infection, antigen specific IgG delays pup-intrinsic humoral immune induction to after weaning. Importantly, pre-existing maternal immunity delays and constrains, rather than ablates, long term humoral immunity. Together, our data move beyond a binary view of passive immunity as protective versus inhibitory, providing a more nuanced understanding in which breastmilk antibodies actively program the neonatal response for optimal immediate protection and long-term immune education in the growing organism.

Boston Scientific invests $1.5B in TAVR developer MiRus, enters $2B share repurchase agreement - MassDevice

Boston Scientific invests $1.5B in TAVR developer MiRus, enters $2B share repurchase agreement&nbsp;&nbsp;MassDevice

Boston Scientific invests $1.5B in MiRus with option to buy its TAVR business - Cardiovascular Business

Boston Scientific invests $1.5B in MiRus with option to buy its TAVR business&nbsp;&nbsp;Cardiovascular Business

Boston Scientific puts $1.5B into MiRus, option to buy its TAVR - Fierce Biotech

Boston Scientific puts $1.5B into MiRus, option to buy its TAVR&nbsp;&nbsp;Fierce Biotech

Boston Scientific buys $1.5B stake in TAVR developer MiRus - MedTech Dive

Boston Scientific buys $1.5B stake in TAVR developer MiRus&nbsp;&nbsp;MedTech Dive

Boston Scientific Invests $1.5B for TAVR Acquisition Option - Medical Device and Diagnostic industry

Boston Scientific Invests $1.5B for TAVR Acquisition Option&nbsp;&nbsp;Medical Device and Diagnostic industry

Boston Scientific invests $1.5 billion in heart valve startup MiRus - qz.com

Boston Scientific invests $1.5 billion in heart valve startup MiRus&nbsp;&nbsp;qz.com

Boston Scientific (NYSE: BSX) commits $1.5B plus $3B option for MiRus TAVR business - Stock Titan

Boston Scientific (NYSE: BSX) commits $1.5B plus $3B option for MiRus TAVR business&nbsp;&nbsp;Stock Titan

Health Matters: Salina Regional – TAVR - KSN.com

Health Matters: Salina Regional – TAVR&nbsp;&nbsp;KSN.com

BSX: Investment secures stake and exclusive option in innovative TAVR technology targeting a $7B market - TradingView

BSX: Investment secures stake and exclusive option in innovative TAVR technology targeting a $7B market&nbsp;&nbsp;TradingView

EmStop initiates IDE study of novel embolic protection device - MassDevice

EmStop initiates IDE study of novel embolic protection device&nbsp;&nbsp;MassDevice

Boston Scientific's $1.5B nickel-free heart valve deal with $3B option - Stock Titan

Boston Scientific's $1.5B nickel-free heart valve deal with $3B option&nbsp;&nbsp;Stock Titan

Boston Scientific Invests in MiRus to Expand TAVR Portfolio - TipRanks

Boston Scientific Invests in MiRus to Expand TAVR Portfolio&nbsp;&nbsp;TipRanks

AIIMS performs first Transcatheter Aortic Valve Implantation procedure - Daily Excelsior

AIIMS performs first Transcatheter Aortic Valve Implantation procedure&nbsp;&nbsp;Daily Excelsior

Boston Scientific Invests $1.5 Billion in MiRus for Exclusive Option on Innovative Nickel-Free Balloon Expandable TAVR Valve - Minichart

Boston Scientific Invests $1.5 Billion in MiRus for Exclusive Option on Innovative Nickel-Free Balloon Expandable TAVR Valve&nbsp;&nbsp;Minichart

Tavi Costa’s Bullish Case for Gold, Silver & Mining Stocks - Discovery Alert

Tavi Costa’s Bullish Case for Gold, Silver & Mining Stocks&nbsp;&nbsp;Discovery Alert

Edwards Lifesciences stock (US28176E1082): heart valve specialist in focus after recent results - AD HOC NEWS

Edwards Lifesciences stock (US28176E1082): heart valve specialist in focus after recent results&nbsp;&nbsp;AD HOC NEWS

Edwards Lifesciences stock (US28176E1082): heart valve specialist in focus after recent earnings - AD HOC NEWS

Edwards Lifesciences stock (US28176E1082): heart valve specialist in focus after recent earnings&nbsp;&nbsp;AD HOC NEWS

Edwards Lifesciences reports double-digit pay increases for executives and median employee - Medical Design & Outsourcing

Edwards Lifesciences reports double-digit pay increases for executives and median employee&nbsp;&nbsp;Medical Design & Outsourcing

Edwards Lifesciences (NYSE:EW) VP Sells $50,306.80 in Stock - MarketBeat

Edwards Lifesciences (NYSE:EW) VP Sells $50,306.80 in Stock&nbsp;&nbsp;MarketBeat

Edwards Lifesciences (EW) CVP Donald Bobo Jr. sells 17,968 shares in open-market trades - Stock Titan

Edwards Lifesciences (EW) CVP Donald Bobo Jr. sells 17,968 shares in open-market trades&nbsp;&nbsp;Stock Titan

Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M - TradingView

Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M&nbsp;&nbsp;TradingView

Edwards Lifesciences exec sells 620 shares after option exercise | EW Insider Trading - Stock Titan

Edwards Lifesciences exec sells 620 shares after option exercise | EW Insider Trading&nbsp;&nbsp;Stock Titan

Edwards Lifesciences (NYSE: EW) Form 144 lists 150,758 units via broker - Stock Titan

Edwards Lifesciences (NYSE: EW) Form 144 lists 150,758 units via broker&nbsp;&nbsp;Stock Titan

Medtronic Bets on Cardiovascular Realignment Amid Stock Pressure and Facility Closures - MedTech Intelligence

Medtronic Bets on Cardiovascular Realignment Amid Stock Pressure and Facility Closures&nbsp;&nbsp;MedTech Intelligence

Medtronic stock (IE00BTN1Y115): diabetes franchise in focus after latest product updates - AD HOC NEWS

Medtronic stock (IE00BTN1Y115): diabetes franchise in focus after latest product updates&nbsp;&nbsp;AD HOC NEWS

Boston Scientific invests $1.5B in MiRus with option to buy its TAVR business - Cardiovascular Business

Boston Scientific invests $1.5B in MiRus with option to buy its TAVR business&nbsp;&nbsp;Cardiovascular Business

Boston Scientific Invests $1.5 Billion MiRus to Expand Structural Heart Portfolio - citybiz

Boston Scientific Invests $1.5 Billion MiRus to Expand Structural Heart Portfolio&nbsp;&nbsp;citybiz

Boston Scientific invests $1.5B in TAVR developer MiRus, enters $2B share repurchase agreement - MassDevice

Boston Scientific invests $1.5B in TAVR developer MiRus, enters $2B share repurchase agreement&nbsp;&nbsp;MassDevice

Boston Scientific returns to heart-valve market with $1.5B investment in startup - The Business Journals

Boston Scientific returns to heart-valve market with $1.5B investment in startup&nbsp;&nbsp;The Business Journals

Boston Scientific shares rise after $1.5B MiRus investment and $2B accelerated buyback - Quiver Quantitative

Boston Scientific shares rise after $1.5B MiRus investment and $2B accelerated buyback&nbsp;&nbsp;Quiver Quantitative

Boston Scientific (NYSE: BSX) commits $1.5B plus $3B option for MiRus TAVR business - Stock Titan

Boston Scientific (NYSE: BSX) commits $1.5B plus $3B option for MiRus TAVR business&nbsp;&nbsp;Stock Titan

Boston Scientific Invests $1.5B In MiRus SIEGEL Valve - Hoodline

Boston Scientific Invests $1.5B In MiRus SIEGEL Valve&nbsp;&nbsp;Hoodline

Boston Scientific Invests in MiRus to Expand TAVR Portfolio - TipRanks

Boston Scientific Invests in MiRus to Expand TAVR Portfolio&nbsp;&nbsp;TipRanks

Boston Scientific's $1.5B nickel-free heart valve deal with $3B option - Stock Titan

Boston Scientific's $1.5B nickel-free heart valve deal with $3B option&nbsp;&nbsp;Stock Titan

Boston Scientific stock (US10117L1017): Q1 earnings beat and raised 2026 outlook - AD HOC NEWS

Boston Scientific stock (US10117L1017): Q1 earnings beat and raised 2026 outlook&nbsp;&nbsp;AD HOC NEWS

Boston Scientific Corp. stock (US10117L1017): focus on latest earnings and growth drivers - AD HOC NEWS

Boston Scientific Corp. stock (US10117L1017): focus on latest earnings and growth drivers&nbsp;&nbsp;AD HOC NEWS

World Transcatheter Heart Valve Replacement TAVI - Market Analysis, Forecast, Size, Trends and Insights - IndexBox

World Transcatheter Heart Valve Replacement TAVI - Market Analysis, Forecast, Size, Trends and Insights&nbsp;&nbsp;IndexBox

The Structural Heart Revolution: Perspectives From Fellowship and Beyond - TCTMD.com

The Structural Heart Revolution: Perspectives From Fellowship and Beyond&nbsp;&nbsp;TCTMD.com

LAA Closure, PFO Closure, and Other Novel Structural Heart Procedures - TCTMD.com

LAA Closure, PFO Closure, and Other Novel Structural Heart Procedures&nbsp;&nbsp;TCTMD.com

Cardiac Wire’s State of The Transcatheter Valve - Cardiac Wire

Cardiac Wire’s State of The Transcatheter Valve&nbsp;&nbsp;Cardiac Wire

Northwestern Mutual Wealth Management Co. Purchases 1,093,692 Shares of Edwards Lifesciences Corporation $EW - MarketBeat

Northwestern Mutual Wealth Management Co. Purchases 1,093,692 Shares of Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Barclays (NASDAQ: TAVI) holds 5.46% of Tavia Acquisition Corp - Stock Titan

Barclays (NASDAQ: TAVI) holds 5.46% of Tavia Acquisition Corp&nbsp;&nbsp;Stock Titan

Tavi Time bidding to go back-to-back in Scone Cup as Lees gears up for big day - ANZ Bloodstock News

Tavi Time bidding to go back-to-back in Scone Cup as Lees gears up for big day&nbsp;&nbsp;ANZ Bloodstock News

Advanced heart valve procedure performed in Dharampur, Valsad - Ahmedabad Mirror

Advanced heart valve procedure performed in Dharampur, Valsad&nbsp;&nbsp;Ahmedabad Mirror

Treating Aortic Valve Stenosis with Transcatheter Aortic Valve Replacement (TAVR) - Bumrungrad International Hospital | Bangkok

Treating Aortic Valve Stenosis with Transcatheter Aortic Valve Replacement (TAVR)&nbsp;&nbsp;Bumrungrad International Hospital | Bangkok

Karpus Management (TAVI) reports 2.18M shares, 18.93% stake - Stock Titan

Karpus Management (TAVI) reports 2.18M shares, 18.93% stake&nbsp;&nbsp;Stock Titan

Are Wall Street Analysts Bullish on Edwards Lifesciences Stock? - Yahoo Finance

Are Wall Street Analysts Bullish on Edwards Lifesciences Stock?&nbsp;&nbsp;Yahoo Finance

Medtronic hires chief operations and supply chain officer - MassDevice

Medtronic hires chief operations and supply chain officer&nbsp;&nbsp;MassDevice

Is TAVR too common among younger patients? | New-look heart failure device delivers | SCAI to study women in the cath lab - Cardiovascular Business

Is TAVR too common among younger patients? | New-look heart failure device delivers | SCAI to study women in the cath lab&nbsp;&nbsp;Cardiovascular Business

Transcatheter Aortic Valve Replacement (TAVR) Market in Latin - openPR.com

Transcatheter Aortic Valve Replacement (TAVR) Market in Latin&nbsp;&nbsp;openPR.com

Heartflow sues AI rival Cleerly | Another win for opportunistic screening | Predicting TAVR outcomes | Key approvals for Abbott - Cardiovascular Business

Heartflow sues AI rival Cleerly | Another win for opportunistic screening | Predicting TAVR outcomes | Key approvals for Abbott&nbsp;&nbsp;Cardiovascular Business

Scaling heart valve manufacturing to deliver life-saving treatments across Europe - Jacobs

Scaling heart valve manufacturing to deliver life-saving treatments across Europe&nbsp;&nbsp;Jacobs

Edwards Lifesciences' (NYSE:EW) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance

Edwards Lifesciences' (NYSE:EW) Conservative Accounting Might Explain Soft Earnings&nbsp;&nbsp;Yahoo Finance

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day&nbsp;&nbsp;MarketWatch

Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom? - The Globe and Mail

Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?&nbsp;&nbsp;The Globe and Mail

Boston Scientific Corp. stock (US10117L1017): Hits 52-week low at $53.10 - AD HOC NEWS

Boston Scientific Corp. stock (US10117L1017): Hits 52-week low at $53.10&nbsp;&nbsp;AD HOC NEWS

QRG Capital Management Inc. Acquires 18,172 Shares of Edwards Lifesciences Corporation $EW - MarketBeat

QRG Capital Management Inc. Acquires 18,172 Shares of Edwards Lifesciences Corporation $EW&nbsp;&nbsp;MarketBeat

Flow-gradient Phenotypes and Functional Recovery After Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis: A COMPARE-TAVI 1 Sub-study

BACKGROUND Patients with severe aortic stenosis (AS) exhibit heterogeneous flow-gradient hemodynamics and ventricular remodeling, which may influence symptomatic, functional, and structural responses to transcatheter aortic valve implantation (TAVI). Thus, we evaluated differences in functional recovery and reverse remodeling after transfemoral TAVI across flow-gradient phenotypes. METHODS In this sub-study of the COMPARE-TAVI 1 trial, 975 patients undergoing transfemoral TAVI were classified as classical low-flow low-gradient (cLFLG, 9.1%), paradoxical low-flow low-gradient (pLFLG, 7.7%), low-flow high-gradient (24.7%), normal-flow low-gradient (NFLG, 13.0%), and normal-flow high-gradient (45.4%). The primary functional outcome was longitudinal change in six-minute walk test distance (6MWTD) from baseline to 1 year follow-up. Secondary endpoints included changes in NYHA functional class and reverse remodeling from baseline to 1 year follow-up along with the incidence and risk of all-cause death and a composite MACE-endpoint. RESULTS Mean 6MWTD increased by 59{+/-}4 meters at 1-month (p=0.000) with no additional improvement at 1-year, but with heterogeneity between groups (p=0.000). Improvements among NFLG, cLFLG and low-flow high-gradient AS were comparable with normal-flow high-gradient AS, while pLFLG AS exhibited significantly increments at 1-year (-28{+/-}15 meters, p=0.007). Patients with NFLG, cLFLG and pLFLG were more symptomatic at baseline (NYHA [&ge;]III: 40.5%, 57.3% and 50.6%, respectively, p=0.000). NYHA improved in all groups at 1-year follow-up (p=0.000), although persistent symptoms at 1-year were most frequent in pLFLG (NYHA [&ge;]II, 38.7%, p=0.012). Reverse remodeling was also comparable between normal-flow high-gradient AS and NFLG, cLFLG, and low-flow high-gradient AS, respectively, but attenuated in pLFLG AS in both unadjusted and adjusted analyses. No differences were observed in the incidence and risk of all-cause death or the composite MACE-endpoint. CONCLUSION TAVI associates with functional recovery across all flow-gradient phenotypes, although with heterogeneous responses. Patients with NFLG showed comparable functional recovery and reverse remodeling at 1-year follow-up compared with normal-flow high-gradient AS, whereas pLFLG demonstrated attenuated benefits across all parameters.

Tavi draugi hosts charity author evening in Riga to raise funds for Ukraine and Latvia - mezha.net

Tavi draugi hosts charity author evening in Riga to raise funds for Ukraine and Latvia&nbsp;&nbsp;mezha.net

TAVR Highlights: Predicting long-term outcomes | SCAI, ACC & STS share a message | Weight loss drug linked to key benefits - Cardiovascular Business

TAVR Highlights: Predicting long-term outcomes | SCAI, ACC & STS share a message | Weight loss drug linked to key benefits&nbsp;&nbsp;Cardiovascular Business

Resilia tissue developed by Edwards Lifesciences associated with long-term durability - Cardiovascular Business

Resilia tissue developed by Edwards Lifesciences associated with long-term durability&nbsp;&nbsp;Cardiovascular Business

Is It Time To Reassess Edwards Lifesciences (EW) After Mixed Returns And Rich P/E Ratio - simplywall.st

Is It Time To Reassess Edwards Lifesciences (EW) After Mixed Returns And Rich P/E Ratio&nbsp;&nbsp;simplywall.st

Edwards Lifesciences (NYSE: EW) lifts Q1 2026 sales on TAVR and TMTT growth - Stock Titan

Edwards Lifesciences (NYSE: EW) lifts Q1 2026 sales on TAVR and TMTT growth&nbsp;&nbsp;Stock Titan

AI helps 3D imaging labs evolve | Catheters recalled over safety risk | New ways to predict TAVR outcomes - Cardiovascular Business

AI helps 3D imaging labs evolve | Catheters recalled over safety risk | New ways to predict TAVR outcomes&nbsp;&nbsp;Cardiovascular Business